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ABSTRACT 
 
THE EFFECT OF T CELL RECEPTOR SPECIFICITY ON CD4+CD25+ 
REGULATORY T CELL FUNCTION IN AN AUTOIMMUNE SETTING 
 
Soyoung Oh 
 
Andrew J. Caton, Ph.D. 
 
 The studies presented in this dissertation examine how the T cell receptor 
(TCR) specificity of CD4+CD25+ regulatory T (Treg) cells affects their function in 
a mouse model of autoimmune arthritis (TS1xHACII mice).  TS1xHACII mice co-
express CD4+ T cells that express the transgenic 6.5 TCR, which is specific for 
the S1 determinant of influenza virus PR8 hemagglutinin (HA), and HA as a neo-
self antigen under the MHC Class II I-Eα promoter.  The majority of adult 
TS1xHACII mice develop inflammatory arthritis that is driven by recognition of S1 
peptide by 6.5+CD4+ T cells.  Notably, arthritis develops despite the presence of 
CD4+CD25+Foxp3+ Treg cells, including a population of 6.5+ cells that are 
specific for the disease target antigen S1 peptide.  However, the administration of 
exogenous CD4+CD25+ Treg cells to pre-arthritic TS1xHACII mice can prevent 
arthritis in TS1xHACII mice, demonstrating that the disease is susceptible to 
CD4+CD25+ Treg cell activity.   
 
 v 
Interestingly, we have found that the ability of CD4+CD25+ Treg cells to 
suppress arthritis in TS1xHACII mice is highly dependent on the TCR 
specificity(s) of the Treg cell population.  Polyclonal CD4+CD25+ Treg cells 
(including cells that have not developed in the presence of the disease target 
antigen S1 peptide), but not CD4+CD25+ Treg cells that are enriched for S1-
specific 6.5+ cells are able to prevent arthritis development in TS1xHACII mice.  
Although polyclonal CD4+CD25+ Treg cells can suppress arthritis in TS1xHACII 
mice, our data suggest that successful CD4+CD25+ Treg cell mediated 
suppression of arthritis is remarkably sensitive to the balance of Treg cells and 
pathogenic 6.5+CD4+ T cells.  We also present data indicating that CD4+CD25+ 
Treg cells that are strongly reactive for a highly expressed disease target antigen 
can be detrimental in the context of certain autoimmune diseases.  Collectively, 
these studies indicate that the antigen-specificity of CD4+CD25+ Treg cells is a 
critical determinant of their ability to suppress arthritis in TS1xHACII mice.  
Moreover the data presented here also suggest that the balance of certain TCR 
specificities between CD4+CD25+ Treg and effector CD4+ T cells plays an 
important role in determining the maintenance of tolerance versus the 
development autoimmunity. 
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Chapter 1: Introduction and Overview 
1.1 Introduction 
 
The adaptive immune system is designed to be highly diverse, allowing for 
the recognition of a wide range of pathogens. However, this diversity must be 
balanced with the requirement of self-tolerance, and within tightly controlled 
numbers of peripheral lymphocytes. During T cell development, gene 
rearrangement mechanisms produce an enormous array of T cell receptors 
(TCRs). This diverse pool of TCRs is subsequently screened for autoreactivity, 
and highly self-reactive T cells are eliminated or functionally suppressed via 
central and peripheral tolerance mechanisms (Palmer 2003; Hogquist et al. 2005; 
Mueller et al. 2010), which include the activity of CD4+CD25+ regulatory T (Treg) 
cells (Sakaguchi 2004).  The combination of these processes allows the adaptive 
immune system to achieve a diverse T cell repertoire while maintaining self-
tolerance.  However, these tolerance mechanisms are not foolproof, and 
approximately 3 to 5 percent of the population develops autoimmunity (Jacobson 
et al. 1997).  
 
How and why CD4+CD25+ Treg cells fail to prevent the development of 
autoimmunity is poorly understood.  The studies presented in this dissertation 
examine the role of CD4+CD25+ Treg cells in modifying a mouse model of 
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inflammatory arthritis that is dependent on the autoreactive CD4+ T cell 
response.   We also address how the antigen-specificity of the CD4+CD25+ Treg 
cells affects their in vivo suppressor function.  This introductory chapter begins 
with an overview of rheumatoid arthritis and mouse models of arthritis with a 
particular focus on how CD4+ T cells can contribute to disease.  The following 
section presents a summary of relevant topics in CD4+CD25+ Treg cell biology.  
The chapter concludes with an overview of the current understanding of 
CD4+CD25+ Treg cell activity in human arthritis and mouse models of disease. 
 
1.2 Rheumatoid Arthritis 
 
Approximately 0.8 percent of the population develops rheumatoid arthritis 
(RA) (Lipsky).  Although the etiology of the disease remains unknown, a major 
genetic risk factor for RA is the MHC Class II allele HLA-DR4 (DRβ1*0401).  
Interestingly, other MHC Class II alleles (HLA-DR5, HLA-DR2, HLA-DR3, and 
HLA-DR7) may be protective, as they are found at lower frequencies in RA 
patients than in individuals who have not developed RA (Lipsky).  However, the 
mechanisms (e.g. deletion of autoreactive T cells, selection of Treg cells) by 
which these particular MHC Class II alleles could confer protection are unknown.  
In addition to the MHC Class II allele HLA-DR4, the gene PTPN22 (protein 
tyrosine phosphatase non-receptor type 22), which encodes the lymphoid 
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tyrosine phosphatase (Lyp) that participates in TCR signal transduction, has 
been identified as another genetic risk factor for RA (Lipsky; (Lundy et al. 2007).  
Collectively, the association of genes that encode MHC Class II and TCR 
signaling molecules with RA development strongly supports a role for CD4+ T 
cells in disease.  Indeed, studies in multiple mouse models of arthritis have 
identified a critical role for CD4+ T cells in arthritis development.  A summary of 
these findings is presented in the following section. 
 
1.3 The role of CD4+ T cells in mouse models of arthritis 
 
Mouse models of inflammatory arthritis possess several characteristics 
that resonate with human RA, and have been an instrumental tool in gaining 
better understanding of this autoimmune disorder.  Work in several different 
arthritis models has clearly demonstrated a requirement for autoreactive CD4+ T 
cells in arthritis pathogenesis.  One of the most commonly used systems to study 
disease is the inductive model of collagen-induced arthritis (CIA).  In CIA, 
disease development is initiated by immunizing mice with bovine type II collagen 
in complete Freund’s adjuvant.  The ensuing antigen-specific CD4+ T cell 
response is required for B cell generation of collagen-specific antibodies that 
drive disease (Luross and Williams 2001).  Although CD4+ T cells are necessary 
for the initial immune response that leads to arthritis (Ranges et al. 1985), CIA is 
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ultimately dependent on the production of collagen-specific antibodies and 
arthritis does not develop in B cell deficient mice (Svensson et al. 1998). 
 
K/BxN mice develop spontaneous arthritis that also requires T and B cell 
responses for disease development.  Arthritis in K/BxN mice is initiated by KRN 
transgenic TCR CD4+ T cell recognition of a glucose-6-phosphate isomerase 
(GPI) peptide presented by the MHC Class II molecule Ag7, which activates GPI-
specific B cells, leading to the production of pathogenic autoantibodies that bind 
to articular surfaces and initiate an inflammatory cascade that leads to joint 
damage (Kouskoff et al. 1996; Matsumoto et al. 1999; Matsumoto et al. 2002).  
Chimeric mice, generated by administration of KRN.RAG-/- bone marrow to 
irradiated BxN.TCRα-/- mice, develop arthritis, demonstrating that CD4+ T cells of 
other specificities are not required for the initiation of arthritis development in 
K/BxN mice (Mangialaio et al. 1999).  The transfer of serum from arthritic K/BxN 
mice into BxN.RAG-/- mice induces arthritis, indicating that the presence of 
autoantibodies alone is sufficient to mediate arthritis development, and that T 
cells are not required for the effector phase of disease (Korganow et al. 1999).  
However, although CD4+ T cells are not necessary for the development of serum 
transfer induced arthritis, they can contribute to disease as co-administration of 
CD4+ T cells with the serum transfers exacerbates arthritis by a mechanism that 
involves IL-17 (Jacobs et al. 2009). 
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 While disease development in CIA and K/BxN arthritis models requires 
both T and B cell responses, it has been also shown that autoreactive CD4+ T 
cells alone can initiate arthritis.  Sakaguchi and colleagues have described the 
SKG mouse, which develops spontaneous arthritis that is attributed to a failure in 
negative selection of autoreactive thymocytes due to a mutation in the ZAP-70 
(ζ-associated protein of 70 kDa) gene (Sakaguchi et al. 2003).  The adoptive 
transfer of SKG CD4+ T cells into RAG-/- mice can induce arthritis, demonstrating 
that B cell antibody production is not required for arthritis development, and that 
CD4+ T cells alone can initiate disease (Hirota et al. 2007).  However, while it is 
evident that autoreactive CD4+ T cells drive arthritis development in SKG mice, 
the nature of the peptide(s) that the cells recognize is unknown.  Moreover, 
arthritis development in SKG mice is also dependent on additional environmental 
cues, as SKG mice housed in specific pathogen free conditions do not develop 
disease (Yoshitomi et al. 2005).  Our lab has recently described another mouse 
model of arthritis that is dependent on autoreactive CD4+ T cells.  TS1xHACII 
mice develop spontaneous inflammatory arthritis that is driven by CD4+ T cell 
recognition of a single systemically presented peptide and does not require B 
cells (Rankin et al. 2008).  Specific aspects of arthritis development in 
TS1xHACII mice will be discussed in greater detail in Chapter 3 of this 
dissertation. 
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 While CD4+ T cells clearly play a critical role in the initiation of the immune 
response that leads to arthritis development, other aspects of the immune 
response can also contribute arthritis pathogenesis.  Dysregulation of 
inflammatory pathways can be a key contributing factor to disease, as the over-
expression of cytokines such as TNF-α and IL-1α, or expression of a mutated IL-
6R gp130 that enhances gp130-mediated signal transducer and activator of 
transcription (STAT3) activation also leads to arthritis development (Keffer et al. 
1991; Niki et al. 2001; Sawa et al. 2006).  Interestingly, the arthritis that develops 
in the IL-6R gp130 mutant mice is attributed to CD4+ T cell activation resulting 
from enhanced homeostatic proliferation, and disease can be ameliorated by 
inhibiting the homeostatic proliferation of CD4+ T cells (Sawa et al. 2006).  In 
SKG mice, genetic deficiencies in IL-6, IL-1, and TNF-α resulted in either 
complete protection from arthritis or delayed disease onset accompanied by 
reduced incidence and disease severity (Hata et al. 2004), demonstrating that 
the autoreactive CD4+ T cells are acting in concert with certain inflammatory 
pathways.  In addition to IL-6, IL-1, and TNF-α, there are reports that IL-17, 
recently identified as defining a unique T helper cell lineage (Harrington et al. 
2005; Park et al. 2005), is also involved in arthritis.  In the next section we will 
summarize the relevant findings on IL-17 in human arthritis and mouse models of 
arthritis.  
 
 7 
1.4 The role of IL-17 in arthritis 
 
The cytokine IL-17 is thought to play a critical role in several autoimmune 
diseases, including experimental autoimmune encephalitis (EAE), psoriasis, and 
arthritis (Afzali et al. 2007; Korn et al. 2009).  In human RA patients, IL-17 has 
been detected in the peripheral blood, serum, synovial fluid, and/or synovium 
(Chabaud et al. 1999; Kotake et al. 1999; Hirota et al. 2007; Sarkar et al. 2010).  
Interestingly in the synovium, IL-17 is primarily found in T cell enriched areas, 
and is mostly secreted by memory CD4+ T cells isolated from the peripheral 
blood of RA patients (Sarkar et al. 2010), suggesting that CD4+ T cells are a 
major source of IL-17 in RA.  IL-17 has also been detected in the synovial fluid 
and joints of arthritic mice (Hirota et al. 2007).  IL-17 may contribute to arthritis 
pathogenesis by a variety of mechanisms.  IL-17 can induce the upregulation of 
cytokines such as IL-1β, TNF-α, and IL-6 (Chabaud et al. 1998; Jovanovic et al. 
1998; Sarkar et al. 2010), which not only contribute to arthritis pathogenesis but 
can also promote additional differentiation of Th-17 cells (Weaver et al. 2007; 
Korn et al. 2009).  IL-17 can also recruit innate immune cells such as monocytes 
or neutrophils, which are potential sources for the cytokines described above, to 
sites of inflammation (Lundy et al. 2007; Shahrara et al. 2009; Pelletier et al. 
2010).  Moreover, the IL-17R is found on chondrocytes, synoviocytes, and 
osteoclasts; and the activation of these cell types has direct implications for 
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arthritis pathogenesis (Sarkar et al. 2010).  Indeed, in vitro studies have 
demonstrated that IL-17 can act upon osteoblasts to induce osteoclastogenesis 
(Sato et al. 2006), and potentially contribute to bone resorption.  Thus, IL-17 can 
act upon cells in the joint and also activate and/or recruit other cell types to the 
primary sites of inflammation and autoimmune pathology.   
 
 Studies in several mouse models of arthritis have demonstrated that IL-17 
plays an important role in disease pathogenesis. Mice lacking the IL-1 receptor 
antagonist (IL1-Ra-/-) develop inflammatory arthritis, and interestingly the CD4+ T 
cells from these mice produce elevated amounts of IL-17 (Nakae et al. 2003).  
When IL1-Ra-/- mice are bred onto an IL17-/- background, the mice are protected 
from arthritis, demonstrating the critical role for IL-17 in mediating the disease 
that develops in IL1-Ra-/- mice (Nakae et al. 2003).  Moreover, treating arthritic 
IL1-Ra-/- mice with anti-IL17 antibody can reduce disease severity (Koenders et 
al. 2008).  Work in the CIA model has shown that increasing systemic IL-17 
production in mice by gene transfer with an adenoviral vector expressing IL-17 
accelerates diseases onset and severity (Lubberts et al. 2001).  Complementary 
studies examining the effects of IL-17 or IL-17R blockade have demonstrated 
that inhibiting the biological activity of IL-17 reduces the severity of CIA (Lubberts 
et al. 2001; Lubberts et al. 2004; Egan et al. 2008).  Furthermore, IL17-/- mice 
exhibit much lower incidence of CIA and reduced disease severity than wildtype 
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mice (Nakae et al. 2003).  Similarly, in an LPS induced model of arthritis, disease 
incidence and severity are reduced in IL17-/- mice (Sato et al. 2006).  
Interestingly, studies in K/BxN and SKG mice indicate that IL-17 production by 
CD4+ T cells is important in arthritis development.  In the K/BxN arthritis model, 
the augmentation of serum transfer induced disease by KRN CD4+ T cells is 
inhibited by treatment with anti-IL17 antibody, indicating that CD4+ T cell 
production of IL-17 was responsible for the exacerbation autoantibody induced 
arthritis (Jacobs et al. 2009).  Additionally, Sakaguchi and colleagues have 
shown that IL-17+/+CD4+, but not IL-17-/-CD4+ T cells from SKG mice, can transfer 
arthritis upon transfer into RAG-/- mice, demonstrating that CD4+ T cell generated 
IL-17 is critical for disease induction (Hirota et al. 2007). 
 
1.5 CD4+CD25+ regulatory T cells 
 
The concept of suppressor T cells was first suggested by experiments in 
which thymectomized mice and adult rats developed autoimmune diseases that 
could be prevented by the transfer of spleen cells from healthy donors (Nishizuka 
and Sakakura 1969; Penhale et al. 1976).  In the extensive work following those 
initial observations, Treg cell populations have been more clearly defined, and 
can be very broadly separated into thymically generated or peripherally 
generated (induced) Treg cells.  Though several subpopulations of Treg cells 
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have been characterized, the best defined is the thymically generated 
CD4+CD25+ Treg cell population that comprises approximately 5 to 10 percent of 
the human and murine peripheral CD4+ T cell repertoires.  This population was 
first characterized by constitutive expression of the IL-2 receptor α chain (CD25) 
(Sakaguchi et al. 1995), which is also upregulated by activated CD4+ T cells.  
Subsequently the forkhead transcription factor Foxp3 was identified as a more 
reliable marker for CD4+CD25+ Treg cells (Fontenot et al. 2003; Hori et al. 2003), 
and Foxp3 was considered to be the “master regulator” of the CD4+CD25+ Treg 
cell lineage. 
 
However a recent set of studies has challenged the notion of Foxp3 as the 
key lineage commitment factor of CD4+CD25+ Treg cells.  Multiple groups have 
reported that a subset of cells that have developed in the absence of Foxp3 
express a genetic signature that is consistent with that of CD4+CD25+Foxp3+ 
cells, suggesting that CD4+CD25+ Treg cell lineage commitment occurs upstream 
of Foxp3 expression (Gavin et al. 2007; Hill et al. 2007; Lin et al. 2007).  
Moreover, Foxp3 expression can be transiently upregulated in activated human T 
cells, which do not acquire regulatory function (Gavin et al. 2006; Mantel et al. 
2006; Wang et al. 2007).  Nonetheless, it is clear that Foxp3 expression is critical 
for CD4+CD25+ Treg cell function, as mice lacking Foxp3 develop severe 
autoimmunity (Fontenot and Rudensky 2005; Kim et al. 2007).  Furthermore, in 
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humans, development of the autoimmune disorder IPEX has been attributed to 
mutations in the FoxP3 gene (Bennett et al. 2001; Gambineri et al. 2003). 
 
1.5.1 The role of TCR specificity in the thymic selection of CD4+CD25+ Treg cells 
 
The initial day three thymectomy experiments indicated that the thymus 
plays an important role in the generation of CD4+CD25+ Treg cells, however, the 
exact nature of the signals (e.g. TCR engagement, cytokines, co-stimulation) that 
guide the thymic development of CD4+CD25+ Treg cells remains unclear.  While 
the observation that there is overlap between the TCR repertoires of CD4+CD25+ 
Treg cells and conventional CD4+ T cells (Hsieh et al. 2004; Hsieh et al. 2006) 
suggests that other signals (e.g. cytokines, co-stimulation) likely also play a role 
in the thymic development of CD4+CD25+ Treg cells, a strong body of work 
supports a significant role for TCR interactions with self-peptides in the thymic 
selection of CD4+CD25+ Treg cells.  The key findings in support of this concept 
are presented below. 
 
 Experiments using transgenic TCRs provided the first evidence that 
CD4+CD25+ Treg cells were selected via TCR interactions with self-peptide. It 
was observed that mice containing CD4+ T cells expressing a transgenic TCR 
specific for the myelin basic protein (MBP) only developed EAE when on a RAG-/- 
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background but not in intact mice (Olivares-Villagomez et al. 1998; Van de Keere 
and Tonegawa 1998; Hori et al. 2002).  Subsequent studies showed that mice on 
an intact background did not develop disease because expression of a 
secondary TCR, resulting from endogenous α chain rearrangements, allowed for 
the selection of MBP-specific CD4+CD25+ Treg cells (Hori et al. 2002), 
suggesting a role for TCR and self-peptide interactions in CD4+CD25+ Treg cell 
selection.  Indeed, studies in other transgenic systems have shown that 
introducing the cognate antigen for the transgenic TCR onto a RAG-/- background 
results in the development of CD4+CD25+ Treg cells expressing the transgenic 
TCR (Apostolou et al. 2002; Kawahata et al. 2002; Walker et al. 2003).   
 
Work from our laboratory has further demonstrated the importance of TCR 
interactions with self peptides for the development of CD4+CD25+ Treg cells.  
Studies in TS1xHA-transgenic mice have demonstrated that CD4+ T cells 
expressing the 6.5 TCR (Kirberg et al. 1994), which confers specificity for the S1 
determinant of PR8 HA, undergo efficient CD4+CD25+ Treg cell selection in 
HA28 mice, which express PR8 HA driven by an SV40 promoter, demonstrating 
that interactions with the agonist peptide can guide CD4+CD25+ Treg cell 
development (Jordan et al. 2001).  The requirement for peptide specificity for 
CD4+CD25+ Treg cell selection appears to be quite stringent, as CD4+ T cells 
bearing a TCR with low reactivity to the S1 peptide are not selected to be 
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CD4+CD25+ Treg cells (Jordan et al. 2001).  Interestingly, while 6.5+CD4+CD25+ 
Treg cells can also be selected in other TS1xHA lineages, the numbers are lower 
than what is generated in TS1xHA28 mice, and this appears to result from 
enhanced deletion of 6.5+ thymocytes due to higher levels of HA expression in 
the thymus (Picca et al. 2006; Simons et al. 2010), indicating that lower levels of 
the cognate antigen favor more abundant CD4+CD25+ Treg cell selection. 
 
1.5.2 The role of TCR specificity in CD4+CD25+ Treg cell function 
 
TCR stimulation is required to activate CD4+CD25+ Treg cell suppressor 
function (Takahashi et al. 1998; Thornton and Shevach 1998). However, in vitro 
studies show that although CD4+CD25+ Treg cell activation is TCR specific, 
CD4+CD25+ Treg cells are able to inhibit responder CD4+ T cells of different TCR 
specificities (Takahashi et al. 1998; Thornton and Shevach 2000), indicating that 
the suppression itself is not antigen-specific.  Correspondingly, work in multiple 
murine autoimmune diseases (e.g. CIA, colitis, EAE, diabetes, gastritis) have 
shown that that the adoptive transfer of polyclonal CD4+CD25+ cells can prevent 
or ameliorate disease (Olivares-Villagomez et al. 1998; Van de Keere and 
Tonegawa 1998; Singh et al. 2001; Sarween et al. 2004; Morgan et al. 2005; 
Zwar et al. 2006; Kelchtermans et al. 2009), indicating that CD4+CD25+ Treg 
cells that are not enriched for disease-associated antigen specific cells can 
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mediate suppression of an organ specific disease.  However, there is also a 
significant body of work suggesting that antigen-specific CD4+CD25+ Treg cells 
are more effective than polyclonal CD4+CD25+ Treg cells at suppressing organ-
specific autoimmune diseases.   
 
 In the nonobese diabetes (NOD) model, the adoptive transfer of in vitro 
expanded CD4+CD25+ cells expressing the BDC2.5 TCR, which recognizes a 
pancreatic β cell islet antigen (Katz et al. 1993), into NOD.BDC2.5 mice (which 
also express the transgenic TCR) can suppress diabetes (Tang et al. 2004; 
Tarbell et al. 2004).  Using a disease transfer model in which diabetes 
development is induced by the administration of splenocytes from diabetic NOD 
mice into NOD.scid mice, Steinman and colleagues also showed that lower 
numbers of in vitro expanded antigen-specific CD4+CD25+ cells could suppress 
disease, whereas greater numbers of in vitro expanded polyclonal CD4+CD25+ T 
cells could not (Tarbell et al. 2004).  Work with induced CD4+CD25+ Treg cells 
also suggests that antigen-specific interactions are important for regulatory 
function.  TGF-β induced regulatory cells expressing the BDC-6.9 TCR can 
suppress diabetes in NOD mice, which contain their cognate antigen, but not 
NOD.C6 mice, which do not contain their cognate antigen (Tonkin et al. 2008).  It 
is possible that the inability to suppress diabetes in NOD.C6 mice may be linked 
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to poor trafficking, expansion, and/or survival at the primary site of autoimmune 
pathology. 
 
Studies in the EAE model also emphasize that CD4+CD25+ Treg cell 
specificity for the target autoantigen is important for the prevention of 
autoimmunity.  As described previously, mice expressing a transgenic TCR 
specific for the encephalotegenic MBP protein spontaneously develop EAE when 
on a RAG-deficient but not wildtype background, and the difference in disease 
development can be attributed to the absence of CD4+CD25+ Treg cells specific 
for EAE associated peptides in the RAG-/- mice (Hori et al. 2002).  In another 
model of EAE where disease is driven by the immune response to the myelin 
proteolipid protein (PLP), the difference between two strains of mice with differing 
susceptibilities to disease appears to be the enhanced representation of PLP-
peptide specific CD4+CD25+ Treg cells in the more resistant strain (Reddy et al. 
2004).  Interestingly, CD4+CD25+ cells isolated from healthy individuals can 
mediate better in vitro suppression of CD4+ T cell proliferation when stimulated 
by MBP proteins than CD4+CD25+ cells isolated from multiple sclerosis (MS) 
patients (Kumar et al. 2006), suggesting that in humans protection may also 
correlate with the presence of CD4+CD25+ Treg cells that are specific for MS-
associated peptides. 
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Studies in day 3 thymectomized mice that develop autoimmune ovarian 
disease (AOD), show that CD4+CD25+ Treg cells isolated from the draining 
lymph nodes are superior to CD4+CD25+ Treg cells isolated from non-draining 
lymph nodes at suppressing AOD (Samy et al. 2005; Samy et al. 2008).  This 
apparent enrichment for disease-specific CD4+CD25+ Treg cells in the draining 
lymph nodes was evident for other organs as well, as CD4+CD25+ Treg cells 
isolated from the lacrimal or prostate draining lymph nodes were the most 
effective at suppressing dacryoadenitis and experimental autoimmune prostatitis 
(EAP) respectively (Samy et al. 2008; Wheeler et al. 2009).  Collectively, these 
observations suggest that draining lymph nodes, which have been shown to 
uniquely present organ-specific peptides (Hoglund et al. 1999; Gagnerault et al. 
2002; Scheinecker et al. 2002), are enriched for CD4+CD25+ Treg cells that are 
specific for antigens derived from the organ.  Recent work examining the 
CD4+CD25+ Treg cell repertoires from various lymph nodes further corroborates 
the concept that regional lymph nodes may be biased towards CD4+CD25+ Treg 
cells that recognize organ-specific antigens, as Treg cells showed distinct 
patterns of TCR usage in different LNs, similar to the skewing of TCR usage 
among antigen-experienced conventional CD4+ T cells in different anatomical 
locations (Lathrop et al. 2008).   
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1.5.3  Mechanisms of CD4+CD25+ Treg cell function 
 
In spite of the clear observations that CD4+CD25+ Treg cells can suppress 
immune responses and prevent autoimmune disease, how they exert their 
regulatory function remains controversial.  Indeed, a myriad of mechanisms by 
which CD4+CD25+ Treg cells can mediate suppression have been reported.  In 
vitro studies indicate that direct cell contact between the regulatory and effector 
populations is necessary, as suppression is prevented when the two cell 
populations are separated in transwell experiments (Takahashi et al. 1998; 
Thornton and Shevach 1998).  Additional work indicates that CD4+CD25+ Treg 
cell production of cytokines such as IL-10 or TGF-β is important for their 
suppressor function (Huang et al. 2005).  Alternatively CD4+CD25+ Treg cells 
have been shown to act as a cytokine sink for cytokines such as IL-2, which can 
promote apoptosis of effector CD4+ T cells (Pandiyan et al. 2007).  It has also 
been suggested that CD4+CD25+ Treg cells may suppress immune responses by 
developing cytotoxic capabilities or modulating antigen presenting cells (APCs) 
(Kryczek et al. 2006; Shevach et al. 2006; Vignali et al. 2008).  Indeed, 
Sakaguchi and colleagues have shown that a key contribution of CTLA-4 to 
CD4+CD25+ Treg cell function may be through regulation of APCs (Wing et al. 
2008).  Interestingly, recent work has also demonstrated that CD4+CD25+ Treg 
cells acquire the ability to suppress particular T-helper (Th) lineages by co-opting 
the transcription factor pathways (IRF-4, RORγt, T-bet) that are key for the 
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differentiation of the respective Th lineage cells (Chaudhry et al. 2009; Koch et 
al. 2009; Zheng et al. 2009).  It is possible that expression of transcription factors 
specific for a certain Th lineage allows CD4+CD25+ Treg cells to acquire 
properties (e.g expression of chemokine or cytokine receptors) that allow them to 
traffic to the site of inflammation and/or compete for other soluble factors that 
may potentiate the CD4+ Th cell response. 
 
1.5.4 Plasticity of CD4+CD25+ Treg cells 
 
CD4+CD25+Foxp3+ Treg cells can produce Th-1 and Th-17 associated cytokines 
 
 Recent studies have challenged the notion of CD4+CD25+ Treg cells as a 
stable population of cells by demonstrating that under certain conditions 
CD4+CD25+ Treg cells can differentiate to acquire properties that are normally 
associated with effector CD4+ T cells.  While multiple groups have documented 
the loss of Foxp3 expression by CD4+CD25+ Treg cells (Hoffmann et al. 2006; 
Duarte et al. 2009; Komatsu et al. 2009; Murai et al. 2009; Tsuji et al. 2009; Zhou 
et al. 2009), there are also reports that CD4+CD25+ Treg cells that maintain 
Foxp3 expression can develop phenotypic properties (e.g. cytokine production) 
that are normally associated with effector CD4+ T cells.  During Toxoplasma 
gondii (T. gondii) infection, which induces a highly polarized Th-1 immune 
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response, a subset of CD4+CD25+Foxp3+ Treg cells differentiates to express the 
transcription factor T-bet and to produce IFN-γ (Oldenhove et al. 2009).  The 
acquisition of Th-1 cell properties by CD4+CD25+ Treg cells is at least partially 
dependent on a lack of IL-2 in the infectious setting, since treatment of T. gondii 
infected mice with an IL-2 α-IL-2 antibody complex that has been shown to 
enhance the biological activity of IL-2 (Boyman et al. 2006) reduces the presence 
of IFN-γ+CD4+CD25+Foxp3+ cells (Oldenhove et al. 2009). 
 
 In light of the complicated and interconnected relationship of CD4+CD25+ 
Treg cells and Th-17 cells (Bettelli et al. 2006; Veldhoen et al. 2006; Mucida et al. 
2007; Zhang et al. 2008; Zhou et al. 2008), there has been much interest in 
determining whether CD4+CD25+Foxp3+ Treg cells can differentiate to produce 
IL-17.  Several groups have shown that IL-17+CD4+CD25+Foxp3+ cells can be 
isolated from human peripheral blood (Ayyoub et al. 2009; Beriou et al. 2009; 
Voo et al. 2009).  The IL-17 producing CD4+CD25+ Treg cells also express CCR6 
(Ayyoub et al. 2009; Beriou et al. 2009; Voo et al. 2009), a chemokine receptor 
that is associated with Th-17 cells (Acosta-Rodriguez et al. 2007; Annunziato et 
al. 2007).  It appears that while IL-1β and IL-6 promote IL-17 production by 
human CD4+CD25+Foxp3+ Treg cells (Beriou et al. 2009; Voo et al. 2009), the 
presence of TGF-β in in vitro cultures is inhibitory to this differentiation process 
(Voo et al. 2009).  Interestingly, there is also evidence that stronger TCR 
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stimulation can favor IL-17 production, as a high but not low dose of α-CD3 
induced IL-17 production by CD4+CD25+Foxp3+ cells (Voo et al. 2009).  
However, despite producing IL-17, CD4+CD25+ Treg cells can inhibit responder 
CD4+ T cells in in vitro suppression assays (Beriou et al. 2009; Voo et al. 2009). 
Murine CD4+CD25+ Treg cells can also be differentiated in vitro to generate a 
population of IL-17+CD4+CD25+Foxp3+ cells (Xu et al. 2007; Osorio et al. 2008; 
Yang et al. 2008). CD4+CD25+Foxp3+ cells expressing RORγt, the transcription 
factor that governs Th-17 differentiation (Ivanov et al. 2006; Yang et al. 2008), 
can be found in mice in vivo, and while also present in the spleen are primarily 
enriched in the lamina propria and mesenteric lymph nodes (Lochner et al. 
2008). 
 
CD4+CD25+ Treg cells can lose Foxp3 expression 
 
 Recent studies have demonstrated that the expression of Foxp3, which is 
critical for maintenance of the CD4+CD25+ Treg cell phenotype (Wan and Flavell 
2007; Williams and Rudensky 2007), can be unstable in CD4+CD25+ Treg cells.  
Using Foxp3EGFP reporter mice, Hori and colleagues showed that a subset of 
CD4+EGFP+ cells transferred into RAG-/- mice or lympho-replete mice lost Foxp3 
expression, and this loss is exacerbated in the RAG-/- hosts (Komatsu et al. 
2009).  CD25 expression appeared to play a critical role in maintenance of Foxp3 
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expression, as CD25+ cells were able to better maintain Foxp3 expression than 
CD25- cells isolated from the same mice.  This observation is consistent with 
previous reports demonstrating that signaling through the IL-2R can potentiate 
Foxp3 expression (Fontenot et al. 2005; Zorn et al. 2006).  Additionally, Foxp3 
loss was most prevalent in the CD4+CD25+ Treg cells that had undergone 
extensive proliferation (Komatsu et al. 2009).  This instability of Foxp3 can also 
be seen in human CD4+CD25+ Treg cells, as prolonged in vitro stimulation and 
expansion of CD4+CD25+ Treg cells isolated from peripheral blood mononuclear 
cells results in the loss of Foxp3 expression in a subset of cells (Hoffmann et al. 
2006; Hoffmann et al. 2009).  While exposure to lymphopenia can induce loss of 
Foxp3 expression in CD4+CD25+ Treg cells, exposure to inflammation during 
autoimmune disease also contributes to the instability of Foxp3 expression 
(Murai et al. 2009; Zhou et al. 2009).  Interestingly, TCR engagement appears to 
enhance this process, as a greater percentage of CD4+CD25+ Treg cells 
expressing the BDC2.5 TCR, which is specific for a pancreatic islet antigen, lost 
Foxp3 than polyclonal CD4+CD25+ Treg cells in NOD mice (Zhou et al. 2009). 
 
 The loss of Foxp3 in CD4+CD25+ Treg cells can be prevented or reduced 
by the activity of cytokines such as TGF-β (Komatsu et al. 2009) or IL-10 (Murai 
et al. 2009), although the mechanisms by which these cytokines are acting 
remain unclear.  Interestingly, a role for IL-10 in maintaining CD4+CD25+ Treg 
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cell Foxp3 expression only becomes apparent in conditions of inflammation.  
Kronenberg and colleagues showed that during colitis, wildtype CD4+CD25+ Treg 
cells transferred into an IL10-/-RAG-/- host, or IL10Rβ-/- CD4+CD25+ Treg cells 
transferred into a RAG-/- host fail to suppress disease, which is associated with 
loss of Foxp3 expression in the CD4+CD25+ Treg cells (Murai et al. 2009).  
However, when IL10Rβ-/- CD4+CD25+ Treg cells were co-transferred with 
wildtype CD4+CD25+ Treg cells so that that RAG-/- mice did not develop colitis, 
the IL10Rβ-/- CD4+CD25+ Treg cells were able to maintain Foxp3 expression, 
indicating that IL-10 is important for the maintenance of Foxp3 expression only 
during conditions of inflammation (Murai et al. 2009). 
 
 Recent studies in both human and murine CD4+CD25+ Treg cells indicate 
that the methylation status of the Foxp3 promoter and the conserved noncoding 
sequence 2 (CNS2) is an important determinant of Foxp3 expression (Kim and 
Leonard 2007; Janson et al. 2008).  Whereas natural CD4+CD25+ Treg cells 
could be characterized by demethylation at the Foxp3 promoter and CNS2, the 
DNA sequences remained methylated in induced CD4+CD25+ Treg cells or 
conventional CD4+ T cells that had transiently upregulated Foxp3 (Baron et al. 
2007; Floess et al. 2007; Polansky et al. 2008).  Moreover, CD4+CD25+ Treg 
cells in which the CNS2 region of the Foxp3 locus has been knocked out show 
deficiencies in maintenance of Foxp3 expression when compared to wildtype 
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CD4+CD25+ Treg cells (Zheng et al. 2010).  Whereas wildtype CD4+CD25+ Treg 
cells could maintain Foxp3 expression after multiple cell divisions, CNS2-
deficient CD4+CD25+ Treg cells exhibited dramatic loss of Foxp3 expression after 
three to four cell divisions (Zheng et al. 2010).  Interestingly, work with human 
CD4+CD25+ Treg cells shows that the cells that lose Foxp3 upon repeated in 
vitro stimulation have methylated the critical regions in the Foxp3 promoter 
(Hoffmann et al. 2009). 
 
CD4+CD25+ Treg cells lose Foxp3 expression can acquire effector properties 
 
 CD4+CD25+ Treg cells that lose Foxp3 can differentiate to acquire effector 
functions. Strober and colleagues first showed that CD4+GFP+ cells purified from 
Foxp3EGFP reporter mice could differentiate to generate both Foxp3+ and Foxp3- 
IL-17 producing cells when cultured in vitro in the presence of IL-6 (Xu et al. 
2007).  Subsequently other groups have also demonstrated that CD4+CD25+ 
Treg cells can lose Foxp3 and acquire the ability to produce IL-17, and suggest 
that the cytokines IL-6, IL-1, and IL-23 play important roles in this process 
(Osorio et al. 2008; Yang et al. 2008).  The dichotomy between CD4+CD25+ Treg 
and Th-17 cells appears to be explained by antagonistic interactions between the 
lineage specific transcription factors Foxp3 and RORγt (Yang et al. 2008; Zhang 
et al. 2008; Zhou et al. 2008).  Although a great deal of focus has been placed on 
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the conversion of CD4+CD25+ Treg cells to Th-17 cells, it has also been shown 
that CD4+CD25+ Treg cells that lose Foxp3 expression can acquire the ability to 
produce other cytokines such as IL-2 and IFN-γ (Duarte et al. 2009; Hoffman et 
al. 2009; Komatsu et al 2009; Murai et al 2009; Zhou et al 2009).  
 
 Upon transfer into T cell deficient mice, CD4+CD25+ Treg cells can lose 
Foxp3 and differentiate into T follicular helper (TFH) cells, which promote germinal 
center formation and IgA secretion by B cells, in the Peyer’s patches (Tsuji et al. 
2009).  Differentiation into TFH cells, but not Foxp3 downregulation, required B 
cell interactions (Tsuji et al. 2009), indicating that environmental signals that do 
not contribute to Foxp3 downregulation can influence the differentiation of 
CD4+CD25+ Treg cells that have lost Foxp3 expression.  The de-differentiation of 
CD4+CD25+ Treg cells can also have overtly negative physiological 
consequences.  In the transfer colitis model, loss of Foxp3 by CD4+CD25+ Treg 
cells results in a failure to prevent disease (Murai et al. 2009).  Work in the NOD 
mouse model of diabetes has demonstrated that the loss of Foxp3 expression in 
CD4+CD25+ Treg cells can directly contribute to disease pathogenesis, as the 
adoptive transfer of ex-Treg cells (CD4+CD25+Foxp3+ cells that no longer 
express Foxp3) into NOD.RAG-/- mice can induce diabetes development (Zhou et 
al. 2009). 
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1.6 CD4+CD25+ Treg cells in human arthritis 
 
In light of the compelling evidence that CD4+CD25+Foxp3+ Treg cells play 
an active role in preventing the spontaneous development of systemic 
autoimmunity, many recent studies have aimed at determining whether some 
deficits in CD4+CD25+ Treg cell activity might contribute to the development of 
autoimmune diseases such as RA.  Interestingly, many of these studies have 
reached the seemingly paradoxical conclusion that autoimmune arthritis can 
develop despite the presence of CD4+CD25+ Treg cells.  For example, it appears 
that CD4+CD25+ Treg cells can be enriched in arthritic patients, since increased 
frequencies of CD4+CD25+ T cells have been found in synovial fluid (i.e. the 
primary disease site) (de Kleer et al. 2004; Mottonen et al. 2005; Ruprecht et al. 
2005; Cao et al. 2006; Lawson et al. 2006) and in some cases also systemically 
in the peripheral blood of arthritic patients (Han et al. 2008).  Indeed, an 
enhanced representation of CD4+CD25+ Treg cells in the joints and synovial fluid 
of affected individuals has been observed in patients with RA, with juvenile 
idiopathic arthritis (JIA), and with other rheumatic diseases in which arthritis is a 
secondary manifestation of disease (de Kleer et al. 2004; Mottonen et al. 2005; 
Ruprecht et al. 2005; Cao et al. 2006; Lawson et al. 2006; Han et al. 2008).  
Identifying CD4+CD25+ Treg cells based only on CD25 expression is limiting, 
however, in that it may also detect activated CD4+ T cells that have upregulated 
the IL2Rα chain.  However, analysis of Foxp3 mRNA and protein expression 
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supported the conclusion that the CD4+CD25bright population isolated from RA 
patients was indeed enriched for Treg cells (de Kleer et al 2004; Ruprecht et al. 
2005; Cao et al. 2006).  A potential explanation for the enrichment of CD4+CD25+ 
Treg cells in arthritic joints is that the expression of specific patterns of 
chemokine receptors leads to preferential trafficking of CD4+CD25+ Treg cells to 
the disease site(s).  Studies of human peripheral blood CD4+CD25+ Treg cells 
have shown that they express certain chemokine receptors, such as CCR4, and 
studies of mouse CD4+CD25+ Treg cells indicated that there are many different 
subsets of chemokine receptor expression on Treg cells, that could promote 
trafficking to specific locations (Iellem et al. 2001; Wei et al. 2006). A comparison 
of CD4+CD25+ T cells from the synovial fluid and peripheral blood of patients with 
active RA showed a significant enrichment in the synovial fluid of CD4+CD25+ 
Treg cells expressing the chemokine receptors CCR4, CCR5, and CXCR4 which 
are associated with migration to sites of inflammation (Jiao et al. 2007).  
Additionally, comparison of the chemokine profiles of dendritic cells and synovial 
tissue from RA patients and healthy individuals indicated that certain chemokines 
are enriched during RA, potentially resulting in the preferential recruitment of a 
variety of immune system cells, including CD4+CD25+ Treg cells (Radstake et al. 
2005; Wei et al. 2006).  Thus in RA patients, disease develops not only despite 
the presence of CD4+CD25+ Treg cells, but in spite of an enrichment of the 
CD4+CD25+ Treg cells at a primary site of autoimmune pathology.  
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These observations raise the question of whether the CD4+CD25+ Treg 
cells that are present in arthritic patients are perhaps dysfunctional, or are 
functional and are either unable to prevent disease, or are modifying it in some 
manner.  There is evidence for both effective and dysfunctional CD4+CD25+ Treg 
cell activity in disease settings. Support for the beneficial effects of CD4+CD25+ 
Treg cells that localize in arthritic joints arose in studies of patients with JIA, 
where greater numbers of CD4+CD25+ T cells were found in patients with 
persistent-oligoarticular JIA (which is a relatively mild form of the disease) than in 
patients with the more severe extended-oligoarticular JIA (de Kleer et al. 2004). 
Additionally, CD4+CD25+ Treg cells isolated from patients with the milder form of 
JIA expressed higher levels of Foxp3 mRNA, which have been correlated with 
better suppressor function, than did CD4+CD25+ Treg cells from patients with 
more severe disease (de Kleer et al. 2004).  Even within individual JIA patients, 
there appeared to be a divergence of CD4+CD25+ Treg cell function based on the 
location from which the CD4+CD25+ Treg cells were isolated.  Results of in vitro 
suppression assays indicated that CD4+CD25+ T cells from the synovial fluid of 
JIA patients were more effective suppressors than those isolated from the 
peripheral blood, suggesting that the CD4+CD25+ Treg cells at the primary 
disease site possessed more potent regulatory function (de Kleer et al. 2004; 
Ruprecht et al. 2005).  From a clinical standpoint, it has also been reported that 
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the duration of remission following corticosteroid treatment in JIA patients 
showed a positive correlation with the number of CD4+CD25+ Treg cells present 
in the synovial fluid (de Kleer et al. 2004).  Thus, in JIA patients there seemed to 
be a correlation between an increased frequency of CD4+CD25+ Treg cells and a 
reduction in disease severity, with the possibility that more effective Treg cells 
localize to the joints and synovial fluid. 
 
The alternative concept of dysfunctional CD4+CD25+ Treg cells in RA has 
been supported by findings that Treg cells isolated from RA patients exhibit 
reduced suppressor function (Ehrenstein et al. 2004; Valencia et al. 2006).  Much 
of this work has examined the possible effects of the inflammatory environment 
in RA on CD4+CD25+ Treg cell function.  Several groups have shown that 
CD4+CD25+ Treg cells isolated from RA patients post-Infliximab (anti-TNF-α) 
treatment show improved regulatory activity in in vitro suppression assays 
(Ehrenstein et al. 2004; Valencia et al. 2006; Nadkarni et al. 2007). CD4+CD25+ 
T cells isolated from patients with active RA, pre-Infliximab treatment, were able 
to suppress the in vitro proliferation, but not cytokine production, of responder 
CD4+ T cells. However, after Infliximab treatment, CD4+CD25+ Treg cells 
originating from RA patients acquired the ability to suppress responder cytokine 
production (Ehrenstein et al. 2004).  The improved suppressive activity of the 
CD4+CD25+ Treg cells also correlated with increased levels of Foxp3 mRNA, and 
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correspondingly, it has been shown that treatment of healthy donor Treg cells 
with TNF-α leads to a reduction in Foxp3 expression and loss of suppressor 
function (Valencia et al. 2006).  Other in vitro work has shown that addition of 
cytokines such as IL-2, IL-7, and IL-15 to suppression assays can abrogate 
CD4+CD25+ Treg cell function, suggesting that multiple cytokines that may be 
elevated in RA patients can negatively affect Treg cell function (Ruprecht et al. 
2005; Valencia et al. 2006; van Amelsfort et al. 2007).  
 
There is also work suggesting that anti-TNF-α treatment may lead to the 
induction of peripheral CD4+CD25+ Treg cells rather than an improvement in the 
function of pre-existing Treg cells (Nadkarni et al. 2007).  After Infliximab 
treatment, an increased percentage of CD4+Foxp3+ cells was observed in the 
peripheral blood of active RA patients.  Corresponding in vitro studies showed 
that upon culture with Infliximab, a subset of CD4+CD25- T cells from RA patients 
expressed Foxp3, which could be prevented by TGF-β blockade.  Interestingly, 
this increase in Foxp3 expressing cells was not observed when CD4+CD25- T 
cells from healthy donors were cultured with Infliximab (Nadkarni et al. 2007).  
The lack of Foxp3 induction in conventional CD4+ T cells from healthy individuals 
upon Infliximab treatment suggests that not only CD4+CD25+ Treg cells, but also 
effector CD4+ T cells from RA patients exhibit phenotypic changes in response to 
the inflammatory environment.  Indeed, there is work suggesting that 
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conventional CD4+ T cells isolated from the synovial fluid of RA patients are 
refractory to suppression by CD4+CD25+ Treg cells (de Kleer et al. 2004; van 
Amelsfort et al. 2007).  While these studies of CD4+CD25+ T cells in RA have 
predominantly focused on the possibility of detrimental effects of the 
inflammatory environment on CD4+CD25+ Treg cell function, more recent work 
has shown that Treg cells from RA patients can exhibit deficiencies in CTLA-4 
regulation that may also affect their suppressor capabilities (Flores-Borja et al. 
2008).  It has also been shown that higher percentages of CD4+CD25+Foxp3+ T 
cells and monocytes from RA patients express GITR and GITR-L respectively 
than in healthy donors (Han et al. 2008).  Ligation of GITR has been linked to 
abrogration of CD4+CD25+ Treg cell function (Shimizu et al. 2002; Ji et al. 2004), 
suggesting another possible mechanism by which Treg cells might be rendered 
dysfunctional in RA patients. 
 
1.7 CD4+CD25+ Treg cells in mouse models of arthritis 
 
Studies in multiple mouse models of inflammatory arthritis have indicated 
that CD4+CD25+ Treg cells are capable of modifying disease, and the role of 
Treg cells has been most extensively studied in the collagen-induced and K/BxN 
arthritis models.  As seen in human arthritis, CD4+CD25+ Treg cells can be found 
in the synovial fluid, joints, and draining lymph nodes of arthritic mice (Morgan et 
 
 31 
al. 2005; Gonzalez-Rey et al. 2007; Nguyen et al. 2007). CD4+CD25+ T cells 
isolated from arthritic mice are capable of exerting suppressor function in in vitro 
assays (Kang et al. 2008; Monte et al. 2008), although in some situations they 
have been found to be less functional than their counterparts in healthy mice 
(Manoury-Schwartz et al. 1997). CD4+CD25+ T cells from IFN-γ receptor 
knockout mice, which develop accelerated and more severe CIA (Manoury-
Schwartz et al. 1997; Vermeire et al. 1997), exhibit less potent suppressive 
activity in vitro and express lower levels of Foxp3 mRNA, akin to the effects of 
TNF-α on Treg cells seen in RA patients (Kelchtermans et al. 2005).  Additional 
work suggested that in the absence of IFN-γ, other cytokines such as IL-17 are 
unchecked and contribute to exacerbated disease (Chu et al. 2007), suggesting 
that the altered and perhaps more severe inflammatory environment in the IFN-γ 
receptor knockout mice is affecting the phenotype and function of CD4+CD25+ 
Treg cells. 
 
 Work examining the impact of CD4+CD25+ Treg cell deficiency on arthritis 
development, achieved by genetic means or antibody depletion, has provided 
evidence that CD4+CD25+ Treg cells indeed modulate the autoimmune response 
in inflammatory arthritis.  K/BxN mice, which develop spontaneous inflammatory 
arthritis initiated by a CD4+ T cell response to a GPI peptide, have been crossed 
to Foxp3-scurfy (Foxp3-sf) mice to determine how a congenital absence of 
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CD4+CD25+Foxp3+ Treg cells affects disease development.  K/BxN.Foxp3-sf 
mice were found to develop an accelerated and more severe disease than K/BxN 
mice containing CD4+CD25+ Treg cells, suggesting that while the Treg cells do 
not ultimately prevent arthritis, their activity is affecting disease pathogenesis and 
severity (Nguyen et al. 2007).  These mice did not suffer from the multi-organ 
autoimmunity associated with Foxp3-sf mice, presumably because the TCR 
repertoire was restricted by expression of the transgenic TCR.  In contrast to the 
effects of a genetic deficiency in CD4+CD25+ Treg cells, CD4+CD25+ T cell 
depletion by antibody treatment did not appear to affect arthritis development in 
K/BxN mice, as neither disease onset nor severity were affected (Kang et al. 
2008).  However, CD4+CD25+ T cell depleted K/BxN mice exhibited more 
extensive lymphocyte infiltration into other organs and also an increase in serum 
anti-dsDNA antibody levels, indicating that the endogenous CD4+CD25+ Treg 
cells are able to modulate other aspects of an autoimmune response even as 
arthritis develops (Kang et al. 2008).  In the CIA model, depletion of CD4+CD25+ 
T cells by antibody treatment did lead to increased disease severity (Morgan et 
al. 2003; Kelchtermans et al. 2005). The effect on arthritis development could be 
reversed by transferring CD4+CD25+ T cells into Treg cell depleted mice, 
suggesting that while the Treg cells are not able to prevent disease development, 
they are reducing severity (Morgan et al. 2003).  
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 Complementary studies involving the transfer of exogenous CD4+CD25+ T 
cells into pre-arthritic mice also suggest that Treg cells are capable of modifying 
arthritis development.  Transferring pre-activated CD4+CD25+ T cells from 
healthy mice or Foxp3-transduced CD4+ T cells ameliorated disease in the CIA 
model (Morgan et al. 2005; Ohata et al. 2007; Kelchtermans et al. 2009).  
However, there appeared to be a limited time frame in which transferred Treg 
cells could modulate arthritis severity. CD4+Foxp3+ T cells were best at 
ameliorating CIA when they were transferred prior to the primary immunization 
with collagen. At later time points, such as after a secondary immunization, a 
greater number of transferred Treg cells was required to achieve a comparable 
reduction in disease severity, and if transferred after the booster immunization 
the Treg cells had no effect on arthritis development (Ohata et al. 2007).  It has 
been shown that as soon as one day post transfer, CD4+CD25+ T cells that have 
been injected systemically can be found in the draining lymph node, synovial 
fluid, and synovial tissue, indicating that the cells are trafficking to the disease 
site (Morgan et al. 2005).  Interestingly CD4+CD25+ T cell transfers were more 
effective at modifying disease severity when the cells were injected systemically 
rather than directly into the joints, raising questions about how and where the 
Treg cells are acting to modulate arthritis (Ohata et al. 2007). Together, the 
results of depletion and addition of Treg cells in multiple mouse models of 
inflammatory arthritis suggest that functional CD4+CD25+ Treg cells are present 
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and able to modulate disease severity and other aspects of the immune 
response (such as lymphocyte infiltration into different tissues and the generation 
of autoantibodies), but that their activity can fail to prevent the development of 
autoimmune arthritis.  
 
There is conflicting data as to whether CD4+CD25+ Treg cells are 
modifying the immune response in an antigen-specific manner, and the 
mechanisms by which Treg cells affect arthritis development remain unclear.  In 
K/BxN.Foxp3-sf mice, there is an accelerated accumulation of anti-GPI 
antibodies in the absence of CD4+CD25+ Treg cells (Nguyen et al. 2007).  There 
is additional evidence for antigen-specific Treg cell-mediated changes in the CIA 
model, with observations of increased collagen-specific T and B cell responses 
after Treg cell depletion, as well as a reduction in collagen-specific antibodies 
after transfer of exogenous Treg cells (Morgan et al. 2003; Ohata et al. 2007).  
However, there is also data showing no alterations in the collagen-specific 
immune response upon manipulation of CD4+CD25+ Treg cells in CIA (Morgan et 
al. 2005; Kelchtermans et al. 2009). The same study did however find decreased 
amounts of TNF-α and IL-6 in the serum of treated mice, which are two cytokines 
that can contribute to arthritis development and have been shown to interfere 
with Treg cell function (Keffer et al. 1991; Pasare and Medzhitov 2003; 
Ehrenstein et al. 2004; Hata et al. 2004; Sawa et al. 2006; Valencia et al. 2006; 
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Nadkarni et al. 2007).  Thus another potential mechanism by which CD4+CD25+ 
Treg cells may affect arthritis development is by altering the inflammatory 
environment. Indeed it appears that the balance of cytokines can play an 
important role in arthritis development and pathogenesis.  Recently, IL-35 has 
been identified as an effector cytokine of CD4+CD25+ Treg cells, and separate 
work has shown that IL-35 treatment reduces disease severity in CIA, possibly by 
reducing IL-17 levels (Collison et al. 2007; Niedbala et al. 2007).  Thus, IL-35 
production by Treg cells may be able to modulate arthritis development by 
altering the inflammatory environment.  Other work also suggests that 
CD4+CD25+ Treg cells may induce changes in the cytokine environment that lead 
to inhibition of osteoclastogenesis.  In an in vitro culture system, high levels of 
cytokines that can inhibit osteoclastogenesis were found and accompanied by 
reduced osteoclast formation when CD4+CD25+ Treg cells were present 
(Kelchtermans et al. 2009). Given that endogenous CD4+CD25+ Treg cells are 
present in the joints, and exogenously administered CD4+CD25+ Treg cells can 
traffic to the disease site one to two days post transfer, it is possible then that 
CD4+CD25+ Treg cells may reduce osteoclastogenesis in the joints and thereby 
modify disease severity. 
 
 The studies presented in the following chapters further examine the role of 
CD4+CD25+ Treg cells in a mouse model of spontaneous arthritis in which 
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disease is driven by CD4+ T cell recognition of a single systemically presented 
peptide.  We also examine how specificity for the target antigen affects the ability 
of CD4+CD25+ Treg cells to suppress arthritis development. 
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Chapter 2: Materials and Methods 
2.1 Transgenic mice 
 
TS1 mice express a transgenic TCR (Vα4, Vβ8.1/2) that is specific for the 
S1 determinant of influenza virus A/PR/8/34 (PR8) HA presented in the context 
of MHC Class II I-Ed and can be identified by the monoclonal antibody 6.5 
(Kirberg et al. 1994).  TS1(SW) mice express a transgenic TCR (Vα8.3, Vβ10) 
that is specific for an analog of S1 peptide that is derived from the influenza virus 
A/SW/33 strain (Jordan et al. 2001). TS2 mice encode a transgenic TCR (Vβ8.3) 
that is specific for the S2 determinant of PR8 HA presented in the context of 
MHC Class II I-Ad (Scott et al. 1994). 
 
HACII mice express the full length PR8 HA transgene driven by an MHC 
Class II I-Eα promoter (Kouskoff et al. 1993; Reed et al. 2003).  HA28 mice 
express a truncated form of PR8 HA (the NH2-terminal 237 amino acids) driven 
by the SV40 early promoter-enhancer region (Cerasoli et al. 1995). 
 
PevSWHA mice (hereafter referred to as PevSW mice) were created by 
linking DNA encoding the HA protein from influenza virus A/SW/33 (SWHA) to 
the human β-globin locus control region.  The SWHA protein contains an analog 
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of the S1(110-120) determinant of PR8 HA, described as the S1(SW) peptide.  
S1(SW) peptide contains two amino acid substitutions relative to the S1 peptide 
from PR8 HA: (1) at position 113 R  K and (2) at position 120 E  T. 
 
C.Cg-Foxp3tm2(EGFP)Tch/J mice (Haribhai et al. 2007), hereafter referred to 
as Foxp3EGFP mice, were purchased from Jackson Laboratories (Bar Harbor, 
ME).  Foxp3EGFP mice were bred to TS1 or HA28 transgenic mice to generate 
TS1.Foxp3EGFP and HA28.Foxp3EGFP mice.  Expression of the EGFP allele was 
determined by PCR and confirmed by flow cytometry. 
 
TCRα-/- mice (Mombaerts et al. 1992) were purchased from Jackson 
Laboratories and bred to homozygosity for the H-2d haplotype. TCRα-/- mice were 
then backcrossed four generations with BALB/c mice before breeding with HA 
transgenic mice. 
 
All mice were bred and maintained on a BALB/c background.  BALB/c 
mice were purchased from Taconic (Germantown, NY).  Mice were maintained in 
specific pathogen free conditions in the Wistar Institute Animal Facility 
(Philadelphia, PA), and all experiments were conducted under protocols 
approved by the Wistar Institute Institutional Animal Care and Use Committee 
(IACUC). 
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2.2 Genotyping of transgenic mice 
 
All transgenic mice were genotyped upon weaning at three to four weeks 
of age.  Tail samples (approximately 1 to 2 mm) were digested overnight at 55° C 
in 180 µl of tail lysis buffer.  Digestion was stopped by heat inactivation at 95° C 
for 10 minutes.  Samples were then used as template DNA for PCR.  PCR was 
performed in 50 µl reactions containing 5 µl 10X PCR amplification buffer, 50 ng 
of appropriate primers, 2 µl of 5 mM dNTPs, 1 unit of Taq polymerase, and 3 µl 
of tail DNA.  PCR reactions were run in a thermocycler for 35 cycles.  For HA and 
TCR transgene tests each cycle consisted of a 1 minute annealing period at 50° 
C (for HA transgene tests) and 65° C (for TCR transgene tests), a 2 minute 
elongation period at 72° C, and a 1 minute denaturation period at 94° C.  An 
additional annealing and elongation step was performed prior to the end of the 
amplification cycles.  For EGFP transgene tests, each cycle consisted of a 3 
minute denaturation period at 94° C, a 1 minute annealing period at 60° C, and a 
1 minute elongation period at 72° C.  An additional elongation step was 
performed prior to the end of amplification cycles.  PCR products were visualized 
on a 1 % agarose gel containing ethidium bromide. 
 
 Primers for genotyping were purchased from Integrated DNA 
Technologies (Coralville, IA).  Primer sequences are shown below. 
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HA 
HA uni-5’   5’-   CCA GCA GAT TTC ATC GAC TAT G  -3’   
HA uni-3’   3’-   CCA GTA ATA GTT CAT CCT CCC   -3’ 
 
TS1 
V2.1 CDR3   5’-   GAA CTG CTC AGC ATA ACT CCC   -3’ 
VβCROSS5’   5’-   GAG GCT GCA GTC ACC CAA AG   -3’ 
 
TS1K 
TS1K β JUNCTION  5’-   CTC AGC ACC CCT GCC AGC CTG   -3’ 
TS1K β Vgene  5’-   ATG GGC TGT AGG CTC CTA AGC   -3’ 
 
TS2 
T2-5-5 CDR3  5’-   CGA AGT ACT GTT CAG CCC AGT   -3’ 
Vβ8 CROSS5’  5’-   GAG GCT GCA GTC ACC CAA AG   -3’ 
 
GFP 
FORWARD   5’-   GCG TAA GCA GGG CAA TAG AGG   -3’ 
REVERSE   5’-   GCA TGA GGT CAA GGG TGA TG   -3’ 
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2.3 Arthritis assessment in TS1xHACII mice 
 
TS1xHACII mice were assessed weekly for visible swelling in the four 
distal joints from post-weaning at 5 to 6 weeks of age until 14 to 15 weeks of age.  
Limbs were also measured with a digital caliper (Fisher Scientific).  Mice were 
assigned a score based on the following index: 0 – no swollen limbs, 1 – one 
swollen limb, 2 – two swollen limbs, 3 – three swollen limbs, and 4 – swelling in 
all four limbs. 
 
2.4 Flow cytometry 
 
Flow cytometry was performed on single cell suspensions prepared from 
the lymph nodes (axillary, brachial, cervical, inguinal, mesenteric, and popliteal) 
or spleens.  1x106 to 3x106 cells were plated in V bottom plates and washed with 
FACS buffer and stained in 100 to 200 µl of FACS buffer with diluted antibodies 
at 4° C for 30 minutes.  The following antibodies were used: anti-CD4 
PerCpCy5.5, PECy7, APC, APCeF780 (L3T4); anti-CD25 PE, PerCpCy5.5 
(PC61); anti-CD44 Alexa700 (IM7); anti-CD62L PerCpCy5.5 (MEL14); anti-CD69 
PE (H1.2F3); anti-CTLA PE (UC10-4B9); anti-GITR PECy7 (DTA-1); anti-IFN-γ 
PE, PECy7, APC (XMG1.2); anti-IL-17 PE, APC (eBio17B7); anti-Thy1.1 
PerCpCy5.5 (HIS51); anti-Vα8.3 FITC (B21.14), anti-Vβ10 PE (B21.5); and anti-
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Vβ8.3 PE (1B3.3).  Anti 6.5-biotin (Kirberg et al 1994) was detected using 
Streptavidin-APC (eBioscience, San Diego, CA) or Streptavidin-Qdot655 
(Invitrogen, Carlsbad CA).  Intracellular Foxp3 was detected using anti-Foxp3 PE 
or eF450 (FJK-16s) according to the manufacturer’s protocols (eBioscience).  In 
some experiments dead cells were identified using the LIVE⁄DEAD® Fixable 
Aqua Dead Cell Stain Kit from Invitrogen.  Greater than 100,000 events per 
sample were collected on FACS Calibur or FACS LSR II flow cytometers (BD 
Biosciences, San Jose, CA), and data was analyzed using FlowJo software 
(Treestar, Ashland, OR). 
 
2.5 Cell sorting 
 
Single cell suspensions were prepared from lymph nodes (axillary, 
brachial, cervical, inguinal, mesenteric) or spleens.  Spleens were subjected to 
red blood cell (RBC) lysis prior to antibody staining.  Cells were resuspended at 
1x107 cells/ml in FACS buffer (NaN3 deficient) and stained with the appropriate 
antibodies at 4° C for 30 minutes.  Cells were washed twice.  When necessary 
the antibody staining step was repeated with secondary reagents.  Cells were 
resuspended at 5x107 cells/ml in preparation for cell sorting.  Sorted cells were 
collected into a 1:1 mixture of Iscove’s Modified Dulbecco’s Medium (IMDM; 
Mediatech, Inc., Herndon, VA) and fetal bovine serum (FBS; Gemini Bio-
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products, West Sacramento, CA).  Cells were sorted at the Wistar Institute’s cell 
sorting facility using a DakoCytomation MoFlo (DakoCytomation) or a BD 
FACSAria cell sorter (BD Biosciences). 
2.6 anti-IL-17 antibody treatment of TS1xHACII mice 
 
TS1xHACII mice were treated with an anti-IL17A antibody (clone M210, 
Amgen), hereafter referred to as anti-IL17, or a Rat IgG2a isotype control 
antibody.  The antibody treatment regimen was three intraperitoneal injections of 
150 µg of either anti-IL17 or the isotype control antibody per mouse three times 
per week (Monday, Wednesday, Friday).  All mice were treated from weaning for 
a duration of nine weeks.  
 
2.7 MACS purification of CD4+ cells 
 
Single cell suspensions were prepared from lymph nodes (axillary, 
brachial, cervical, inguinal, mesenteric) or spleens.  Cells were resuspended at 
1x107 cells/ml in FACS buffer (NaN3 deficient) and stained with biotinylated 
antibodies to B220, CD8, and MHC Class II at 4° C for 30 minutes.  Cells were 
washed twice, resuspended at 2x108 cells/ml, and then incubated with 
streptavidin bound microbeads (Miltenyi Biotec, Auburn, CA) at 4° C for an 
additional 30 minutes.  Cell suspensions were run through a CS column (Miltenyi 
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Biotec, Auburn, CA) attached to a magnet.  The purity of cells collected in the 
flow through were analyzed by flow cytometry.  CD4+ cell purity was consistently 
≥ 90 percent. 
 
2.8 CFSE labeling 
 
Cells were resuspended at 1x107 cells/ml into sterile serum-free 
Dulbecco’s Phosphate Buffered Saline (DPBS) (Mediatech, Manassas, VA).  A 
1:1000 dilution of CFSE (Invitrogen) was added to the cell suspension and 
incubated at room temperature for approximately 3.5 to 4 minutes.  At end of the 
incubation, an equal volume of FBS was added to the cell suspension to quench 
the CFSE-labeling reaction.  Cells were then washed and resuspended into 
either sterile serum-free DPBS for adoptive transfer experiments, or into 
supplemented IMDM with 10% FBS and 100 µl/ml gentamycin for in vitro culture 
experiments. 
 
2.9 Adoptive transfers 
 
Cells purified by cell sorting were washed once and then resuspended at 
1x107 cells/ml in sterile DPBS and injected into the tail veins of recipient mice.  In 
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some experiments donor cells were labeled with CFSE prior to the adoptive 
transfers. 
 
2.10 Analysis of in vivo CD4+CD25+ Treg cell proliferation 
 
Sorted CD4+CD25+ cells were CFSE-labeled and adoptively transferred 
into recipient mice.  Three to ten days post-transfer systemic LNs (axillary, 
brachial, cervical, inguinal, mesenteric) were isolated and single cell suspensions 
were prepared and stained with the appropriate antibodies.   Cells were analyzed 
by flow cytometry to determine proliferation as defined by CFSE dilution. 
 
2.11 Intracellular cytokine staining 
 
Cells were plated at 1x106 to 4x106 cells/ml in supplemented IMDM with 
10% FBS and 100 µl/ml gentamycin and stimulated with 50 ng of PMA (Sigma-
Aldrich, St. Louis, MO), 1µM ionomycin (Sigma-Aldrich), and a 1:1000 dilution of 
Brefeldin-A (eBiosciences) for four hours.  At the end of incubation, cells were 
isolated and stained for appropriate antibodies as described previously.  Cytokine 
production was analyzed by flow cytometry. 
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2.12 Unfractionated LN cultures 
 
Systemic LN (axillary, brachial, cervical, inguinal, mesenteric) cells were 
plated at 2x106 to 5x106 cells/ml in supplemented IMDM with 10% FBS and 100 
µl/ml gentamycin and cultured for three to four days at 72° C.  Culture 
supernatants were collected for analysis by ELISA or Luminex. 
 
2.13 In vitro CD4+CD25+ Treg cell suppression assays 
 
CFSE-labeled MACS-purified CD4+ T cells from TS1 or TS2 mice were 
cultured with either 0.1 µg/ml of soluble anti-CD3 (145-2C11), 0.3 or 1 µM of S1 
peptide (110-120; SFERFEIFPKE), 1 µM of S2 peptide (HNTNGVTAACSHE), or 
HACII splenocytes.  Irradiated BALB/c splenocytes were used as feeder cells 
when soluble anti-CD3 or peptide was used.  Purified CD4+CD25+ cells from 
TS1xHA28, TS1xHACII, or TS1(SW)xPevSW mice were added at a 1:2 Treg cell 
to responder cell ratio. CD4+CD25+ cells were stimulated with either 0.1 µg/ml of 
soluble anti-CD3, titrated doses of S1 peptide (0.3 or 1 µM), 1 µM of S1(SW) 
peptide (SFEKFEIFPKT), or HACII splenocytes.  Cells were resuspended in 
supplemented IMDM with 10% FBS and 100 µl/ml gentamycin in 96- or 24-well 
flat bottom plates and cultured for three to four days at 36° C.  Cells were plated 
at a final volume of 4x106 to 6x106 cells/ml.  At the end of the culture period 
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responder CD4+ T cell proliferation (based on CFSE profiles) and/or cytokine 
production was analyzed by flow cytometry. 
 
2.14 ELISA 
 
ELISAs were performed on supernatants collected from unfractionated LN 
cultures.  Cytokine antibodies and standards were purchased from eBioscience 
and ELISAs were conducted according to the manufacturer’s instructions. 
Purified anti-IL17A (clone eBioTC11-18H10.1) was used as the capture antibody 
and biotinylated anti-IL17A (eBio17B7) was used as the detection antibody.  
ExtrAvidin® alkaline phosphatase was purchased from Sigma-Aldrich. 
 
2.15 Luminex 
 
Luminex analysis was run on unfractionated LN cell culture supernatants 
using Milliplex kits (Millipore, Billerica, MA).  Assays were conducted by the 
University of Pennsylvania Human Immunology Core. 
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2.16 Statistical analyses 
 
Statistical analyses were conducted using unpaired two-tailed Student’s t-
tests assuming unequal variances.  Results of arthritis incidence were analyzed 
using two-tailed Fisher’s exact test. p ≤ 0.05 was considered significant. 
 
2.17 Solutions 
 
Phosphate buffered saline (PBS): 2.2 mM NaH2PO4 [Anhydrous], 12.6 mM 
Na2HPO4 [Anydrous], 6.2 mM KCl, and 170mM NaCl (solution pH 7.4) 
 
FACS buffer: PBS, 2 % fetal bovine serum (FBS; Gemini Bio-products, West 
Sacramento, CA), 0.08 NaN3 
 
Supplemented Iscove’s Modified Dulbecco’s Medium (IMDM; Mediatech, Inc., 
Herndon, VA), 10% FBS, 5x10-5 M 2-mercaptoethanol, 5 µg/ml iron saturated 
human transferrin, and 100 µl/ml gentamycin 
 
RBC lysis buffer: 0.15 M NH4Cl and 0.01 M Tris (pH 7.5) 
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ELISA developing buffer: 0.1 M NaHCO3, 0.001 M MgCl2 (pH 9.8) and 1 mg/ml 
PNPP (Sigma-Aldrich) 
 
Tail lysis buffer: 50 mM Tris (pH 8.0), 50 mM KCl, 2.5 mM EDTA, 0.45 % Tween 
20, 0.45% NP-40 
 
10x PCR amplification buffer: 0.5M KCl, 0.1M Tris (pH 8.4), 25mM MgCl2-6H2O 
 
TE: 0.01 M Tris-HCl (pH 8.0) and 0.01 M EDTA 
 
5 mM dNTPs: 5 mM dATP, 5 mM dTTP, 5 mM, dCTP, 5 mM dGTP in TE 
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Chapter 3: Polyclonal CD4+CD25+ Treg cells can prevent arthritis 
development in TS1xHACII mice 
3.1 Introduction 
 
TS1 mice express a TCR transgene that recognizes the major I-Ed-
restricted T cell determinant from the influenza virus PR8 HA (termed S1) and 
can be detected using the anti-clonotypic mAb 6.5 (Kirberg et al. 1994).  HACII 
mice express a transgene encoding the PR8 HA under the control of a MHC 
class II I-Eα promoter (Reed et al. 2003).  The majority of TS1xHACII mice, 
which co-express S1-specific 6.5+CD4+ T cells and HA as a self-antigen, develop 
spontaneous inflammatory arthritis that is driven by recognition of the S1 peptide 
by 6.5+CD4+ T cells, since TS1xHACII mice on a RAG-/- background develop 
disease (Rankin et al. 2008).  Moreover, TS1xHACII mice on a JH-/- background, 
which lack mature circulating B cells, also develop arthritis, demonstrating that 
neither antibody production nor antigen presentation by B cells is required for 
disease development.  Despite extensive deletion of 6.5+ thymocytes, some 
6.5+CD4+ T cells reach the periphery of TS1xHACII mice, interact with S1 peptide 
presented by antigen presenting cells, and gradually accumulate in number. 
TS1xHACII mice develop enlarged popliteal LNs, which drain the lower joints, 
and increased cytokine (e.g. IL-17, IFN-γ, IL-6, TNF-α) production by systemic 
 
 51 
LN cells (Rankin et al. 2008).  Additionally, arthritic TS1xHACII mice contain 
CD4+CD25+Foxp3+ cells, including a population that is specific for the target 
antigen S1 peptide that is recognized by the pathogenic 6.5+CD4+ T cells (Rankin 
et al. 2008).  A schematic summarizing the key aspects of arthritis development 
in TS1xHACII mice is presented in Figure 3-1. 
 
Finding that arthritis develops in TS1xHACII mice despite the presence of 
CD4+CD25+Foxp3+ cells is consistent with observations of normal, and even 
increased, frequencies of CD4+CD25+ Treg cells in human arthritis patients (de 
Kleer et al. 2004; Mottonen et al. 2005; Ruprecht et al. 2005; Cao et al. 2006; 
Lawson et al. 2006), and in other mouse models of arthritis (Morgan et al. 2005; 
Gonzalez-Rey et al. 2007; Nguyen et al. 2007).  Although the representation and 
function of CD4+CD25+ Treg cells has been analyzed in human and murine 
arthritis, the role of CD4+CD25+ Treg cells in disease development, and how the 
antigen-specificity of the Treg cell population can affect this, remains unclear.  
TS1xHACII mice are a powerful system in which to study how CD4+CD25+ Treg 
cells can affect arthritis pathogenesis as identification of the disease initiating 
target antigen (S1 peptide) allows us to more carefully examine whether and how 
CD4+CD25+ Treg cells affect the pathogenic S1-specific 6.5+CD4+ T cells, other 
CD4+ T cells (not specific for the disease initiating target antigen), or innate 
immune cells that may contribute to arthritis pathogenesis. 
x
x
x
DN DP SP
Thymus
+
+ Popliteallymph node
Cytokine secretion
IL-17, IFN-γ,
IL-6, TNF-α
ARTHRITIS
6.5+CD4+ T cell
HA-expressing APC
Foxp3+ Treg cell
Figure 3-1 Key steps in the development of spontaneous inflammatory arthritis in 
TS1xHACII mice.  TS1xHACII.JH-/- mice, which lack mature circulating B cells develop 
arthritis, indicating that antibody production and/or antigen presentation by B cells is 
not required for disease development.  Moreover, TS1xHACII.RAG-/- mice also 
develop arthritis, demonstrating that recognition of the S1 peptide by 6.5+CD4+ T cells 
is sufficient to mediate disease.  Although CD4+CD25+Foxp3+ Treg cells are present in 
arthritic mice, whether and how they participate in arthritis development remains 
unclear. (A) 6.5+ thymocytes undergo extensive deletion in response to S1 peptide 
(B) 6.5+CD4+ T cells that have evaded negative selection accumulate in the periphery 
of TS1xHACII mice.  Interactions between 6.5+CD4+ T cells and HA-expressing APCs 
results in reciprocal activation of the cell populations. (C) CD4+ T cells differentiate to 
produce inflammatory cytokines. (D) An enhanced immune response develops in the 
joint-draining popliteal LNs of TS1xHACII mice.
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We show here that pre-arthritic TS1xHACII mice contain expected 
frequencies of CD4+CD25+Foxp3+ cells, indicating that arthritis development 
cannot be attributed to an absence of CD4+CD25+Foxp3+ cells in young 
TS1xHACII mice.  The endogenous CD4+CD25+Foxp3+ cells in TS1xHACII mice 
appear activated and are present in the joint-draining LNs.  Additionally, purified 
CD4+CD25+cells from TS1xHACII mice exhibit in vitro regulatory function.  
Although these observations suggest that the arthritis that develops in 
TS1xHACII mice may be refractory to CD4+CD25+ Treg cell activity, we show that 
the administration of exogenous polyclonal CD4+CD25+ cells can prevent arthritis 
development in TS1xHACII mice, most likely by inhibiting the pathogenic Th-17 
response.  Moreover, specificity for a critical disease target antigen within the 
CD4+CD25+ Treg cell population is not required for disease suppression, as 
BALB/c CD4+CD25+ cells, which have not developed in the presence of the HA 
protein from which the S1 peptide is derived, can also prevent arthritis 
development in TS1xHACII mice.  Strikingly, transfer of TS1xHACII CD4+CD25+ 
cells that have been depleted of 6.5+CD4+CD25+ cells (which comprise Foxp3+ 
and Foxp3- cells) reduces arthritis incidence in TS1xHACII mice, demonstrating 
that endogenous CD4+CD25+ cells from TS1xHACII mice do possess in vivo 
regulatory function and suggesting that CD4+CD25+ Treg cell function can be 
remarkably sensitive to the balance of Treg and effector cells. 
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3.2 Results 
 
3.2.1 Arthritis development in TS1xHACII mice is accompanied by the 
accumulation of peripheral 6.5+CD4+ T cells 
 
The majority of adult TS1xHACII mice develop spontaneous inflammatory 
arthritis (Rankin et al. 2008). To better characterize the kinetics of disease, a 
cohort of TS1xHACII mice were assessed weekly for arthritis development.  Mice 
with at least one affected limb (defined by visible swelling) were designated as 
arthritic.  The majority of mice did not exhibit disease symptoms until 11 weeks of 
age, at which point over 50 percent of the cohort was arthritic (Figure 3-2 A).  
Disease incidence increased in older mice, with 73 percent of TS1xHACII mice 
developing arthritis by 14 weeks of age (Figure 3-2 A).  Analysis of 16 week old 
TS1xHACII mice showed that the majority (62.5 percent) of arthritic animals 
developed disease in all four limbs, and no arthritic mice possessed fewer than 
two affected limbs (Figure 3-2 B).  Thus, the majority of TS1xHACII mice develop 
spontaneous inflammatory arthritis in which all four limbs are affected. 
 
 The recognition of S1 peptide by 6.5+CD4+ T cells is a critical initiating step 
in arthritis development in TS1xHACII mice (Rankin et al. 2008).  We examined 
the frequency of 6.5+CD4+ cells in unfractionated systemic LN (axillary, brachial,  
A
Figure 3-2 6.5+CD4+ T cells accumulate in the periphery of arthritic TS1xHACII mice 
(A) Arthritis incidence over time in TS1xHACII mice. n=11. (B) Numbers of affected 
limbs per mouse in 16 week old TS1xHACII mice. Each circle represents an individual 
mouse.  Line represents the average number of arthritic limbs.  (C) Dot plots show 
6.5+CD4+ cells in the LNs (axillary, brachial, cervical, inguinal, and mesenteric) of pre-
arthritic TS1xHACII, arthritic TS1xHACII, and control TS1 mice.  Numbers indicate the 
percentage of 6.5+ cells among CD4+ cells. Graph shows the average percentage of 
6.5+ cells in pre-arthritic and arthritic TS1xHACII mice.  n ≥ 7 mice per age group.  
Statistical significance was calculated using the Student’s t-test. (D) Numbers of total 
CD4+ (left graph) and 6.5+CD4+ (right graph) cells in TS1xHACII (gray bars) and TS1 
(black bars) mice of different ages.  n ≥ 3 mice per age group. (E) Numbers of total 
popliteal LN cells in TS1xHACII (gray bars) and TS1 (black bars) mice of different ages. 
(F) The number of total CD4+ (gray bars) and 6.5+CD4+ (black bars) in 11 weeks and 
older TS1xHACII and TS1 mice.  For (E) and (F) n ≥ 4 mice per age group.  Bar 
graphs show average values ± SEM.
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cervical, inguinal, and mesenteric) cells from 6 week old TS1xHACII, 13 week old 
TS1xHACII, and control single transgenic TS1 mice.  In comparison to TS1 mice, 
both pre-arthritic and arthritic TS1xHACII mice contained markedly reduced 
percentages of 6.5+CD4+ cells (Figure 3-2 C, left panel).  The decrease in 
6.5+CD4+ T cells in TS1xHACII mice when compared to TS1 mice reflects their 
development in the presence of HA as a self-antigen.  The representation of 
6.5+CD4+ cells appeared to be slightly higher in arthritic TS1xHACII mice in 
comparison to pre-arthritic TS1xHACII mice (Figure 3-2 C, right panel), though 
the difference was not statistically significant (p=0.08, Student’s t-test).   
 
We next analyzed the numbers of CD4+ cells in the systemic LNs of 
TS1xHACII and TS1 mice at different ages.  At 6 to 7 weeks of age, TS1xHACII 
mice possessed dramatically fewer total CD4+ and 6.5+CD4+ cells in comparison 
to TS1 mice (Figure 3-2 D).  Over time, total CD4+ and 6.5+CD4+ cell numbers 
increased in TS1xHACII mice, with 12 to 13 week old arthritic mice containing the 
highest numbers of both populations, although the cellularities did not equal 
those of age-matched TS1 mice (Figure 3-2 D).  We also examined the popliteal 
LNs, which drain the lower joints, in TS1xHACII and TS1 mice at different ages.  
Although the total cellularity of popliteal LNs was much lower in young 
TS1xHACII mice in comparison to young TS1 mice, as TS1xHACII mice aged 
popliteal LN cellularities increased dramatically, and arthritic mice (11 weeks and 
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older) contained larger popliteal LNs than age-matched TS1 mice (Figure 3-2 E, 
left panel).  In contrast to what was observed in systemic LNs (Figure 3-2 D), the 
popliteal LNs of older TS1xHACII and TS1 mice contained comparable numbers 
of total CD4+ cells and of 6.5+CD4+ cells (Figure 3-2 E, right panel).   
 
Collectively, these data demonstrate that 6.5+CD4+ T cells, which are 
specific for the S1 autoantigen, accumulate in the periphery of TS1xHACII mice.   
 
3.2.2 TS1xHACII mice contain CD4+CD25+Foxp3+ cells, including cells that 
are specific for the target autoantigen that initiates disease development 
 
To examine the representation of  CD4+CD25+Foxp3+ cells within 
TS1xHACII and TS1 mice of different ages, LN cells were stained for expression 
of CD4, CD25, and the transcription factor Foxp3.  The percentage of 
CD25+Foxp3+ cells in CD4+ LN cells of young (6 to 7 week old) TS1xHACII mice 
fell within the expected range of 5 to 10 percent of peripheral CD4+CD25+ Treg 
cells (Figure 3-3 A).  Additionally, TS1xHACII mice of all ages contained similar 
frequencies of CD4+CD25+Foxp3+ cells, and within each age group the 
percentages were higher than those in age-matched TS1 mice (Figure 3-3 A).  
These data show that young, pre-arthritic TS1xHACII mice contain a normal  
Figure 3-3 TS1xHACII mice contain S1-specific CD4+CD25+Foxp3+ cells (A) Graph
shows the percentage of CD25+Foxp3+ cells among LN (axillary, brachial, cervical,
inguinal, mesenteric) CD4+ cells from TS1xHACII (gray bars) and TS1 (black bars) 
mice of different ages.  n ≥ 3 mice group.  Bar graphs show average values ± SEM. 
(B) LN cells from arthritic TS1xHACII mice were stained for 6.5, CD4, CD25, and 
Foxp3.  Dot plot on right shows 6.5 and Foxp3 expression within CD4+CD25+ cells 
in TS1xHACII mice.  Numbers indicate the percentages of cells within the respective
gates. (C) CTLA-4 and GITR expression on 6.5+ (solid line) and 6.5- (dotted line) 
CD4+CD25+Foxp3+ LN cells from TS1xHACII mice. (D) CTLA-4 and GITR 
expression on CD4+CD25+Foxp3+ LN cells from TS1xHACII (solid line) or control 
(HACII or BALB/c) mice.
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representation of CD4+CD25+Foxp3+ cells that is similar to the frequency found in 
arthritic TS1xHACII mice. 
 
To determine whether TS1xHACII mice contain CD4+CD25+Foxp3+ cells 
specific for the disease-initiating antigen (S1 peptide), we analyzed systemic LN 
cells for expression of 6.5, CD4, CD25, and Foxp3. CD4+CD25+ LN cells from 
TS1xHACII mice contained a 6.5+ population, which comprised both Foxp3+ and 
Foxp3- cells (Figure 3-3 B).  The majority of the cells within the CD4+CD25+ pool 
that did not express the 6.5 TCR did express Foxp3 (Figure 3-3 B).  To examine 
the phenotype of 6.5+ and 6.5- CD4+CD25+Foxp3+ cells in TS1xHACII mice, we 
analyzed their expression of the Treg cell markers CTLA-4 and GITR.  Whereas 
the 6.5-CD4+CD25+Foxp3+ cells exhibited more diffuse distribution of CTLA-4 and 
GITR expression, 6.5+CD4+CD25+Foxp3+ cells had more uniform expression of 
high levels of both CTLA-4 and GITR (Figure 3-3 C).  The unfractionated 
(including both 6.5+ and 6.5- cells) population of CD4+CD25+Foxp3+ cells from 
TS1xHACII mice contained a larger population of cells that expressed high levels 
of CTLA-4 and GITR than CD4+CD25+Foxp3+ cells from healthy mice (single 
transgenic HACII or BALB/c) (Figure 3-3 D).   
 
Together, these data show that TS1xHACII mice of all ages contain 
normal frequencies of CD4+CD25+Foxp3+ cells.  Moreover, a subset of the 
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CD4+CD25+Foxp3+ cells expresses the 6.5 TCR, which confers specificity for the 
target autoantigen that initiates arthritis development in TS1xHACII mice, and 
appeared activated in comparison to 6.5-CD4+CD25+Foxp3+ cells. 
 
3.2.3 CD4+CD25+ cells from TS1xHACII mice possess in vitro suppressor 
function 
 
 We conducted in vitro suppression assays to determine whether 
CD4+CD25+ cells from TS1xHACII mice possessed regulatory function.  CFSE-
labeled CD4+ T cells were cultured alone or with FACS-purified CD4+CD25+cells 
from TS1xHACII mice at a 1:2 Treg:responder cell ratio and stimulated with 
soluble anti-CD3.  Three days later we examined the CFSE division profile and 
cytokine production of the responder CD4+ T cells.  In the presence of 
TS1xHACII CD4+CD25+ cells, a greater percentage of responder CD4+ T cells 
remained undivided, and the cells that did proliferate underwent fewer rounds of 
division (Figure 3-4 A, left panel).  Additionally, when cultured alone, 48.6 percent 
of responder CD4+ T cells produced IFN-γ, in contrast to 13.2 percent when co-
cultured with CD4+CD25+ cells from TS1xHACII mice (Figure 3-4 A, right panel).  
These data indicate that CD4+CD25+ cells from TS1xHACII mice can suppress 
proliferation and cytokine production by responder CD4+ T cells. 
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Figure 3-4 CD4+CD25+ cells in TS1xHACII mice possess in vitro suppressor function 
CFSE-labeled CD4+ TS1 T cells were cultured with CD4+CD25+ T cells purified from 
TS1xHACII mice at a 1:2 Treg:responder cell ratio and stimulated with (A) soluble 
anti-CD3 (0.1 μg/ml) or (B) with a high (1 μM) or low (0.3 μM) dose of S1 peptide. 
(A) Three days later responder CD4+ T cell proliferation and cytokine production
were analyzed by flow cytometric analysis.  Histogram shows the CFSE profiles of 
responder CD4+ T cells when cultured alone (solid histogram) or in the presence of 
TS1xHACII CD4+CD25+ cells (black line).  Dot plots show IFN-γ production by 
responder CD4+ T cells cultured alone (left) or with TS1xHACII CD4+CD25+ cells 
(right).  Numbers indicate the percentages of IFN-γ+ cells.  (B) Histograms show the 
CFSE profiles of responder CD4+ T cells after three days of culture in the absence 
(left plots) or presence (middle plots) of TS1xHACII CD4+CD25+ cells. Numbers 
indicate the percentage of undivided cells.  Histograms on the right show overlaid 
CFSE profiles of responder CD4+ T cells cultured alone (solid gray) or with 
TS1xHACII CD4+CD25+ cells (dotted black line).
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 To examine whether CD4+CD25+ cells from TS1xHACII mice could exert 
suppressor function in response to stimulation by S1 peptide, we conducted in 
vitro suppression assays using S1 peptide to stimulate the cells.  CFSE-labeled 
CD4+ cells from TS1 mice were cultured with or without CD4+CD25+ cells from 
TS1xHACII mice with a high (1 µM) or low (0.3 µM) dose of S1 peptide as a 
stimulus.  At the high dose of S1 peptide, the presence of CD4+CD25+ cells from 
TS1xHACII mice resulted in an increased percentage of undivided responder 
CD4+ T cells (19.8 percent versus 9.6 percent when responder cells were 
cultured alone), but had little effect on the extent of division of proliferating cells 
(Figure 3-4 B, upper panel).  In contrast, at the low dose of S1 peptide, co-culture 
of TS1xHACII CD4+CD25+ cells not only resulted in a higher representation of 
undivided cells (34.1 percent versus 18.3 percent), but also less accumulation of 
responder CD4+ T cells at later cell divisions (Figure 3-4 B, lower panel).   
 
These data show that CD4+CD25+ cells from TS1xHACII mice possess in 
vitro suppressor function.  Moreover, regulatory activity (as defined by inhibition 
of responder CD4+ T cell proliferation) of the CD4+CD25+ cells can be activated 
by interactions with S1 peptide. 
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3.2.4 CD4+CD25+Foxp3+ cells are present in the joint-draining LNs of 
TS1xHACII mice 
 
Since alterations in CD4+CD25+ Treg cell distribution can contribute to the 
development of autoimmune disease (Siegmund et al. 2005; Sather et al. 2007), 
we examined whether CD4+CD25+Foxp3+ cells were equally distributed 
throughout the lymphoid organs of TS1xHACII mice.  To assess this we isolated 
LNs that drain the lower joints (popliteal), upper limbs (axillary and brachial), as 
well as the spleen and other LNs (cervical, inguinal, and mesenteric) that are not 
primary joint-draining sites, and stained the cells for CD4, CD25, and Foxp3 
expression.  The different lymphoid organs contained comparable percentages of 
CD4+CD25+Foxp3+ cells (Figure 3-5 A), indicating that the joint-draining LNs 
were not deficient in CD4+CD25+Foxp3+ cells.  Work in other autoimmune 
disease systems suggests that draining LNs are enriched for target organ 
antigen-specific CD4+CD25+ Treg cells (Samy et al. 2005; Samy et al. 2008; 
Wheeler et al. 2009), and we wanted to examine whether the representation of 
6.5+CD4+CD25+Foxp3+ cells (which are specific for the arthritis initiating antigen) 
was enhanced in the popliteal LNs of TS1xHACII mice.  To address this, we 
compared the distribution of total CD4+CD25+Foxp3+ and 6.5+CD4+CD25+Foxp3+ 
cells in the popliteal and non-draining LNs of TS1xHACII mice.  Interestingly, 
while the distribution of total CD4+CD25+Foxp3+ cells was similar in draining and  
Figure 3-5 6.5+CD4+CD25+Foxp3+ cells are enriched in the popliteal LNs of 
TS1xHACII mice (A) Foxp3 and CD25 expression in CD4+ cells from joint-draining
and non-draining lymphoid organs in TS1xHACII mice.  Numbers indicate the 
percentage of CD25+Foxp3+ cells within the CD4+ gate. (B) Graphs show the 
percentages of Foxp3+ cells within total CD4+ (left graph) or 6.5+CD4+ (right graph) 
cells in the popliteal and non-draining (cervical, inguinal, and mesenteric) LNs in 
TS1xHACII mice.  Two symbols connected by a line represent data from one 
mouse.
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non-draining LNs (Figure 3-5, left panel), 6.5+CD4+CD25+Foxp3+ cells were 
enriched in the popliteal LNs (Figure 3-5, right panel). 
 
 Together, these data demonstrate that unfractionated (including both 6.5+ 
and 6.5- cells) CD4+CD25+Foxp3+ cells are present at similar frequencies in 
draining and non-draining LNs in TS1xHACII mice.  However, the presence of 
6.5+CD4+CD25+Foxp3+ cells, which are specific for the disease initiating target 
antigen, is enriched in the popliteal LNs. 
 
3.2.5 Polyclonal CD4+CD25+ Treg cells can prevent arthritis development in 
TS1xHACII mice 
 
 We have shown that TS1xHACII mice develop arthritis despite the 
presence of endogenous CD4+CD25+Foxp3+ cells (including a population that is 
specific for the disease initiating target antigen) that are present in the joint 
draining LNs and possess in vitro suppressor function.  It is possible that the 
arthritis that develops in TS1xHACII mice is refractory to Treg cell activity, and to 
address this we examined whether arthritis could be modified by the 
administration of exogenous CD4+CD25+ Treg cells prior to disease onset.  To 
test this, we purified CD4+CD25+ cells from HACII mice, which express the HA 
transgene (under the same MHC II I-Eα promoter as TS1xHACII mice) without 
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any additional transgenic modifications to the TCR repertoire, and are isogenic 
with respect to the self peptides that are present in TS1xHACII mice.  Thus, 
although CD4+CD25+ cells from HACII mice do not contain any 6.5+Foxp3+ cells 
(Figure 3-6 A), the CD4+CD25+Foxp3+ cells present in HACII mice have 
developed in the presence of HA as a self-antigen.  
 
We adoptively transferred 1x106 CD4+CD25+ cells purified from HACII 
mice into pre-arthritic TS1xHACII mice and tracked the recipients weekly for 
disease development.  In comparison to a cohort of unmanipulated TS1xHACII 
mice, mice that received HACII CD4+CD25+ cells showed a marked reduction in 
arthritis development (Figure 3-6 B).  In 15 week old TS1xHACII mice, arthritis 
incidence was significantly lower in TS1xHACII mice that received HACII 
CD4+CD25+ cells (18.2 percent) than in unmanipulated TS1xHACII mice (80 
percent) (*p=0.0089, Fisher’s exact test) (Figure 3-6 C).  Moreover, among 
arthritic mice, the number of affected limbs was lower in TS1xHACII mice that 
received HACII CD4+CD25+ cells (one affected limb) in comparison to 
unmanipulated TS1xHACII mice (which had three to four affected limbs) (Figure 
3-6 D).  Therefore, the average number of affected limbs per mouse was 
significantly lower in TS1xHACII mice that received HACII CD4+CD25+ cells than 
in unmanipulated TS1xHACII mice (***p<0.0001, Mann-Whitney). 
Figure 3-6 The adoptive transfer of CD4+CD25+ cells from HACII mice can prevent 
arthritis development in TS1xHACII mice (A) Dot plots show 6.5 and Foxp3 staining 
of CD4+CD25+ LN cells from HACII mice. (B) 1x106 HACII CD4+CD25+ cells were 
adoptively transferred into 5 to 6 week old TS1xHACII mice.  Graph shows the 
average number of arthritic limbs per mouse (±SEM) over time of unmanipulated 
(   , n=10) and HACII CD4+CD25+ cell recipient (  , n=11) TS1xHACII mice. 
(C) Arthritis incidence in 15 week old unmanipulated or HACII CD4+CD25+ cell 
recipient TS1xHACII mice.  Statistical significance was calculated using Fisher’s 
exact test. (D) The number of arthritic limbs per mouse in cohorts of unmanipulated 
and HACII CD4+CD25+ cell recipient TS1xHACII mice.  Each circle represents an 
individual mouse. Statistical significance was calculated by the Mann-Whitney test.
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These data show that the administration of exogenous CD4+CD25+ cells 
can prevent arthritis in TS1xHACII mice, demonstrating that the arthritis that 
develops in TS1xHACII mice can be modified by CD4+CD25+ Treg cell activity. 
 
3.2.6 Protective CD4+CD25+ Treg cells do not alter the accumulation or 
activation of 6.5+CD4+ T cells in TS1xHACII mice 
 
 To determine whether the accumulation and activation of 6.5+CD4+ T cells 
were altered in TS1xHACII mice that received protective CD4+CD25+ cells from 
HACII mice (from here on referred to as protected TS1xHACII mice), we 
examined the number and phenotype of CD4+ T cells in unfractionated systemic 
LNs (axillary, brachial, cervical, inguinal, and mesenteric) of unmanipulated 
TS1xHACII mice, and of mice that received HACII CD4+CD25+ cells.  There was 
little difference in the total cellularity of in the numbers of CD4+ cells in the LNs of 
arthritic versus protected TS1xHACII mice (Figure 3-7 A).  Additionally, the 
administration of CD4+CD25+ cells from HACII mice did not affect the 
accumulation of peripheral 6.5+CD4+ T cells, as unmanipulated arthritic and 
protected TS1xHACII mice contained comparable numbers of 6.5+CD4+ cells 
(Figure 3-7 B).  To examine whether HACII CD4+CD25+ Treg cells altered the 
activation phenotype of CD4+ T cells in TS1xHACII mice, we analyzed the 
expression of CD62L, CD44, and CD69 on both 6.5+CD4+ and 6.5-CD4+ T cells.   
Figure 3-7 Protective HACII CD4+CD25+ Treg cells do not inhibit the accumulation 
or activation of 6.5+CD4+ T cells in TS1xHACII mice. (A) Numbers of total (gray bar) 
and CD4+ (black bar) cells in the systemic LNs (axillary, brachial, cervical, inguinal, 
mesenteric) of unmanipulated and HACII CD4+CD25+ Treg cell recipient TS1xHACII 
mice. n=11 per group. (B) Numbers of 6.5+CD4+ T cells in the systemic LNs of 
unmanipulated and HACII CD4+CD25+ Treg cell recipient TS1xHACII mice.  n=11 per 
group. (C) CD62L, CD44, and CD69 expression on 6.5+ (upper panel) and 6.5- (lower 
panel) CD4+ cells from unmanipulated TS1xHACII (dashed line), HACII CD4+CD25+ 
Treg cell recipient TS1xHACII (solid line), or control TS1 (solid histogram) mice. Bar 
graphs show average values ± SEM. 
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In comparison to control 6.5+CD4+ T cells from TS1 mice (which are not exposed 
to HA as a self-antigen), 6.5+CD4+ T cells from both arthritic and protected 
TS1xHACII mice appeared activated, and possessed very similar profiles of 
CD62L, CD44, and CD69 expression (Figure 3-7 C, upper panel).  In contrast, 
the expression patterns of CD62L, CD44, and CD69 on 6.5-CD4+ T cells from 
arthritic and protected TS1xHACII mice were nearly identical to those of 6.5-CD4+ 
T cells from single transgenic TS1 mice (Figure 3-7 C, lower panel), and reflected 
a phenotype consistent with that of naïve cells.   
 
Taken together, these data indicate that HACII CD4+CD25+ Treg cells do 
not prevent arthritis development by inhibiting the accumulation or activation of 
peripheral 6.5+ and 6.5- CD4+ T cells in TS1xHACII mice. 
 
3.2.7 Preferential reduction of IL-17 in the popliteal LNs of TS1xHACII mice 
that received protective CD4+CD25+ Treg cells 
 
We analyzed protected TS1xHACII mice to determine whether HACII 
CD4+CD25+ Treg cells modified the accumulation of popliteal LN cells that 
normally occurs in TS1xHACII mice (Figure 3-2 E).  TS1xHACII mice that 
received HACII CD4+CD25+ cells contained significantly lower numbers of total 
popliteal LN cells (*p=0.018, Student’s t-test), as well as lower, though not 
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statistically significant (p=0.06, Student’s t-test), numbers of CD4+ cells (Figure 3-
8 A).  Although the numbers of popliteal LN CD4+ cells were not significantly 
reduced in TS1xHACII mice that received HACII CD4+CD25+ cells, CD4+ cells in 
protected TS1xHACII mice could possess altered effector properties, and to 
examine this we analyzed intracellular cytokine production by popliteal LN CD4+ 
T cells in arthritic and protected TS1xHACII mice.  Popliteal LN cells were 
stimulated for four hours with PMA and ionomycin, and then stained for CD4 and 
intracellular IL-17 and IFN-γ expression.  Strikingly, TS1xHACII mice that 
received HACII CD4+CD25+ cells exhibited a reduction in the representation of 
IL-17, but not IFN-γ, producing CD4+ popliteal LN cells when compared to 
unmanipulated TS1xHACII mice (Figure 3-8 B).  Whereas the difference in the 
percentages of IL-17+CD4+ popliteal LN cells was significantly lower in 
TS1xHACII mice that received HACII CD4+CD25+ cells than in unmanipulated 
TS1xHACII mice (*p=0.04, Student’s t-test), the representation of IFN-γ 
producing cells was comparable between the two groups (Figure 3-8 C).  
However, numbers of both IFN-γ+CD4+ (*p=0.04, Student’s t-test) and IL-
17+CD4+ (*p=0.02, Student’s t-test) cells were significantly lower in TS1xHACII 
mice that received HACII CD4+CD25+ cells than in unmanipulated TS1xHACII 
mice, consistent with the reduced total cellularity of the popliteal LNs. 
 
Figure 3-8 Protective HACII CD4+CD25+ Treg cells inhibit Th-17 cells in the popliteal 
LNs of TS1xHACII mice (A) Numbers of total (gray bar) and CD4+ (black bar) cells in 
the popliteal LNs of unmanipulated and HACII CD4+CD25+ Treg cell recipient 
TS1xHACII mice.  (total cells, *p=0.018; CD4+ cells, p=0.06). (B) Popliteal LN cells 
were stimulated for 4 hours with PMA and ionomycin and stained for intracellular 
IL-17 and IFN-γ.  Dot plots show IL-17 and IFN-γ production by CD4+ T cells from 
unmanipulated and HACII CD4+CD25+ Treg cell recipient mice.  Numbers indicate the 
percentage of cytokine-producing cells in each gate. (C) Average percentages of 
IFN-γ and IL-17 producing CD4+ T cells in the popliteal LNs of unmanipulated and 
HACII CD4+CD25+ Treg cell recipient TS1xHACII mice. (D) Numbers of IFN-γ+CD4+ 
and IL-17+CD4+ cells in the popliteal LNs of unmanipulated and HACII CD4+CD25+ 
Treg cell recipient TS1xHACII mice.  Bar graphs show average values ± SEM.  
Statistical significance was calculated using the Student’s t-test.  n=11 per group for 
all data.
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Together, these data show that the administration of HACII CD4+CD25+ 
Treg cells limits the accumulation of cells in the popliteal LNs of TS1xHACII mice.  
Interestingly, the protective HACII CD4+CD25+ Treg cells appear to preferentially 
inhibit Th-17 cell formation, which has been associated with several autoimmune 
diseases, including arthritis (Afzali et al. 2007; Korn et al. 2009). 
 
3.2.8 Protective CD4+CD25+ Treg cells suppress the systemic Th-17 
response in TS1xHACII mice 
 
 To examine whether the transfer of HACII CD4+CD25+ cells suppressed 
systemic IL-17 production in TS1xHACII mice, we set up unfractionated LN 
(axillary, brachial, cervical, inguinal, and mesenteric) cultures with cells from 
arthritic and protected TS1xHACII mice.  Three days later, supernatants were 
collected and analyzed for IL-17 production by ELISA.  Unfractionated LN 
cultures from unmanipulated arthritic TS1xHACII mice produced significantly 
higher concentrations of IL-17 than LN cultures from healthy control TS1 mice 
(*p=0.025, Student’s t-test) (Figure 3-9 A), indicating that increased levels of IL-
17 accompany arthritis development.  Interestingly, protected TS1xHACII mice 
exhibited reduced systemic IL-17 production, as unfractionated LN cultures from 
TS1xHACII mice that received HACII CD4+CD25+ cells produced significantly 
lower amounts of IL-17 in comparison to unmanipulated arthritic TS1xHACII mice  
Figure 3-9 Protective HACII CD4+CD25+ Treg cells inhibit systemic IL-17 production 
in TS1xHACII mice.  Unfractionated LN (axillary, brachial, cervical, inguinal, and 
mesenteric) cells from unmanipulated TS1xHACII, HACII CD4+CD25+ Treg cell 
recipient TS1xHACII, or control TS1 mice were cultured for three days, and 
supernatants were collected and analyzed for (A) IL-17, (B) IL-1β and IL-1α, and 
(C) IL-6.  Statistical signficance was calculated using the Student’s t-test.  All 
TS1xHACII mice, n=5 per group. TS1 mice, n=3 per group.
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(*p=0.01, Student’s t-test) (Figure 3-9 A), again suggesting that IL-17 production 
by LN cells serves as a correlate for disease status.  Thus, HACII CD4+CD25+ 
cells not only reduce IL-17 production in the popliteal LNs (Figure 3-8 C), but also 
reduce systemic IL-17 production in TS1xHACII mice. 
 
To examine whether HACII CD4+CD25+ cells could also suppress 
cytokines involved in the differentiation of IL-17 producing cells, we also analyzed 
unfractionated LN culture supernatants for cytokines associated with Th-17 
development (i.e. IL-1 and IL-6).  LN cultures from protected TS1xHACII mice 
produced significantly lower levels of IL-1β than LN cultures from arthritic 
TS1xHACII mice (*p=0.016, Student’s t-test), and also lower, but not statistically 
significant, levels of IL-1α (p=0.059, Student’s t-test) (Figure 3-9 B).  Whereas IL-
1α concentrations were significantly higher in LN cultures from unmanipulated 
TS1xHACII mice than LN cultures from control TS1 mice (*p=0.047, Student’s t-
test), the difference in IL-1β levels was not significantly increased (p=0.08, 
Student’s t-test). Therefore, although administration of HACII CD4+CD25+ cells 
results in significant downregulation of IL-1β levels in unfractionated LN cultures 
from TS1xHACII mice, unlike IL-17, production of IL-1β may not correlate with 
disease status.  Unfractionated LN cultures from TS1xHACII mice that received 
HACII CD4+CD25+ cells did not produce significantly lower levels of IL-6 than LN 
cultures from unmanipulated TS1xHACII mice (p=0.11, Student’s t-test) (Figure 
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3-9 C).  Additionally, the difference in IL-6 concentrations between LN cultures 
from arthritic TS1xHACII and control TS1 mice did not reach statistical 
significance (p=0.3, Student’s t-test).  
 
Collectively, these data demonstrate that the administration of HACII 
CD4+CD25+ cells inhibits systemic production of IL-17 and also IL-1β, which has 
been linked to Th-17 differentiation (Sutton et al. 2006; Acosta-Rodriguez et al. 
2007; Koenders et al. 2008).  The amount of IL-17 produced by LN cultures 
appeared to be a direct correlate to the disease status of TS1xHACII mice, 
suggesting that this cytokine may be important for the development of arthritis.   
 
3.2.9 IL-17 is critical for the development of spontaneous autoimmune 
arthritis in TS1xHACII mice 
 
The finding that arthritic TS1xHACII mice produced significantly higher 
amounts of IL-17 than both healthy control TS1 mice (Figure 3-9 A) and 
protected TS1xHACII mice that received HACII CD4+CD25+ Treg cells (Figure 3-
8 C and Figure 3-9 A), suggested that increased IL-17 production correlates with 
arthritis in TS1xHACII mice.  To determine whether IL-17 is critical for arthritis 
development in TS1xHACII mice, we treated TS1xHACII mice with either anti-
IL17 (blocks IL-17A, clone M210, Amgen) or an isotype control antibody and 
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tracked the mice weekly for disease development.  Blockade of IL-17 
dramatically reduced arthritis incidence in TS1xHACII mice, as only 8.3 percent 
(1 of 12) of anti-IL17 antibody treated TS1xHACII mice developed disease in 
comparison to 100 percent of isotype control treated TS1xHACII mice 
(**p=0.004, Fisher’s exact test) (Figure 3-10 A).  Given that all of the isotype 
control treated TS1xHACII mice had three or four arthritic limbs, whereas only 
one anti-IL17 antibody treated TS1xHACII mouse developed arthritis (Figure 3-
10 B), the average number of arthritic limbs per mouse in anti-IL17 treated 
TS1xHACII mice was significantly lower than in unmanipulated TS1xHACII mice 
(**p=0.001, Mann-Whitney). 
 
These data clearly demonstrate that IL-17 activity is critical for arthritis 
development in TS1xHACII mice.  Moreover, this finding indicates that the 
reduction in regional and systemic IL-17 production observed in TS1xHACII mice 
that received HACII CD4+CD25+ cells (Figure 3-8 C and 3-9 A), may be the key 
mechanism by which protective CD4+CD25+ Treg cells can prevent arthritis 
development in TS1xHACII mice. 
A
Figure 3-10 IL-17 is critical for the development of arthritis in TS1xHACII mice 
(A) Arthritis incidence in 14 week old TS1xHACII mice that were treated with 
anti-IL17 antibody (n=12) or an isotype control antibody (n=6).  Statistical significance 
was calculated using Fisher’s exact test. (B) The numbers ofarthritic limbs per mouse 
in 14 week old TS1xHACII mice treated with anti-IL17 or isotype control antibodies.  
Each circle represents an individual mouse.  Line represents the average number of 
arthritic limbs.  Statistical significance was calculated using the Mann-Whitney test. 
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3.2.10 CD4+CD25+ cells from TS1xHACII mice can modify arthritis 
development if 6.5+CD4+CD25+ cells are depleted 
 
 The ability of exogenously administered HACII CD4+CD25+ cells to 
prevent arthritis development in TS1xHACII mice (Figure 3-6) demonstrates that 
arthritis in TS1xHACII mice can be modulated by CD4+CD25+ Treg cell activity, 
and raises the question of why the endogenous CD4+CD25+Foxp3+ cells in 
TS1xHACII mice fail to prevent arthritis.  One possibility is that despite containing 
a normal percentage of CD4+CD25+Foxp3+ cells in arthritic TS1xHACII mice 
(Figure 3-3 A), pre-arthritic TS1xHACII mice may not contain sufficient numbers 
of the cells to prevent arthritis from developing (Figure 3-2 D).  Thus, we 
examined whether increasing the CD4+CD25+ Treg cell population by 
administering CD4+CD25+ cells isolated from other TS1xHACII mice to pre-
arthritic TS1xHACII mice would be able to prevent arthritis development.  
However, CD4+CD25+ cells from TS1xHACII mice contain a population of 6.5+ 
cells, which comprise Foxp3+ and Foxp3- cells (Figure 3-3 B).  Given that 
recognition of S1 peptide by 6.5+CD4+ T cells is critical for disease initiation in 
TS1xHACII mice, we decided to examine the effects of administering both 
unfractionated (i.e. contains both 6.5+ and 6.5- cells) and 6.5-depleted 
TS1xHACII CD4+CD25+ cells on arthritis development in TS1xHACII mice. 
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 To address this we purified CD4+CD25+ cells from TS1xHACII mice that 
were either unfractionated or were depleted of 6.5+ cells (Figure 3-11 A, left 
panel).  We adoptively transferred 1x106 of these unfractionated or 6.5-depleted 
TS1xHACII CD4+CD25+ cells into pre-arthritic TS1xHACII mice and tracked the 
recipients for arthritis development.  Unmanipulated TS1xHACII mice, and mice 
that received unfractionated CD4+CD25+ TS1xHACII cells averaged a similar 
number of arthritic limbs per mouse at each time point during the nine week 
period of analysis.  However, TS1xHACII mice that received 6.5-depleted 
CD4+CD25+ TS1xHACII cells averaged fewer affected limbs per mouse (Figure 
3-11 A, right panel).  This lower average number of arthritic limbs could reflect 
either an overall reduction in arthritis incidence within the population, or similar 
disease incidence that is accompanied by arthritic TS1xHACII mice possessing 
fewer numbers of affected limbs, which is indicative of reduced disease severity 
in individual arthritic mice. 
 
 To further examine this we assessed the kinetics of arthritis incidence in 
unmanipulated, unfractionated TS1xHACII CD4+CD25+ cell recipient, and 6.5-
depleted TS1xHACII CD4+CD25+ cell recipient TS1xHACII mice.  Unmanipulated 
TS1xHACII mice and those that received unfractionated CD4+CD25+ TS1xHACII 
cells exhibited comparable kinetics in the development of disease incidence, and 
by 15 weeks of age over 90 percent of unmanipulated and 100 percent of  
A
B
C
Figure 3-11 The adoptive transfer 6.5-depleted TS1xHACII CD4+CD25+ cells can 
modify arthritis in TS1xHACII mice (A) 1x106 unfractionated CD4+CD25+cells or 
6.5-CD4+CD25+ cells from TS1xHACII mice were adoptively transferred into pre-
arthritic TS1xHACII mice.  Dot plots show 6.5 staining in sorted CD4+CD25+ cells that 
were or were not depleted of 6.5+ cells.  Number indicates the percentage of 6.5+ cells.  
Graph shows the average number of arthritic limbs per mouse (±SEM) over time of 
unmanipulated (   , n=11), unfractionated TS1xHACII CD4+CD25+cell recipient (  , n=6), 
and 6.5-depleted TS1xHACII CD4+CD25+ cell recipient (   , n=10) TS1xHACII mice. 
(B) Arthritis incidence over time in unmanipulated, unfractionated TS1xHACII 
CD4+CD25+ cell recipient, and 6.5-depleted TS1xHACII CD4+CD25+ cell recipient 
TS1xHACII mice. Statistical significance was calculated using Fisher’s exact test. 
(C) Graphs show the numbers of arthritic limbs per mouse in 12 week old (top) and 15 
week old (bottom) unmanipulated, unfractionated TS1xHACII CD4+CD25+ cell recipient, 
and 6.5-depleted TS1xHACII CD4+CD25+ cell recipient TS1xHACII mice.  Each circle 
represents an individual mouse.  Line represents the average number of arthritic limbs 
per mouse.  Statistical significance was calculated using the Mann-Whitney test.
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unfractionated TS1xHACII CD4+CD25+ cell recipient mice had developed arthritis 
(Figure 3-11 B).  In contrast, TS1xHACII mice that received 6.5-depleted 
TS1xHACII CD4+CD25+ cells showed much lower arthritis incidence at each time 
point when compared to unmanipulated TS1xHACII mice, and by 15 weeks of 
age only 50 percent of the mice had developed arthritis (Figure 3-11 B).  
However, the difference in arthritis incidence between unmanipulated TS1xHACII 
mice and TS1xHACII mice that received 6.5-depleted TS1xHACII CD4+CD25+ 
cells did not reach statistical significance (p=0.06, Fisher’s exact test). 
 
Moreover, the administration of unfractionated CD4+CD25+ TS1xHACII 
cells to TS1xHACII mice did not affect the number of affected limbs in arthritic 
mice.  Among 12 week old arthritic TS1xHACII mice, 55.6 percent (5 of 9) of 
unmanipulated TS1xHACII mice and 50 percent (3 of 6) of unfractionated 
CD4+CD25+ TS1xHACII cell recipient TS1xHACII mice had three or four affected 
limbs (Figure 3-11 C, upper panel).  By 15 weeks of age 60 percent (6 of 10) of 
arthritic unmanipulated TS1xHACII mice and 83.3 percent (5 of 6) of arthritic 
unfractionated CD4+CD25+ TS1xHACII cell recipient mice had three or four 
affected limbs (Figure 3-11 C, lower panel).  Thus, there was little difference in 
the degree of arthritis incidence or in the numbers of affected limbs between 
unmanipulated TS1xHACII mice and mice that received unfractionated 
CD4+CD25+ TS1xHACII cells. 
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Among TS1xHACII mice that received 6.5-depleted CD4+CD25+ 
TS1xHACII cells, only 20 percent (2 of 10) were arthritic, with two or four affected 
limbs, by 12 weeks of age (Figure 3-11 C, upper panel).  Furthermore, since the 
majority of 12 week old 6.5-depleted CD4+CD25+ TS1xHACII cell recipient mice 
were not arthritic, the average number of affected limbs was significantly lower 
than in unmanipulated TS1xHACII mice (*p=0.019, Mann-Whitney).  By 15 weeks 
of age, 5 of 10 (50 percent) TS1xHACII mice that received 6.5-depleted 
CD4+CD25+ TS1xHACII cells were arthritic, and among arthritic animals 60 
percent (3 of 5) had three or four affected limbs (Figure 3-11 C, lower panel).  
Although the average number of affected limbs in 15 week old TS1xHACII mice 
that received 6.5-depleted TS1xHACII CD4+CD25+ cells was greater than in 12 
week old mice, the difference in the average number of arthritic limbs between 15 
week old 6.5-depleted CD4+CD25+ TS1xHACII cell recipient and unmanipulated 
TS1xHACII mice remained significant (*p=0.05, Mann-Whitney). 
 
Thus, the administration of CD4+CD25+ cells from TS1xHACII mice that 
were depleted of the 6.5+ pool, but not unfractionated TS1xHACII CD4+CD25+ 
cells, could reduce arthritis incidence in TS1xHACII mice. Collectively, these data 
demonstrate that endogenous CD4+CD25+ cells from TS1xHACII mice possess 
in vivo regulatory activity and can modulate arthritis development in TS1xHACII 
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mice, but that their efficacy is contingent upon depletion of the 6.5+CD4+CD25+ 
population, which is a mixture of Foxp3+ and Foxp3- cells.   
 
3.2.11 Suppressor function of CD4+CD25+ Treg cells is highly sensitive to 
balance of Treg and effector cells 
 
Depletion of 6.5 TCR expressing cells allows endogenous CD4+CD25+ 
cells from TS1xHACII mice to modulate arthritis development (Figure 3-11).  
Since the elimination of 6.5+CD4+CD25+ cells removes both Foxp3+ and Foxp3- 
cells (Figure 3-3 B), the enhanced ability of 6.5-depleted TS1xHACII CD4+CD25+ 
cells to suppress arthritis could be explained by the absence of 
6.5+CD4+CD25+Foxp3- cells specific for the disease initiating target antigen (S1 
peptide).  This result suggests that the efficacy of CD4+CD25+ Treg cell activity 
could be highly sensitive to the balance of Treg and effector cells.  To further 
address this, we examined whether introducing a small population of 
conventional 6.5+CD4+ T cells to HACII CD4+CD25+ Treg cells could affect the 
ability of the protective Treg cells to suppress arthritis in TS1xHACII mice.  We 
purified CD4+CD25- cells from TS1xHA28 mice, which co-express the 6.5 TCR 
and the HA transgene under an SV40 promoter (Jordan et al. 2001), to obtain a 
source of potentially autoreactive 6.5+CD4+ T cells that have developed in the 
presence of HA, as 6.5+CD4+CD25- cells in TS1xHA28 mice have evaded 
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negative selection despite exposure to HA in the thymus (Jordan et al. 2001).  
Approximately 30 percent of CD4+CD25- cells from TS1xHA28 mice are 6.5+ and 
Foxp3- (Figure 3-12 A). 
 
We adoptively transferred a mixture of 1x106 cells that contained 95 
percent protective HACII CD4+CD25+ cells and 5 percent TS1xHA28 CD4+CD25- 
cells (mixed cell) into pre-arthritic TS1xHACII mice and tracked the recipients for 
arthritis development.  Strikingly, the incidence of arthritis was the same (62.5 
percent) in 15 week old unmanipulated TS1xHACII mice and mice that received 
the mixture of HACII CD4+CD25+ cells and TS1xHA28 CD4+CD25- cells (Figure 
3-12 B).  Notably, arthritis incidence was higher in TS1xHACII mice that received 
the mixture of protective HACII CD4+CD25+ cells and TS1xHA28 CD4+CD25- 
cells than in TS1xHACII mice that received HACII CD4+CD25+ cells (Figure 3-12 
B), although the difference between the two cohorts did not reach statistical 
significance (p=0.07, Fisher’s exact test).  The average number of arthritic limbs 
per mouse was also higher, though not statistically significant (p=0.08, Mann-
Whitney), among TS1xHACII mice that received the mixture of protective HACII 
CD4+CD25+ cells and TS1xHA28 CD4+CD25-  cells than in TS1xHACII mice that 
received only HACII CD4+CD25+ cells (Figure 3-12 C).  
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Collectively, these data show that the presence of a small population of 
CD4+CD25- cells enriched for expression of the 6.5 TCR can alter the ability of 
protective HACII CD4+CD25+ Treg cells to suppress arthritis in TS1xHACII mice.  
These results suggest that the efficacy of CD4+CD25+ Treg cells is remarkably 
sensitive to the balance of Treg and effector cells. 
 
3.2.12 Polyclonal CD4+CD25+ Treg cells that have not developed in the 
presence of HA can prevent arthritis development in TS1xHACII mice 
 
 We have shown that the transfer of CD4+CD25+ cells purified from HACII 
mice to pre-arthritic TS1xHACII mice can prevent arthritis development in 
TS1xHACII mice (Figure 3-6).  Furthermore, the adoptive transfer of endogenous 
CD4+CD25+ cells from TS1xHACII mice that have been depleted of 
6.5+CD4+CD25+ cells can also ameliorate arthritis in TS1xHACII mice (Figure 3-
11).  Together, these data demonstrate that CD4+CD25+ cells that do not express 
the 6.5 TCR (which is specific for the disease initiating target antigen) can modify 
arthritis development in TS1xHACII.  However, although the CD4+CD25+ cells 
from HACII or TS1xHACII mice do not express the 6.5 TCR, both cell populations 
have developed in the presence of S1 peptide as a self antigen.  Therefore, it is 
possible that CD4+CD25+ cells from HACII and TS1xHACII mice contain a 
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population of S1-reactive cells, and that specificity for S1 peptide is required for 
Treg cell modulation of arthritis in TS1xHACII mice.   
 
To examine whether CD4+CD25+ cells that have not developed in the 
presence of S1 peptide would also be able to prevent arthritis development in 
TS1xHACII mice, we purified CD4+CD25+ cells from BALB/c mice, which have 
the same genetic background as TS1xHACII mice, but contain no modifications 
to the TCR repertoire and do not express HA as a self-peptide.  Thus, BALB/c 
CD4+CD25+ cells have not experienced the S1 peptide, which drives initiation of 
arthritis in TS1xHACII mice.  As expected CD4+CD25+ LN cells from BALB/c 
mice express Foxp3 but no 6.5 (Figure 3-13 A).  We adoptively transferred 1x106 
BALB/c CD4+CD25+ cells into pre-arthritic TS1xHACII mice and tracked the 
recipients for disease development.  TS1xHACII mice that received BALB/c 
CD4+CD25+ cells exhibited a marked reduction in arthritis development in 
comparison to unmanipulated TS1xHACII mice (Figure 3-13 B).  In contrast to 
the 80 percent (8 of 10) of unmanipulated TS1xHACII mice that developed 
arthritis, a significantly lower percentage (22 percent, 2 of 9) of BALB/c 
CD4+CD25+ cell recipient TS1xHACII mice were arthritic by 15 weeks of age  
Figure 3-13 The adoptive transfer of CD4+CD25+ cells from BALB/c mice can prevent
arthritis in TS1xHACII mice (A) Dot plots show 6.5 and Foxp3 staining of CD4+CD25+ 
LN cells from BALB/c mice. (B) 1x106 BALB/c CD4+CD25+ cells were adoptively
transferred into 5 to 6 week old TS1xHACII mice.  Graph shows the average number 
of arthritic limbs per mouse (±SEM) over time of unmanipulated (   , n=10) and 
BALB/c CD4+CD25+ cell recipient (   , n=9) TS1xHACII mice. (C) Arthritis incidence in 
15 week old unmanipulated or BALB/c CD4+CD25+ cell recipient TS1xHACII mice.
Statistical significance was calculated using Fisher’s exact test. (D) The number of
arthritic limbs per mouse in cohorts of unmanipulated and BALB/c CD4+CD25+ cell 
receipient TS1xHACII mice.  Each circle represents an individual mouse.  Line 
represents the average number of arthritic limbs per mouse.  Statistical significance 
was calculated using the Mann-Whitney test.
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(*p=0.02, Fisher’s exact test) (Figure 3-13 C).  Furthermore, similar to the 
observations in TS1xHACII mice that received HACII CD4+CD25+ cells, arthritic 
TS1xHACII mice that received BALB/c CD4+CD25+ cells had only one affected 
limb in comparison to arthritic unmanipulated TS1xHACII mice, which developed 
disease in three to four limbs (Figure 3-13 D).  The reduction in the number of 
affected limbs among arthritic TS1xHACII mice coupled with the decrease in 
disease incidence, resulted in a significantly lower average number of arthritic 
limbs per mouse in TS1xHACII mice that received BALB/c CD4+CD25+ cells in 
comparison to unmanipulated TS1xHACII mice (***p=0.0001, Mann-Whitney). 
 
 These data demonstrate that CD4+CD25+ Treg cells that have not 
developed in the presence of the disease initiating target antigen can effectively 
suppress arthritis development in TS1xHACII mice.   
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3.3 Summary of Results and Discussion 
 
3.3.1 TS1xHACII mice contain endogenous CD4+CD25+Foxp3+ cells, 
including a population that expresses the 6.5 TCR and recognizes the 
disease initiating target antigen 
 
A key feature of the TS1xHACII arthritis model is that we have defined the 
disease-initiating antigen.  TS1xHACII mice on a RAG-/- background develop 
arthritis, demonstrating that recognition of the S1 peptide by 6.5+CD4+ T cells 
alone is sufficient to mediate disease (Rankin et al. 2008).  Arthritis develops in 
TS1xHACII mice despite profound deletion of HA-specific thymocytes and is 
accompanied by the gradual accumulation of total CD4+ and 6.5+CD4+ T cells in 
the systemic LNs (Figure 3-2 D).  Interestingly, older, arthritic TS1xHACII mice 
and age-matched TS1 mice contain comparable numbers of total CD4+ cells and 
6.5+CD4+ cells in the popliteal LNs, which drain the lower joints, but not in 
systemic LNs (Figure 3-2 D and E).  Moreover, the total cellularity of popliteal 
LNs was also higher in older, arthritic TS1xHACII mice than in age-matched TS1 
mice (Figure 3-2 E), suggesting an increased presence of other immune system 
cells in addition to the accumulation of CD4+ cells.  The accumulation of 
6.5+CD4+ T cells and arthritis development in TS1xHACII mice occurs despite the 
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presence of a normal frequency of CD4+CD25+Foxp3+ cells in TS1xHACII mice 
of all ages (Figure 3-3 A).  Furthermore, TS1xHACII mice also contain 
6.5+CD4+CD25+Foxp3+ cells, which are specific for the S1 peptide that initiates 
disease development. 
 
We found that unfractionated (including both 6.5- and 6.5+ cells) 
CD4+CD25+Foxp3+ cells from TS1xHACII mice and CD4+CD25+Foxp3+ cells 
from healthy mice (HACII or BALB/c) had comparable patterns of CTLA-4 and 
GITR expression, indicating that the disease environment does not significantly 
alter the expression of these CD4+CD25+ Treg cell markers. CTLA-4 in particular 
has been shown to be an important mediator of CD4+CD25+ Treg cell function 
(Wing et al. 2008), and altered CTLA-4 regulation can be associated with 
dysfunctional CD4+CD25+ Treg cell activity in RA patients (Flores-Borja et al. 
2008).  Indeed, CD4+CD25+Foxp3+ cells from TS1xHACII mice appeared to be 
more activated than their counterparts from healthy mice, as a larger subset of 
TS1xHACII CD4+CD25+Foxp3+ cells expressed higher levels of CTLA-4 and 
GITR.  Interestingly, we found that within the population of TS1xHACII 
CD4+CD25+Foxp3+ cells, 6.5+ cells expressed higher levels of both CTLA-4 and 
GITR in comparison to 6.5- cells (Figure 3-3 C), suggesting that the S1-specific 
6.5+CD4+CD25+Foxp3+ cells may be more activated in response to interactions 
with their cognate antigen.  Thus CD4+CD25+Foxp3+ cells from TS1xHACII mice 
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are not deficient in classic CD4+CD25+ Treg cells markers such as CTLA-4 and 
GITR.  
 
Although CD4+CD25+Foxp3+ cells are present in TS1xHACII mice, it was 
possible that they possessed dysfunctional suppressor activity, as has been 
reported with CD4+CD25+ Treg cells isolated from human RA patients 
(Ehrenstein et al. 2004; Valencia et al. 2006).  We found that unfractionated 
CD4+CD25+ cells from TS1xHACII mice were able to inhibit both the proliferation 
and cytokine production of responder CD4+ T cells in response to stimulation with 
soluble anti-CD3 (Figure 3-4 A), demonstrating that the CD4+CD25+ cells that are 
present in TS1xHACII mice possess effective in vitro suppressor function.  
Furthermore, TS1xHACII CD4+CD25+ cells stimulated with S1 peptide could also 
inhibit the in vitro proliferation of responder CD4+ T cells (Figure 3-4 B), indicating 
that the CD4+CD25+ cells could exert suppressor function in response to the 
disease-initiating target antigen.  We found that the CD4+CD25+ cells from 
TS1xHACII mice were more effective at inhibiting responder CD4+ T cell 
proliferation when a low dose (0.3 µM) of S1 peptide was used as a stimulus 
(Figure 3-4 B).  However, it is possible that we are underestimating the regulatory 
activity of S1-responsive CD4+CD25+ cells, as we did not isolate 6.5+CD4+CD25+ 
cells from TS1xHACII mice for the suppression assays.  Therefore, although we 
set up the assays using a 1:2 unfractionated TS1xHACII CD4+CD25+ cell to 
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responder cell ratio, the effective ratio of S1-specific CD4+CD25+ cells to 
responder cells is much lower.  For a more accurate assessment of the in vitro 
suppressor function of 6.5+CD4+CD25+ cells from TS1xHACII mice, the 
suppression assay should be conducted using a 1:2 ratio of TS1xHACII 
6.5+CD4+CD25+ cells to responder cells. 
 
We also examined the presence CD4+CD25+Foxp3+ cells in lymphoid 
organs throughout TS1xHACII mice, since alterations in CD4+CD25+ Treg cell 
distribution in lymphoid organs and other tissues can precede the development of 
autoimmune disease (Siegmund et al. 2005; Sather et al. 2007).  Strikingly, while 
we did not observe differences in the distribution of unfractionated 
CD4+CD25+Foxp3+ cells between the draining and non-draining LNs in 
TS1xHACII mice, we found that 6.5+CD4+CD25+Foxp3+ cells were enriched in 
the popliteal LNs (which drain the lower joints and are the site of an enhanced 
immune response in arthritic mice) in comparison to non-draining LNs in 
TS1xHACII mice (Figure 3-5 B).  Interestingly, studies have suggested that 
draining LNs may be enriched for CD4+CD25+ Treg cells that are specific for 
antigens derived from regional organs (Samy et al. 2005; Samy et al. 2008; 
Wheeler et al. 2009).  Indeed, although S1 peptide is presented systemically in 
TS1xHACII mice, it is possible that there is increased presentation of HA-derived 
peptides in the popliteal LNs, which could lead to an enrichment of 
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6.5+CD4+CD25+Foxp3+ cells in the draining LNs.  Thus, TS1xHACII mice develop 
spontaneous inflammatory arthritis despite the presence of CD4+CD25+Foxp3+ 
cells (including a population of 6.5+CD4+CD25+Foxp3+ cells that recognize the 
disease initiating target antigen) that are present in the LNs draining the joints, 
which are a primary site of autoimmune pathology.  
 
3.3.2 Exogenous CD4+CD25+ Treg cells can inhibit the pathogenic Th-17 
response in TS1xHACII mice 
 
We have shown that the administration of exogenous CD4+CD25+ cells 
from HACII or BALB/c mice can prevent arthritis, demonstrating that the 
endogenous effector CD4+ T cells (and other immune cells) that contribute to 
arthritis pathogenesis in TS1xHACII mice are not refractory to CD4+CD25+ Treg 
cell activity (Figure 3-6 and 3-13).  The adoptive transfers of CD4+CD25+ cells 
from HACII and BALB/c mice not only dramatically reduced arthritis incidence in 
TS1xHACII mice, but also appeared to reduce disease severity because 
TS1xHACII mice that received HACII or BALB/c CD4+CD25+ cells possessed 
significantly fewer arthritic limbs than unmanipulated TS1xHACII mice.  Thus, 
HACII and BALB/c CD4+CD25+ Treg cells could modify the degree of disease in 
an individual TS1xHACII mouse in addition to affecting arthritis incidence on a 
population level. 
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HACII CD4+CD25+ Treg cells did not mediate arthritis prevention by 
inhibiting the accumulation of disease initiating S1-specific 6.5+CD4+ T cells in 
TS1xHACII mice, as arthritic unmanipulated TS1xHACII mice and protected 
TS1xHACII mice that received HACII CD4+CD25+ cells contained similar 
numbers of total CD4+ and 6.5+CD4+ T cells in the systemic LNs.  Furthermore, 
protective HACII CD4+CD25+ Treg cells did not alter expression of CD62L, 
CD44, and CD69 on 6.5+ or 6.5- CD4+ T cells in TS1xHACII mice (Figure 3-7 C), 
as 6.5+CD4+ T cells appeared activated and antigen-experienced in both arthritic 
and protected TS1xHACII mice.  Thus, HACII CD4+CD25+ Treg cells do not 
prevent arthritis development by suppressing the accumulation or activation of 
the disease initiating 6.5+CD4+ T cells in TS1xHACII mice.  Instead, HACII 
CD4+CD25+ Treg cells appear to suppress arthritis development by inhibiting the 
pathogenic Th-17 response.  In comparison to arthritic unmanipulated 
TS1xHACII mice, TS1xHACII mice that received protective HACII CD4+CD25+ 
cells exhibited a preferential reduction in the representation of IL-17+CD4+ cells in 
the popliteal LNs (Figure 3-8 B and C), as well as a significant decrease in IL-17 
production by systemic LNs (Figure 3-9 A).  Work in the SKG model of arthritis 
has suggested that homeostatic expansion of CD4+ T cells in a lymphopenic 
environment can contribute to the development of Th-17 cells (Hirota et al. 2007).  
Given the lymphopenia in young TS1xHACII mice, it is possible that the 
accumulation of peripheral CD4+ T cells is a contributing factor to the 
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development of IL-17 producing CD4+ T cells.  However, as described previously, 
protective HACII CD4+CD25+ Treg cells did not alter the accumulation of 6.5+ or 
6.5- CD4+ T cells in TS1xHACII mice (Figure 3-7 A and B), suggesting that they 
are inhibiting Th-17 differentiation by a different mechanism. 
 
Interestingly, TS1xHACII mice that received protective HACII CD4+CD25+ 
cells also produced significantly lower amounts of systemic IL-1β (Figure 3-9 B), 
a cytokine that is associated with promoting IL-17 production (Sutton et al. 2006; 
Acosta-Rodriguez et al. 2007) and arthritis pathogenesis (Koenders et al. 2006; 
Koenders et al. 2008).  The reduction in IL-1β suggests that protective 
CD4+CD25+ Treg cells may suppress IL-17+CD4+ cells by inhibiting other 
cytokines that are required for Th-17 differentiation.  While much work has been 
done to identify the parameters defining in vitro Th-17 differentiation (Mangan et 
al. 2006; Veldhoen et al. 2006; Korn et al. 2009), the key players in in vivo IL-17 
induction remain unclear, though there is speculation that an as yet unidentified 
innate immune system cell may play a role in in vivo Th-17 development (Korn et 
al. 2009).  CD4+CD25+ Treg cells can suppress the innate immune response 
(Maloy et al. 2003), and a potential explanation for decreased IL-17 production in 
protected TS1xHACII mice is that the exogenous CD4+CD25+ Treg cells are 
acting upon an innate immune system cell that is instrumental in inducing the 
differentiation of Th-17 cells.  Moreover, IL-1β has also been shown to induce 
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synoviocyte production of CCL20 (Hirota et al. 2007), the chemokine that binds 
CCR6, which is preferentially expressed on Th-17 cells (Acosta-Rodriguez et al. 
2007; Annunziato et al. 2007).  Thus, it is possible that a decrease in IL-1β 
production reduces not only Th-17 cell differentiation, but also the trafficking of 
IL-17 producing CD4+ cells to the joints or joint-draining LNs.  However, IL-17 
can also act to induce IL-1 expression (Koenders et al. 2006), and it is possible 
that lower levels of IL-1β result from direct CD4+CD25+ Treg cell suppression of 
IL-17+CD4+ cells in protected TS1xHACII mice. 
 
In addition to the reduction of regional and systemic cytokine responses, 
protected TS1xHACII mice contained significantly smaller popliteal LNs than 
unmanipulated arthritic TS1xHACII mice, indicating that the CD4+CD25+ Treg 
cells may also inhibit the accumulation of popliteal LN cells that normally occurs 
in TS1xHACII mice (Figure 3-2 E).  Work in other murine autoimmune disease 
models has illustrated the importance of the regional LN immune response in the 
development of autoimmunity (Hoglund et al. 1999; Samy et al. 2005).  In the 
NOD diabetes model, excision of the pancreatic LNs in young mice prevented 
diabetes onset, demonstrating that the local immune response is required for 
disease pathogenesis (Gagnerault et al. 2002).  Thus, although the disease 
initiating target autoantigen is presented systemically in TS1xHACII mice, it is 
possible that the popliteal LNs present elevated levels of S1 peptide that 
 
 99 
effectively prime the pathogenic 6.5+CD4+ T cells, and that inhibition of this 
regional response by exogenous CD4+CD25+ Treg cells is sufficient to prevent 
arthritis development.  Indeed, recent work in other murine arthritis models 
suggests that CD4+ T cells play a more prominent role in the joint-draining LNs 
than in the joints themselves (Angyal et al. 2010). 
 
It is also possible that CD4+CD25+ Treg cell suppression of regional IL-17 
production prevents the accumulation of popliteal LN cells in TS1xHACII mice.  
IL-17 can induce innate immune cell migration (Lundy et al. 2007; Pelletier et al. 
2010), and the reduction of the local Th-17 response could inhibit the recruitment 
of innate immune and antigen presenting cells, which make up the majority of the 
cells in the popliteal LNs of TS1xHACII mice (Rankin et al. 2008).  Indeed, IL-17 
has been shown to induce monocyte trafficking in arthritis (Shahrara et al. 2009), 
and additional work has demonstrated that monocytes isolated from human RA 
patients can induce Th-17 differentiation of CD4+ T cells (Evans et al. 2009).  
This relationship suggests the possibility of a feedback loop where IL-17 recruits 
innate immune cells such as monocytes, which can further enhance local IL-17 
production by promoting Th-17 cell differentiation.  Thus, the effects of 
exogenous CD4+CD25+ Treg cell inhibition on the Th-17 response would be 
amplified by breaking this cycle. 
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3.3.3 Specificity for the disease initiating target antigen is not required for 
CD4+CD25+ Treg cell suppression of arthritis in TS1xHACII mice 
 
The CD4+CD25+ Treg cells that most effectively suppressed arthritis 
development in TS1xHACII mice were purified from single transgenic HACII or 
BALB/c mice, which provide a polyclonal population of CD4+CD25+ Treg cells 
without transgenic modifications to their endogenous T cell repertoires.  HACII 
mice express the HA transgene (under the same MHC Class II I-Eα promoter as 
in TS1xHACII mice), but not the transgenic 6.5 TCR.  Accordingly, CD4+CD25+ 
cells in HACII mice are the appropriate control population for 6.5-CD4+CD25+ 
cells from TS1xHACII mice in that they also develop in the presence of the HA 
protein from which the disease target antigen (S1 peptide) is derived.  Therefore, 
while CD4+CD25+ cells from HACII mice do not express the 6.5 TCR that is 
specific for S1 peptide, it is possible that there are other S1 peptide or HA 
reactive cells within the population of CD4+CD25+ cells because they developed 
in the presence of HA as a self antigen.  Thus, it is possible that CD4+CD25+ 
Treg cells from HACII mice are capable of preventing arthritis development in 
TS1xHACII mice because a subset of cells can recognize and respond to the S1 
peptide or other HA-derived peptides.  Indeed eight CD4+ T cell epitopes have 
been identified in PR8 HA (Gerhard et al. 1991).  However, BALB/c CD4+CD25+ 
Treg cells, which have not experienced the S1 peptide or the HA protein from 
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which S1 peptide is derived, are also able to suppress arthritis in TS1xHACII 
mice.  This result clearly demonstrates that a population of CD4+CD25+ Treg 
cells without any enrichment for S1-specific or other HA reactive cells can 
effectively shut down S1 peptide initiated autoimmune arthritis in TS1xHACII 
mice.  How might CD4+CD25+ Treg cells from BALB/c mice suppress arthritis 
development in TS1xHACII mice?  One possibility is that CD4+ T cells of other 
specificities have been recruited to the effector phase of arthritis, and that 
CD4+CD25+ Treg cells from BALB/c mice are able to suppress the pathogenic 
CD4+ T cells that are not S1-peptide or HA-specific. 
 
3.3.4 CD4+CD25+ Treg cell activity is highly sensitive to the balance of Treg 
and effector cells 
 
Strikingly, whereas the administration of unfractionated (includes 6.5- and 
6.5+ cells) TS1xHACII CD4+CD25+ cells could not suppress arthritis, TS1xHACII 
CD4+CD25+ cells that had been depleted of 6.5+ cells could modulate arthritis 
development in TS1xHACII mice.  Since 6.5+CD4+CD25+ cells present in 
TS1xHACII mice contain both Foxp3+ and Foxp3- cells, the enhanced ability of 
TS1xHACII 6.5-CD4+CD25+ cells to reduce arthritis incidence in TS1xHACII mice 
could be attributed to the absence of an activated population of 
6.5+CD4+CD25+Foxp3- cells (which are specific for the disease initiating target 
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antigen), suggesting that CD4+CD25+ Treg cell activity is sensitive to the balance 
of Treg and effector cells.  Indeed, the introduction of a small population of 
6.5+CD4+CD25- cells (obtained from TS1xHA28 mice) to protective HACII 
CD4+CD25+ cells altered the efficacy of the HACII CD4+CD25+ cells in preventing 
arthritis development.  The same percentage of unmanipulated TS1xHACII mice 
and TS1xHACII mice that received the mixture of HACII CD4+CD25+ cells and 
TS1xHA28 6.5+CD4+CD25- cells developed arthritis, whereas administration of 
HACII CD4+CD25+ cells alone dramatically reduced arthritis incidence in recipient 
TS1xHACII mice.  Collectively, these data indicate that the balance of 
CD4+CD25+ Treg and effector CD4+ T cells is an important determinant of 
successful Treg cell activity.  Moreover, the marked effects of either depleting or 
introducing a small population of 6.5+CD4+ T cells in the adoptive Treg cell 
transfers to pre-arthritic TS1xHACII mice further emphasizes the particular 
importance of 6.5+CD4+ T cells for arthritis pathogenesis.  Indeed, the 
development of arthritis in TS1xHACII.RAG-/- mice demonstrates that 6.5+CD4+ T 
cells alone are sufficient to mediate disease (Rankin et al. 2008), indicating that 
CD4+ T cells of other specificities are not required in later stages of disease. 
 
Although the administration of TS1xHACII 6.5-CD4+CD25+ cells reduced 
arthritis incidence in TS1xHACII mice, the cells were not as effective as HACII or 
BALB/c CD4+CD25+ cells at preventing arthritis development.  The effect of the 
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transferred 6.5-CD4+CD25+ cells appeared to wane over time, as the percentage 
of arthritic mice among TS1xHACII mice that received the 6.5-CD4+CD25+ cells 
continued to increase during the nine week period of analysis (Figure 3-11 B).  It 
is possible that TS1xHACII 6.5-CD4+CD25+ cells merely delay arthritis onset in 
recipient in TS1xHACII mice, and that eventually disease incidence in 
TS1xHACII mice that received TS1xHACII 6.5-CD4+CD25+ cells would be 
comparable to that in unmanipulated TS1xHACII mice.  Despite using expression 
of the 6.5 TCR to deplete 6.5+CD4+CD25+ cells (which contain both Foxp3+ and 
Foxp3- cells) from the endogenous CD4+CD25+ pool in TS1xHACII mice, it is 
possible that some S1-specific 6.5+CD4+CD25+ remain in the depleted population 
of TS1xHACII CD4+CD25+ cells.  The 6.5+CD4+CD25+ cells may have 
downregulated expression of the 6.5 TCR in response to interactions with the S1 
peptide, or may express two TCRs (due to secondary TCR alpha chain 
rearrangements) resulting in lower levels of 6.5 expression that are not detected 
by staining with the mAb 6.5.  Thus, it is possible that the presence of a 
contaminating population of S1-specific CD4+CD25+ cells interferes with the in 
vivo suppressor function of endogenous 6.5-CD4+CD25+ cells from TS1xHACII 
mice.  
 
Another explanation for the difference in efficacy of TS1xHACII 6.5-
CD4+CD25+ cells and HACII or BALB/c CD4+CD25+ cells in preventing arthritis 
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development in TS1xHACII mice is that the 6.5-CD4+CD25+ cells from 
TS1xHACII mice are less functional than their counterparts in healthy mice.  This 
is consistent with reports that CD4+CD25+ Treg cells from human RA patients are 
dysfunctional due to their exposure to the inflammatory cytokines (e.g. TNF-α) in 
the disease setting (Ehrenstein et al. 2004; Valencia et al. 2006; Nadkarni et al. 
2007).  However, it is clear that CD4+CD25+ cells from HACII or BALB/c mice are 
able to maintain their regulatory effects for up to nine to ten weeks post transfer 
in TS1xHACII mice, indicating that CD4+CD25+ Treg cell activity can occur in the 
context of high levels of inflammatory cytokines.  Still, the CD4+CD25+ T cells in 
TS1xHACII mice might have unique properties that render them susceptible to 
these effects.  Thus, although we examined expression of CD4+CD25+ Treg cell 
markers such as CTLA-4 and GITR on CD4+CD25+ cells from TS1xHACII and 
HACII or BALB/c mice (Figure 3-3 D), we have not analyzed expression of 
cytokine receptors on the respective CD4+CD25+ cell populations. CD4+CD25+ 
cells from TS1xHACII mice may express higher levels of certain cytokine 
receptors than CD4+CD25+ cells from HACII or BALB/c mice, making them more 
susceptible to the inhibitory effects of cytokines, such as IL-6 (Pasare and 
Medzhitov 2003) or TNF-α (Ehrenstein et al. 2004; Valencia et al. 2006; Nadkarni 
et al. 2007), on Treg cell regulatory activity.  Indeed the impact of the presence of 
S1-specific CD4+CD25+ cells described earlier, could be exacerbated if the 
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TS1xHACII CD4+CD25+ cells possess dysfunctional, or less functional, 
regulatory activity. 
 
 The data presented in this chapter show that CD4+CD25+ Treg cells from 
HACII and BALB/c mice can effectively suppress arthritis development in 
TS1xHACII mice.  Interestingly, a fundamental difference between the two 
populations is the antigen specificity of the CD4+CD25+ Treg cells.  In contrast to 
CD4+CD25+ cells in HACII mice, CD4+CD25+ cells in BALB/c mice have not 
developed in the presence of HA, and thus could not be selected on S1 peptide 
or any other HA-derived peptides.  These results have interesting implications for 
how the antigen specificity of CD4+CD25+ Treg cells can affect their ability to 
suppress autoimmune disease.  In the following chapter we address the role of 
antigen specificity in CD4+CD25+ Treg cell function by examining how enrichment 
in specificity for a target autoantigen (S1 peptide) affects the ability of 
CD4+CD25+ Treg cells to suppress arthritis development in TS1xHACII mice. 
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Chapter 4: CD4+CD25+ Treg cells that are enriched in specificity for a 
disease target antigen fail to suppress arthritis in TS1xHACII mice 
4.1 Introduction 
 
Whereas a role for TCR specificity in the thymic development of 
CD4+CD25+ Treg cells has been established (Jordan et al. 2001; Apostolou et al. 
2002; Hori et al. 2002; Walker et al. 2003), how TCR specificity influences the 
phenotype and function of peripheral CD4+CD25+ Treg cells is less clear.  In vitro 
studies have shown that while CD4+CD25+ Treg cells require antigen-specific 
TCR engagement to activate their regulatory function, they are able to suppress 
responder CD4+ T cells of different TCR specificities (Takahashi et al. 1998; 
Thornton and Shevach 1998), indicating that the suppression itself is not antigen-
specific.  However, work in several different models of murine autoimmune 
disease indicates that the activation of antigen- or disease-specific CD4+CD25+ 
Treg cells can be critical for the effective suppression of organ-specific 
autoimmunity (Hori et al 2002; Reddy et al. 2004; Tarbell et al. 2004; Samy et al. 
2005).  In the EAE system, disease development has been linked to an absence 
of CD4+CD25+ Treg cells that are specific for the EAE-associated peptides that 
drive disease, demonstrating that CD4+CD25+ Treg cell recognition of the target 
autoantigen is critical for EAE prevention (Hori et al. 2002; Reddy et al. 2004).  
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However, while studies in both human arthritis patients and mouse models of 
arthritis indicate that CD4+CD25+ Treg cells do modify the immune response 
during arthritis (Morgan et al. 2003; de Kleer et al. 2004; Kelchtermans et al. 
2005; Nguyen et al. 2007; Kang et al. 2008), whether and how the TCR 
specificity for disease target antigen(s) affects CD4+CD25+ Treg cell function is 
unknown. 
 
TS1xHACII mice, in which arthritis development is driven by 6.5+CD4+ T 
cell recognition of the systemically presented S1 peptide, provide a powerful 
system with which to examine whether TCR specificity influences CD4+CD25+ 
Treg cell suppression of arthritis.  In the previous chapter, we showed that 
CD4+CD25+ Treg cells from BALB/c mice, which have not developed in the 
presence of S1 peptide (or any other HA-derived peptide), could prevent arthritis 
development in TS1xHACII mice.  Here we examine whether CD4+CD25+ Treg 
cells specific for the disease target antigen S1 peptide can also suppress arthritis 
in TS1xHACII mice.  TS1xHA28 mice are a rich source of 6.5+CD4+CD25+Foxp3+ 
Treg cells that are generated intrathymically based on the specificity of the 6.5 
TCR for the S1 peptide (which is expressed at low levels driven by an SV40 
promoter enhancer) (Jordan et al. 2001).  Moreover, CD4+CD25+ cells from 
TS1xHA28 mice possess in vivo regulatory function, as they have been shown to 
suppress anti-double-stranded DNA B cell responses in an antigen-specific 
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manner (Seo et al. 2002).  Thus, use of TS1xHA28 CD4+CD25+ cells allows us to 
examine whether expression of a TCR that possesses high reactivity for a 
disease target antigen affects the ability of CD4+CD25+ Treg cells (which are 
capable of suppressing other in vivo immune responses) to prevent arthritis 
development in TS1xHACII mice. 
 
 The data presented in this chapter show that CD4+CD25+ Treg cells that 
are enriched in specificity for a critical disease target antigen fail to prevent 
arthritis development in TS1xHACII mice. CD4+CD25+ Treg cells from TS1xHA28 
mice, which contain a high frequency of 6.5+Foxp3+ cells that possess high 
reactivity for the S1 peptide, do not reduce either arthritis incidence or severity in 
TS1xHACII mice.  This result is recapitulated by the adoptive transfer of 
GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP reporter mice, confirming that 
a highly pure population of CD4+CD25+Foxp3+ Treg cells enriched for 6.5 
expression cannot suppress a disease that is initiated by recognition of S1 
peptide by the endogenous 6.5+CD4+ T cells in TS1xHACII mice.  Interestingly, 
CD4+CD25+ Treg cells from TS1(SW)xPevSW mice, which are enriched for 
expression of a transgenic TCR (TS1(SW) TCR) with low reactivity for S1 peptide 
are able to modulate arthritis development in TS1xHACII mice, although these 
cells are not as effective as CD4+CD25+ Treg cells obtained from HACII or 
BALB/c mice.  In addition, we show that signals through the TCR can shape the 
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phenotype and differentiation of CD4+CD25+ Treg cells, as interactions with high 
levels of cognate antigen can induce cytokine production and CD25 
downregulation by CD4+CD25+ Treg cells.  Collectively, we demonstrate that the 
presence of S1 peptide-reactive CD4+CD25+ Treg cells is detrimental to 
CD4+CD25+ Treg cell mediated suppression of arthritis development in 
TS1xHACII mice. 
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4.2 Results 
 
4.2.1 In vitro suppressor function of CD4+CD25+ cells from TS1xHA28 mice 
can be activated by S1 peptide 
 
 In the previous chapter we showed that the prospective administration of 
exogenous polyclonal CD4+CD25+ Treg cells could prevent arthritis in 
TS1xHACII mice.  We next addressed whether CD4+CD25+ Treg cells that 
express the 6.5 TCR (which recognizes S1 peptide and is also expressed by the 
endogenous pathogenic CD4+ T cells) would also be able to suppress arthritis 
development in TS1xHACII mice.  To examine this, we made use of TS1xHA28 
mice, which produce a high frequency of 6.5+CD4+CD25+Foxp3+ Treg cells 
(Jordan et al. 2001).  Antibody staining and flow cytometric analysis of LN cells 
from TS1xHA28 mice showed that the majority of CD4+CD25+cells co-express 
high levels of the 6.5 TCR and the transcription factor Foxp3 (Figure 4-1 A).  To 
demonstrate that the regulatory activity of TS1xHA28 CD4+CD25+ cells could be 
activated in an antigen-specific manner, we conducted in vitro suppression 
assays using S1 peptide as a stimulus.  CFSE-labeled CD4+ T cells were 
cultured with or without TS1xHA28 CD4+CD25+ cells at a 1:2 Treg:responder cell  
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Figure 4-1 CD4+CD25+ cells from TS1xHA28 mice are enriched in 6.5+Foxp3+ cells
(A) LN cells from TS1xHA28 mice were stained with the mAb 6.5, CD4, CD25, and
Foxp3.  Number indicates the percentage of 6.5+Foxp3+ cells among CD4+CD25+
cells from TS1xHA28 mice. (B) CFSE-labeled CD4+ T cells were cultured alone or
in the presence of CD4+CD25+ cells from TS1xHA28 mice at a 1:2 Treg:responder
cell ratio.  CD4+CD25+ cells were stimulated with S1 peptide.  Dot plots show CFSE
versus IFN-γ production after three days of culture.  Plots are gated on total CD4+
cells.  Numbers in plots indicate the percentage of IFN-γ+ cells among the responder
CD4+ cell population.
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ratio.  After three days of culture, the cells were stimulated with PMA and 
ionomycin and stained for intracellular IFN-γ production.  In the absence of 
TS1xHA28 CD4+CD25+ cells, the responder CD4+ T cells underwent extensive 
proliferation, and 42 percent of the cells produced IFN-γ (Figure 4-1 B).  When 
co-cultured with CD4+CD25+ cells from TS1xHA28 mice, responder CD4+ T cells 
proliferated less, and only 2.5 percent of the cells produced IFN-γ (Figure 4-1 B).  
Thus, S1 peptide can induce potent regulatory activity in CD4+CD25+ cells 
purified from TS1xHA28 mice, which contain a high frequency of 6.5+Foxp3+ 
cells. 
 
4.2.2 CD4+CD25+ Treg cells enriched in specificity for a disease target 
antigen fail to suppress arthritis in TS1xHACII mice 
 
 To examine whether CD4+CD25+ cells enriched in specificity for S1 
peptide could suppress arthritis in TS1xHACII mice, we purified and adoptively 
transferred 1x106 CD4+CD25+ cells from TS1xHA28 mice into young, pre-arthritic 
TS1xHACII mice and tracked the recipient mice for arthritis development.  
Unmanipulated TS1xHACII mice and those that received TS1xHA28 CD4+CD25+ 
cells displayed similar kinetics of disease development (Figure 4-2 A), and by 14 
weeks of age, 80 percent of unmanipulated (8 of 10) and 88.9 percent of 
TS1xHA28 CD4+CD25+ cell recipient (8 of 9) TS1xHACII mice were arthritic 
Figure 4-2 TS1xHA28 CD4+CD25+ cells do not suppress arthritis development in
TS1xHACII mice (A) 1x106 CD4+CD25+ cells purified from TS1xHA28 mice were
adoptively transferred into pre-arthritic TS1xHACII mice.  Graph shows the average
number of arthritic limbs per mouse (±SEM)  over time for unmanipulated (   , n=10) 
and TS1xHA28 CD4+CD25+ cell recipient (   , n=9) TS1xHACII mice. (B) Arthritis 
incidence in 15 week old unmanipulated TS1xHACII mice and TS1xHACII mice that 
received TS1xHA28 CD4+CD25+ cells. (C) The number of arthritic limbs per mouse 
among unmanipulated TS1xHACII mice and TS1xHACII mice that received 
TS1xHA28 CD4+CD25+ cells.  Each circle represents an individual mouse.  Line 
represents the average number of arthritic limbs per mouse.
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(Figure 4-2 B).  Furthermore, the majority (5 of 8) of arthritic mice from both the 
unmanipulated cohort of TS1xHACII mice and the cohort that received 
TS1xHA28 CD4+CD25+ cells developed disease in all four limbs (Figure 4-2 C).  
Thus, in contrast to HACII and BALB/c CD4+CD25+ cells, which dramatically 
reduced arthritis incidence in TS1xHACII mice (Figures 3-6 and 3-13), 
CD4+CD25+ cells from TS1xHA28 mice were unable to prevent arthritis 
development in TS1xHACII mice.  Moreover, CD4+CD25+ cells from TS1xHA28 
mice did not reduce disease severity in TS1xHACII mice, as arthritic mice that 
did or did not receive TS1xHA28 CD4+CD25+ cells exhibited similar numbers of 
affected limbs. 
 
The use of CD4 and CD25 expression to purify Treg cells is limiting in that 
it includes activated conventional CD4+ T cells that have upregulated IL2Rα 
expression.  Accordingly, it is possible that the failure of TS1xHA28 CD4+CD25+ 
cells to prevent arthritis in TS1xHACII mice is due to the presence of 
contaminating 6.5+CD4+CD25+Foxp3- T cells.  To more rigorously purify 
CD4+CD25+ Treg cells based on Foxp3 and CD25 expression rather than on 
CD25 expression alone, we crossed TS1xHA28 mice with Foxp3EGFP mice 
(Haribhai et al. 2007), to generate TS1xHA28.Foxp3EGFP mice.  We examined the 
CD4+CD25+ Treg cell profile in TS1xHA28.Foxp3EGFP mice by staining LN cells 
for expression of 6.5, CD4, CD25, and Foxp3.  GFP+CD25+ cells were clearly 
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identifiable among CD4+ cells, and the majority of GFP+CD4+CD25+ cells co-
expressed high levels of the 6.5 TCR and Foxp3 (Figure 4-3 A).  For adoptive 
transfers into TS1xHACII mice, we purified CD4+CD25+ Treg cells from 
TS1xHA28.Foxp3EGFP mice based on expression of CD4, CD25, and GFP. 
 
We transferred 1x106 TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells into 
pre-arthritic TS1xHACII mice and evaluated the recipient mice for arthritis 
development.  Over the course of nine weeks, there was no significant difference 
in the kinetics of disease development between unmanipulated TS1xHACII mice 
and TS1xHACII mice that received GFP+CD4+CD25+ cells from 
TS1xHA28.Foxp3EGFP mice (Figure 4-3 A).  At 15 weeks of age, 85.7 percent of 
unmanipulated TS1xHACII mice (6 of 7) and 72.7 percent of GFP+CD4+CD25+ 
cell recipient TS1xHACII mice (8 of 11) had developed arthritis (Figure 4-3 B).  
Although arthritis incidence was lower in TS1xHACII mice that received 
GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice, the percentage of 
arthritic animals is consistent with previous observations of disease incidence in 
unmanipulated cohorts of TS1xHACII mice (Figure 3-2 A).  Furthermore, in a 
second cohort of TS1xHACII mice that received TS1xHA28.Foxp3EGFP 
GFP+CD4+CD25+ cells, approximately 90 percent of TS1xHACII mice developed 
arthritis (data not shown), indicating that the GFP+CD4+CD25+ cells do not 
reduce disease incidence in TS1xHACII mice.  Among TS1xHACII mice that 
Figure 4-3 TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells do not prevent arthritis in 
TS1xHACII mice (A) 1x106 TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells were
adoptively transferred into TS1xHACII mice.  Graph shows the average number of
arthritic limbs per mouse (±SEM) over time for unmanipulated (   , n=7) TS1xHACII 
mice and GFP+CD4+CD25+ cell recipient (   , n=11) TS1xHACII mice.  Dot plots show 
CD4, CD25, 6.5, and Foxp3 staining of LN cells from TS1xHA28.Foxp3EGFP mice. 
(B) Arthritis incidence in 15 week old unmanipulated TS1xHACII mice and TS1xHACII 
mice that received GFP+CD4+CD25+ cells. (C) The number of arthritic limbs per 
mouse among unmanipulated TS1xHACII mice and TS1xHACII mice that received 
GFP+CD4+CD25+ cells.  Each circle represents an individual mouse.  Line represents 
the average number of arthritic limbs per mouse.
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developed arthritis, 50 percent of unmanipulated TS1xHACII mice (3 of 6) and 
62.5 percent of TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cell recipient TS1xHACII 
mice (5 of 8) developed disease in all four limbs, and in both cohorts of mice no 
arthritic mouse possessed fewer than two affected limbs (Figure 4-3 C).  Thus, 
GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice, which are heavily 
enriched for 6.5+Foxp3+ cells, fail to suppress arthritis development in TS1xHACII 
mice. 
 
Taken together, these data indicate that CD4+CD25+Foxp3+ Treg cells that 
are enriched in specificity for the target antigen S1 peptide fail to suppress 
arthritis development in TS1xHACII mice. Moreover, the adoptive transfer of 
TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells and TS1xHA28 CD4+CD25+ cells 
appear to have similar effects in TS1xHACII mice, indicating that the failure of 
TS1xHA28 CD4+CD25+ cells to prevent arthritis in TS1xHACII mice cannot be 
solely attributed to the presence of 6.5+CD4+CD25+Foxp3- cells in the initial 
transfer population. 
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4.2.3 Donor CD4+CD25+ Treg cells that are enriched for expression of the 
6.5 TCR persist in TS1xHACII mice 
 
Because CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice expressed 
GFP, we could determine whether the donor GFP+CD4+CD25+ cells persisted in 
arthritic TS1xHACII mice.  Lymphoid organs from 15 week old TS1xHACII mice 
were examined for the presence of TS1xHA28.Foxp3EGFP cells, which were 
identified by co-expression of GFP and the Foxp3 antibody.  Nine to ten weeks 
after the initial transfer, the donor GFP+CD4+CD25+ cells could be detected in 
LNs that drain the lower (popliteal) and upper (axillary & brachial) limbs, as well 
is in the spleen and LNs (cervical, inguinal, and mesenteric) that are not primary 
joint-draining sites (Figure 4-4 A).  GFP+Foxp3+ cells were found at the highest 
percentages in the spleens of TS1xHACII mice that received 
TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells, and among LNs, the 
representation of GFP+Foxp3+CD4+ cells was comparable between joint-draining 
and non-draining LNs (Figure 4-4 B).  Moreover, the recovered 
CD4+GFP+Foxp3+ cells were enriched for high levels of CTLA-4 expression when 
compared to endogenous CD4+CD25+Foxp3+ cells in TS1xHACII mice (Figure 4-
4 C), suggesting that the 6.5+ cells within the TS1xHA28.Foxp3EGFP 
GFP+CD4+CD25+ population were activated upon interactions with their cognate 
antigen. 
Figure 4-4 TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells persist in TS1xHACII
mice  (A) Dot plots show GFP versus Foxp3 antibody staining in CD4+ cells 
from lymphoid organs of TS1xHACII mice ten weeks post transfer of 1x106 
GFP+CD4+CD25+ cells.  Numbers indicate the percentage of GFP+Foxp3+ cells 
among CD4+ cells. (B) The percentages of GFP+Foxp3+ cells among CD4+ cells 
from lymphoid organs of TS1xHACII mice ten weeks post transfer of 1x106 
GFP+CD4+CD25+ cells.  Bars show average values ± SEM.  n=6.  (C) CTLA-4 
staining of endogenous CD4+CD25+Foxp3+ cells (dotted line) and donor 
TS1xHA28.Foxp3EGFP GFP+Foxp3+CD4+ cells (solid line) at ten weeks post 
transfer into TS1xHACII mice.
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  Thus, GFP+CD4+CD25+ cells enriched in specificity for the target antigen 
S1 peptide fail to suppress arthritis in TS1xHACII mice despite persisting in 
TS1xHACII mice for up to ten weeks post transfer, trafficking to the joint draining 
LNs, and upregulating functional markers such as CTLA-4. 
 
4.2.4 CD4+CD25+ Treg cells enriched for expression of the 6.5 TCR do not 
suppress the Th-17 response in popliteal LNs of TS1xHACII mice 
 
We previously showed that protective HACII CD4+CD25+ cells could inhibit 
the regional Th-17 response that develops in the popliteal LNs of TS1xHACII 
mice (Figure 3-8).  To determine whether the inability of TS1xHA28 CD4+CD25+ 
cells to suppress arthritis in TS1xHACII mice could be attributed to a failure to 
inhibit the local Th-17 response, or if disease develops despite TS1xHA28 
CD4+CD25+ cell mediated reduction of IL-17 producing CD4+ T cells in the 
popliteal LNs in TS1xHACII mice, we analyzed IL-17 and IFN-γ production by 
CD4+ T cells in the popliteal LNs of unmanipulated TS1xHACII mice, and of 
TS1xHACII mice that received TS1xHA28 CD4+CD25+ cells.  Popliteal LN cells 
were stimulated for four hours with PMA and ionomycin, and then stained for 
CD4 and intracellular IL-17 and IFN-γ.  CD4+ cells in the popliteal LNs of 
TS1xHACII mice that received TS1xHA28 CD4+CD25+ cells contained similar 
percentages of IL-17-producing cells and slightly higher percentages of IFN-γ-
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producing cells (ns, p=0.31, Student’s t-test) in comparison to unmanipulated 
arthritic TS1xHACII mice (Figure 4-5 A and B).  Thus, CD4+CD25+ cells from 
TS1xHA28 mice did not reduce the Th-17 response in the popliteal LNs of 
TS1xHACII mice. 
 
Whereas the administration of HACII CD4+CD25+ cells resulted in 
significantly smaller popliteal LNs in TS1xHACII mice (Figure 3-8 A), TS1xHACII 
mice that received TS1xHA28 CD4+CD25+ cells did not exhibit a decrease in 
popliteal LN cellularity, and actually averaged higher popliteal LN cellularities 
than unmanipulated TS1xHACII mice, although the difference was not 
statistically significant (p=0.16, Student’s t-test) (Figure 4-5 C).  Correspondingly, 
TS1xHA28 CD4+CD25+ cell recipient TS1xHACII mice also contained higher 
numbers of IFN-γ+CD4+ (ns, p=0.09, Student’s t-test) and IL-17+CD4+ (ns, 
p=0.18, Student’s t-test) cells when compared to unmanipulated TS1xHACII mice 
(Figure 4-5 D).  Although the difference in cell numbers did not reach statistical 
significance, it is clear that unlike protective HACII CD4+CD25+ cells, CD4+CD25+ 
cells from TS1xHA28 mice were unable to inhibit the immune response that 
develops in the popliteal LN cells of TS1xHACII mice. 
 
Although we demonstrated that GFP+CD4+CD25+ cells from 
TS1xHA28.Foxp3EGFP mice failed to suppress arthritis in TS1xHACII mice (Figure 
Figure 4-5 TS1xHA28 CD4+CD25+ cells do not suppress the Th-17 response in
popliteal LNs of TS1xHACII mice (A) Popliteal LN cells were stimulated for 4 hours 
with PMA and ionomycin and then stained for intracellular IL-17 and IFN-γ.  Dot 
plots show IL-17 and IFN-γ production by CD4+ T cells from unmanipulated and 
TS1xHA28 CD4+CD25+ cell recipient TS1xHACII mice.  Numbers indicate the 
percentage of cytokine-producing cells in each gate. (B) Percentages of IL-17 and 
IFN-γ producing popliteal LN CD4+ T cells in unmanipulated and TS1xHA28 
CD4+CD25+ cell recipient  TS1xHACII mice. (C) Numbers of total (gray bar) and CD4+ 
(black bar) cells in the popliteal LNs of unmanipulated and TS1xHA28 CD4+CD25+ 
cell recipient TS1xHACII mice. (total cells, p=0.16) (D) Numbers of IFN-γ+CD4+ and 
IL-17+CD4+ cells in the popliteal LNs of unmanipulated and TS1xHA28 CD4+CD25+ 
cell recipient TS1xHACII mice.  Statistical significance was calculated using the 
Student’s t-test.  Bar graphs show average values ± SEM. unmanipulated TS1xHACII 
mice, n=5; TS1xHA28 CD4+CD25+ cell recipient TS1xHACII mice, n=8
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4-3), we wanted to examine whether a more rigorously purified population of 
CD4+CD25+Foxp3+ Treg cells enriched in specificity for S1 peptide could inhibit 
the regional immune response that develops in the popliteal LNs of TS1xHACII 
mice.  Popliteal LN cells from unmanipulated TS1xHACII mice and TS1xHACII 
mice that received TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells were stimulated 
for four hours with PMA and ionomycin, and then stained for CD4 and 
intracellular IL-17 and IFN-γ.  In comparison to unmanipulated TS1xHACII mice, 
TS1xHACII mice that received TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells 
contained slightly higher percentages of IFN-γ producing CD4+ popliteal LN cells 
and lower percentages of IL-17 producing CD4+ popliteal LN cells (Figure 4-6 A 
and B).  However, the changes in the representation of IFN-γ (ns, p=0.5, 
Student’s t-test) and IL-17 (ns, p=0.25, Student’s t-test) producing CD4+ cells in 
the popliteal LNs of TS1xHACII mice that received TS1xHA28.Foxp3EGFP 
GFP+CD4+CD25+ cells were not statistically significant when compared to 
unmanipulated TS1xHACII mice. 
 
TS1xHACII mice that received GFP+CD4+CD25+ cells averaged higher, 
though not statistically significant (p=0.13, Student’s t-test), numbers of popliteal 
LN cells when compared to unmanipulated TS1xHACII mice (Figure 4-6 C). 
Thus, despite the reduction in the percentage of IL-17-producing CD4+ cells in 
the popliteal LNs, TS1xHACII mice that received TS1xHA28.Foxp3EGFP  
Figure 4-6 TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells do not suppress the Th-17 
response in the popliteal LNs of TS1xHACII mice (A) Popliteal LN cells were 
stimulated for 4 hours  with PMA and ionomycin and then stained for intracellular 
IL-17 and IFN-γ.  Dot plots show IL-17 and IFN-γ production by CD4+ T cells from 
unmanipulated and GFP+CD4+CD25+ cell recipient TS1xHACII mice.  Numbers 
indicate the percentage of cytokine-producing cells in each gate. (B) Percentages of 
IL-17 and IFN-γ producing popliteal LN CD4+ T cells in unmanipulated TS1xHACII
mice and GFP+CD4+CD25+ cell recipient  TS1xHACII  mice.  (C) Numbers of total 
(gray bar) and CD4+ (black bar) cells in the popliteal LNs of unmanipulated and 
GFP+CD4+CD25+ cell recipient TS1xHACII mice. (total cells, p=0.13) (D) Numbers 
of IFN-γ+CD4+ and IL-17+CD4+ cells in the popliteal LNs of unmanipulated and 
GFP+CD4+CD25+ cell recipient TS1xHACII mice.  Statistical significance was
calculated using the Student’s t-test.  Bar graphs show average values ± SEM. n=9 
mice per group for all analyses.
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GFP+CD4+CD25+ cells averaged higher numbers of IL-17+CD4+ popliteal LN 
cells than unmanipulated TS1xHACII mice (Figure 4-6 D).  There was also a 
corresponding increase in the numbers of IFN-γ+CD4+ cells in the popliteal LNs of 
TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cell recipient TS1xHACII mice (Figure 4-
6 D).  Although the increases in total, IL-17+CD4+ (p=0.11, Student’s t-test), and 
IFN-γ+CD4+ (p=0.5, Student’s t-test) popliteal LN cells of TS1xHACII mice that 
received TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells did not reach statistical 
significance, these data suggest that the TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ 
Treg cells not only fail to inhibit the immune response in the popliteal LNs of 
TS1xHACII mice, but may even exacerbate the accumulation of immune cells in 
the joint-draining LNs. 
 
Collectively, these data demonstrate that a highly pure population of 
CD4+CD25+ Treg cells that are enriched for 6.5+Foxp3+ cells fails to inhibit the 
regional Th-17 response and the accumulation of immune cells in the popliteal 
LNs of TS1xHACII mice.   
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4.2.5 CD4+CD25+ Treg cells enriched for expression of the 6.5 TCR do not 
suppress the systemic Th-17 response in TS1xHACII mice 
 
 To further analyze IL-17 production in TS1xHACII mice that received 
CD4+CD25+ cells enriched for 6.5+ cells, we set up unfractionated LN (axillary, 
brachial, cervical, inguinal, and mesenteric) cultures with cells from 
unmanipulated TS1xHACII mice and TS1xHACII mice that received TS1xHA28 
CD4+CD25+ cells.  After three days of culture, supernatants were collected and 
analyzed for IL-17 production.  Unfractionated LN cultures from unmanipulated 
and TS1xHA28 CD4+CD25+ cell recipient TS1xHACII mice contained 
comparable concentrations of IL-17  (Figure 4-7 A).  Indeed LN cells from 
TS1xHACII mice that received TS1xHA28 CD4+CD25+ cells produced slightly 
higher amounts of IL-17 than LN cells from unmanipulated TS1xHACII mice, 
although the difference was not statistically significant (p=0.16, Student’s t-test).  
Thus, CD4+CD25+ cells from TS1xHA28 mice failed to inhibit both the regional 
and systemic Th-17 response in TS1xHACII mice.   
 
We also examined whether TS1xHA28 CD4+CD25+ cells affected the 
production of cytokines associated with Th-17 differentiation (i.e. IL-1 and IL-6) in 
TS1xHACII mice.  Interestingly, LN cultures from TS1xHACII mice that received 
TS1xHA28 CD4+CD25+ cells produced significantly higher levels of IL-1α 
Figure 4-7 TS1xHA28 CD4+CD25+ cells fail to suppress the systemic Th-17 response 
in TS1xHACII mice.  Unfractionated LN (axillary, brachial, cervical, inguinal, and 
mesenteric) cells from unmanipulated TS1xHACII, TS1xHA28 CD4+CD25+ Treg cell 
recipient TS1xHACII, or control TS1 mice were cultured for three days, and 
supernatants were collected and analyzed for (A) IL-17, (B) IL-1β and IL-1α , and 
(C) IL-6.  Statistical signficance was calculated using the Student’s t-test.  Bar graphs 
show average values ± SEM. unmanipulated TS1xHACII mice, n=5; TS1xHA28 
CD4+CD25+ Treg cell recipient TS1xHACII mice, n=8; control TS1 mice, n=3.
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(*p=0.017, Student’s t-test) and increased, though not statistically significant 
(p=0.1, Student’s t-test), amounts of IL-1β in comparison to LN cultures from 
unmanipulated TS1xHACII mice (Figure 4-7 B).  The production of IL-6 by 
unfractionated LN cells from TS1xHACII mice that received TS1xHA28 
CD4+CD25+ cells was also slightly higher than in unmanipulated TS1xHACII mice 
(Figure 4-7 C), though the difference did not reach statistical significance (p=0.5, 
Student’s t-test).  Thus, TS1xHACII mice that received TS1xHA28 CD4+CD25+ 
cells produced similar or even increased levels of cytokines associated with Th-
17 differentiation in comparison to unmanipulated TS1xHACII mice.  This stands 
in marked contrast to TS1xHACII mice that received HACII CD4+CD25+ cells, 
which averaged lower amounts of IL-1 and IL-6 than unmanipulated TS1xHACII 
mice (Figure 3-9 B and C). 
 
Collectively, these data demonstrate that CD4+CD25+ Treg cells enriched 
in specificity for a disease target antigen not only fail to inhibit the pathogenic Th-
17 response in TS1xHACII mice, but may also enhance the production of 
cytokines that can contribute to the differentiation of IL-17 producing cells.   
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4.2.6 Strong antigenic stimulation coupled with lymphopenia can induce 
CD4+CD25+Foxp3+ Treg cells to produce IL-17 
 
 While CD4+CD25+ Treg cells enriched for 6.5+ cells that possess high 
reactivity for S1 peptide are unable to prevent arthritis development in 
TS1xHACII mice, BALB/c CD4+CD25+ Treg cells that have no developmental 
exposure to S1 peptide can suppress arthritis (Figure 3-13).  Collectively, these 
results suggest that expression of the 6.5 TCR, which possesses high reactivity 
for the S1 peptide, may be detrimental to the ability of CD4+CD25+ Treg cells to 
prevent arthritis TS1xHACII mice.  Work in humans has shown that activated, 
“memory” CD4+CD25+Foxp3+ Treg cells are capable of producing IL-17 (Ayyoub 
et al. 2009; Beriou et al. 2009; Voo et al. 2009), and that cytokine production can 
be preferentially induced by strong stimulation of the CD4+CD25+ Treg cells (Voo 
et al. 2009).  To examine whether 6.5+CD4+CD25+Foxp3+ cells exposed to 
strong, chronic antigenic stimulation could develop the ability to produce IL-17, 
we purified and adoptively transferred 6.5+GFP+CD4+CD25+ cells from 
TS1xHA28.Foxp3EGFP mice into HACII.Tcrα-/- or Tcrα-/- recipient mice (Figure 4-8 
A, upper panel).  In both hosts, 6.5+GFP+CD4+CD25+ cells would enter a 
lymphopenic environment (as is also the condition in young TS1xHACII mice), 
but in HACII.Tcrα-/- mice the donor CD4+CD25+ Treg cells would also encounter 
high levels of their cognate antigen S1 peptide.   
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One week after transfer, LN cells were isolated from HACII.Tcrα-/- and 
Tcrα-/- mice, stimulated for four hours with PMA and ionomycin, and stained with 
intracellular IL-17 and IFN-γ to determine cytokine production.  Donor 
CD4+CD25+ Treg cells, which were identified by co-expression of GFP and 
Foxp3, were present in the LNs of both HACII.Tcrα-/- and Tcrα-/- mice, though 
there was a far greater percentage in HACII.Tcrα-/- mice (Figure 4-8 A, lower left 
panel), most likely due to enhanced expansion of the 6.5+GFP+CD4+CD25+ cells 
in response to S1 peptide.  Although donor 6.5+GFP+CD4+CD25+ cells could be 
detected in both HACII.Tcrα-/- and Tcrα-/- mice, we observed notable cytokine 
production only in GFP+Foxp3+ cells recovered from HACII.Tcrα-/- mice (Figure 4-
8 A, lower right panel), indicating that TCR interactions with self-peptide can 
promote cytokine production in CD4+CD25+Foxp3+ Treg cells.  Interestingly, the 
GFP+Foxp3+ cells in HACII.Tcrα-/- mice preferentially produced IL-17 (7.6 
percent) over IFN-γ (2.1 percent). 
 
To examine the effects of exposure to high levels of cognate antigen 
coupled with lymphopenia on Th-17 differentiation of conventional CD4+ T cells, 
we purified CD4+ cells from TS1 Thy1.1+ mice (which are enriched for 6.5+ cells), 
and adoptively transferred the cells into HACII.Tcrα-/-, Tcrα-/-, or BALB/c mice 
which all expressed Thy1.2.  One week post transfer LN cells from HACII.Tcrα-/-,  
Figure 4-8 6.5+CD4+CD25+Foxp3+ cells produce IL-17 and IFN-γ upon exposure to 
high levels of cognate antigen in a lymphopenic environment (A) 1x106 6.5+GFP+
CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice were transferred into HACII.TCRα-/- 
or TCRα-/- mice.  One week later LN cells were stimulated for 4 hours with PMA and 
ionomycin and stained for CD4, Foxp3, IL-17, and IFN-γ.  Upper panel, Dot plots show 
representative purities from cell sorts.  Numbers indicate the percentages of 
CD4+CD25+ cells and 6.5+GFP+ cells.  Lower panel, Left dot plots show donor 
GFP+Foxp3+ donor Treg cells within CD4+ cells.  Numbers indicate the  percentage of 
GFP+Foxp3+ cells.  Right dot plots show IL-17 and IFN-γ staining in GFP+Foxp3+CD4+ 
cells.  Numbers indicate the percentages of the respective cytokines. (B) 1x106 CD4+ 
T cells from TS1 Thy1.1 mice were transferred into HACII.TCRα-/-, TCRα-/- , or BALB/c 
mice. One week later LN cells were stimulated for 4 hours with PMA and ionomycin 
and stained for Thy1.1, CD4, Foxp3, IL-17, and IFN-γ.  Left dot plots show donor 
Thy1.1+CD4+ cells among CD4+ cells.  Numbers indicate the percentage of Thy1.1+
Foxp3- cells.  Right dot plots show IL-17 and IFN-γ staining in Thy1.1+Foxp3-CD4+ 
cells. Numbers indicate the percentages of the respective cytokines. 
B
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Tcrα-/-, and BALB/c mice were stimulated with PMA and ionomycin and stained 
for Thy1.1, CD4, IL-17, and IFN-γ.  The donor Thy1.1+CD4+ cells were present in 
all recipient mice (Figure 4-8 B, left panel), albeit at the highest frequency in 
HACII.Tcrα-/- mice, which most likely reflects the expansion of the 6.5+CD4+ T 
cells in response to S1 peptide.  Donor CD4+ cells produced cytokines in Tcrα-/- 
but not BALB/c mice (Figure 4-8 B, right panel), indicating that exposure to 
lymphopenic environments could induce the differentiation of conventional CD4+ 
T cells.  In Tcrα-/- mice, the highest percentage of Thy1.1+CD4+Foxp3- cells 
produced IL-17 (24.4 percent), followed by 13.1 percent of IFN-γ producing cells, 
and 7.2 percent of IL-17+IFN-γ+ double-producers (Figure 4-8 B).  In contrast, in 
HACII.Tcrα-/- mice, Thy1.1+CD4+Foxp3- cells primarily produced IFN-γ (30.4 
percent), with lower percentages of cells producing IL-17 (1.2 percent) or co-
producing IL-17 and IFN-γ (1.2 percent) (Figure 5-1 B).   
 
These data show that signals received through the TCR can induce 
CD4+CD25+Foxp3+ Treg cells to differentiate to produce cytokines.  Moreover, 
upon exposure to a lymphopenic environment containing high levels of their 
cognate antigen CD4+CD25+Foxp3+ Treg cells preferentially produced IL-17 
rather than IFN-γ.  Interestingly, while conventional CD4+ T cells preferentially 
produced IL-17 in Tcrα-/- mice, introduction of high levels of HA skewed the cells 
towards IFN-γ production.  These results suggest that upon exposure to high 
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levels of cognate antigen in the context of a lymphopenic environment, 
CD4+CD25+ Treg cells preferentially produce IL-17, whereas conventional CD4+ 
T cells preferentially produce IFN-γ. 
 
4.2.7 6.5+CD4+CD25+ Treg cells from TS1xHA28.Foxp3EGFP mice do not 
differentiate to produce IL-17 in TS1xHACII mice 
 
We next examined whether 6.5+CD4+CD25+ Treg cells could also acquire 
the ability to produce IL-17 or IFN-γ in TS1xHACII mice.  To test this, we purified 
and transferred 1x106 6.5+GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP 
mice into young pre-arthritic TS1xHACII, older arthritic TS1xHACII, or control 
HACII mice.  Pre-arthritic and arthritic TS1xHACII mice were used to determine 
whether the additional “space” available in young, lymphopenic TS1xHACII mice 
contributes to the differentiation of CD4+CD25+ Treg cells.  HACII mice were 
used to examine how strong antigenic stimulation without the inflammation found 
in TS1xHACII mice would affect cytokine production by CD4+CD25+ Treg cells.  
Donor CD4+CD25+ Treg cells (identified by co-expression of GFP and Foxp3) 
were present in the LNs of pre-arthritic TS1xHACII, older arthritic TS1xHACII, 
and single transgenic HACII mice one week post transfer (Figure 4-9 A, upper 
panel).  The increased percentage of GFP+Foxp3+ cells in young, pre-arthritic 
TS1xHACII mice is due to the lower number of CD4+ cells in young TS1xHACII 
 
 134 
mice, and GFP+Foxp3+ cell recoveries were comparable in the three different 
recipients (data not shown).  However, in contrast to what was observed in 
HACII.Tcrα-/- mice, the transferred 6.5+GFP+CD4+CD25+ cells produced 
negligible amounts of IL-17 and IFN-γ in all three recipients (Figure 4-9 A, lower 
panel).  Moreover, 6.5+GFP+CD4+CD25+ cells did not produce either IL-17 or 
IFN-γ two or three weeks post transfer into pre-arthritic or arthritic TS1xHACII 
mice (data not shown). 
 
We next examined whether localization to the popliteal versus non-joint 
draining LNs might affect the differentiation of CD4+CD25+Foxp3+ Treg cells in 
TS1xHACII mice.  To address, this we analyzed the cytokine profile of donor 
GFP+CD4+CD25+ Treg cells from the popliteal and non-draining LNs in 15 week 
old TS1xHACII mice that had received 1x106 TS1xHA28.Foxp3EGFP 
GFP+CD4+CD25+ cells ten weeks earlier.  Although GFP+Foxp3+ cells were 
present in both the draining and non-draining LNs (Figure 4-9 B, left panel), the 
GFP+Foxp3+ cells did not produce IL-17 or IFN-γ in either the popliteal or non-
draining LNs of TS1xHACII mice (Figure 4-9 B, right panel).  These data 
demonstrate that GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice do not 
differentiate to produce either IL-17 or IFN-γ even after ten weeks in TS1xHACII 
mice.  Furthermore, the micro-environment of the draining LN did not favor 
induction of IL-17 or IFN-γ production by the donor CD4+CD25+ Treg cells, as  
Figure 4-9 TS1xHA28.Foxp3EGFP 6.5+CD4+CD25+Foxp3+ cells do not produce IL-17 or 
IFN-γ in TS1xHACII mice (A) 1x106 TS1xHA28.Foxp3EGFP  6.5+GFP+CD4+CD25+ cells 
were adoptively transferred into HACII, young pre-arthritic TS1xHACII, or arthritic 
TS1xHACII mice.  One week post transfer LN cells from recipient mice were 
stimulated with PMA and ionomycin, and stained for CD4, Foxp3, IL-17, and IFN-γ.  
Upper panel, dot plots show donor GFP+Foxp3+ Treg cells among CD4+ cells.
Numbers indicate the percentage of GFP+Foxp3+ cells.  Lower panel, dot plots are 
gated on GFP+Foxp3+CD4+ cells.  Numbers indicate the percentages of IL-17 and 
IFN-γ producing cells. (B) TS1xHACII mice that received 1x106 TS1xHA28.Foxp3EGFP 
GFP+CD4+CD25+ cells (from Figure 4-3) were analyzed 10 weeks post transfer.  
Popliteal and non-draining (cervical, inguinal, mesenteric) LNs were stimulated as 
described in part (A) to determine IL-17 and IFN-γ production by GFP+Foxp3+ cells.  
Numbers indicate the percentages of GFP+Foxp3+ and cytokine-producing cells in the 
respective dot plots.  
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GFP+CD4+CD25+ cells in both the popliteal and non-draining LNs in TS1xHACII 
mice did not produce either cytokine. 
 
Thus, while 6.5+CD4+CD25+Foxp3+ cells can acquire the ability to produce 
IL-17 in response to strong TCR signals, they do not undergo this phenotypic 
change upon transfer into TS1xHACII mice, and it is unlikely that IL-17 
production by 6.5+CD4+CD25+Foxp3+ cells explains the inability of CD4+CD25+ 
Treg cells enriched for S1-specificity to prevent arthritis development in 
TS1xHACII mice. 
 
4.2.8 Strong antigenic stimulation induces CD4+CD25+ Treg cell 
downregulation of CD25 
 
 In addition to observations that CD4+CD25+Foxp3+ Treg cells can produce 
cytokines (such as IL-17 and IFN-γ) that are associated with activated 
conventional CD4+ T cells (Ayyoub et al. 2009; Beriou et al. 2009; Oldenhove et 
al. 2009; Voo et al. 2009), recent work has demonstrated that CD4+CD25+ Treg 
cells can also lose Foxp3 expression and subsequently acquire effector functions 
(Xu et al. 2007; Osorio et al. 2008; Yang et al 2008; Duarte et al. 2009; Hoffman 
et al. 2009; Komatsu et al. 2009; Murai et al. 2009; Zhou et al. 2009).  The 
plasticity of the CD4+CD25+ Treg cell population has been most apparent in 
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conditions of lymphopenia and inflammation (Komatsu et al. 2009; Murai et al. 
2009; Zhou et al. 2009).  While we have shown that 6.5+CD4+CD25+Foxp3+ cells 
do not differentiate to produce IL-17 or IFN-γ in TS1xHACII mice, we could not 
eliminate the possibility that a subset of TS1xHA28 CD4+CD25+ Treg cells in 
TS1xHACII mice might undergo phenotypic changes that could contribute to the 
loss of Foxp3 expression and regulatory function.  CD25 has been shown to play 
an important role not only in the survival of CD4+CD25+ Treg cells (D'Cruz and 
Klein 2005; Fontenot et al. 2005; Setoguchi et al. 2005), but also in the 
maintenance of Foxp3 expression (Fontenot et al. 2005; Zorn et al. 2006).  
Indeed, recent work showed CD4+CD25-Foxp3+ cells were more susceptible to 
losing Foxp3 expression than CD4+CD25+Foxp3+ cells (Komatsu et al. 2009).   
 
To determine the effects of the the environment in TS1xHACII mice on 
CD25 expression by CD4+CD25+ Treg cells from TS1xHA28 mice upon 
exposure, we adoptively transferred CFSE-labeled CD4+CD25+ cells purified 
from TS1xHA28 mice into TS1xHACII, HACII, or BALB/c mice and analyzed the 
donor cells three days post transfer. CFSE-labeling the TS1xHA28 CD4+CD25+ 
cells allows us to examine their proliferation in the respective host mice, and also 
to distinguish the donor 6.5+ cells from endogenous 6.5+CD4+ cells in TS1xHACII 
mice.  As expected, we observed no CFSE dilution by TS1xHA28 CD4+CD25+ 
cells in BALB/c mice, which do not express HA as a self antigen (Figure 4-10, 
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upper panel).  In contrast, TS1xHA28 CD4+CD25+ cells underwent extensive 
proliferation in both TS1xHACII and HACII mice (Figure 4-10, upper panel), since 
the 6.5+CD4+CD25+ cells encounter high levels of their cognate antigen (S1 
peptide) in both hosts.  Proliferation of TS1xHA28 CD4+CD25+ cells was 
comparable in TS1xHACII and HACII mice, indicating that competition for S1 
peptide with endogenous TS1xHACII 6.5+CD4+ T cells was not inhibitory to 
TS1xHA28 CD4+CD25+ cell proliferation in TS1xHACII mice.   
 
Three days post transfer, the majority of transferred TS1xHA28 
CD4+CD25+ cells maintained high levels of CD25 expression in BALB/c mice, 
and only 7.1 percent of the cells were Foxp3+CD25- (Figure 4-10, lower panel).  
In contrast, a larger population of Foxp3+CD25- cells was present among donor 
TS1xHA28 CD4+CD25+ cells in TS1xHACII and HACII mice.  In TS1xHACII mice, 
27.3 percent of the transferred TS1xHA28 CD4+CD25+ cells were Foxp3+CD25-, 
and 35.2 percent of donor TS1xHA28 CD4+CD25+ cells were Foxp3+CD25- in 
HACII mice (Figure 4-10, lower panel).  The enhanced loss of CD25 expression 
by TS1xHA28 CD4+CD25+ cells in TS1xHACII and HACII mice but not BALB/c 
mice demonstrates that TCR signals and/or cell proliferation contribute to CD25 
downregulation by CD4+CD25+ Treg cells.  Moreover, TS1xHA28 CD4+CD25+ 
cells exhibited similar degrees of CD25 downregulation in TS1xHACII and HACII  
 
Figure 4-10 Exposure to high levels of cognate antigen induces CD25 downregulation 
in CD4+CD25+ Treg cells.  1x106 CFSE-labeled CD4+CD25+ cells from TS1xHA28 mice 
were adoptively transferred into BALB/c, TS1xHACII, or HACII mice.  Three days post 
transfer, LN cells from recipient mice were analyzed for the proliferation (upper panel) 
and the Foxp3 and CD25 expression profile (lower panel) of the donor Treg cells.  
Flow plots are gated on CFSE+ cells.  Lower panel, Numbers indicate the percentage 
of cells in each quadrant.
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mice, indicating that a strong antigenic stimulus alone, rather than high levels of 
antigen in addition to inflammation can induce CD25 downregulation. 
 
Together, these data show CD4+CD25+ cells from TS1xHA28 mice can 
undergo in vivo proliferation in response to S1 peptide, and that a subset of cells 
loses CD25 expression upon exposure to high levels of their cognate antigen in 
TS1xHACII and HACII mice. 
 
4.2.9 CD4+CD25+ Treg cells can maintain CD25 expression in the presence 
of low levels of their cognate antigen 
 
We next examined whether the maintenance of CD25 expression by 
TS1xHA28 CD4+CD25+ cells differed in conditions that induced strong (defined 
as high levels of HA) versus weak (defined as low levels of HA) proliferation by 
transferring CFSE-labeled TS1xHA28 CD4+CD25+ cells into HACII or HA28 
mice, which contain high and low levels of HA respectively.  Three and ten days 
post transfer LN cells were isolated from HACII and HA28 recipient mice and 
stained for 6.5, CD4, CD25, and Foxp3 expression.  At three days post transfer, 
the majority of TS1xHA28 CD4+CD25+ cells in HACII mice had undergone 
several rounds of division, whereas in HA28 mice most of the TS1xHA28 
CD4+CD25+ cells remained CFSE bright and only a small subset of cells had 
 
 141 
begun to proliferate (Figure 4-11 A, left panel).  By ten days post transfer, 
TS1xHA28 CD4+CD25+ cells had proliferated further in HACII mice, and some 
cells had completely diluted their CFSE (Figure 4-11 A, right panel).  TS1xHA28 
CD4+CD25+ cells in HA28 mice also proliferated more by day ten in comparison 
to day three post transfer, with some cells undergoing three or four cell divisions 
(Figure 4-11 A, right panel).  Consistent with our previous observations (Figure 4-
10), by three days after the initial transfer a subset of TS1xHA28 CD4+CD25+ 
cells in HACII mice downregulated CD25 expression (Figure 4-11 B, left panel), 
and by ten days post transfer into HACII mice the representation of both 
Foxp3+CD25- and Foxp3-CD25- cells was increased within the donor TS1xHA28 
CD4+CD25+ cell population (Figure 4-11 B, right panel).  In contrast, TS1xHA28 
CD4+CD25+ cells maintained high levels of CD25 expression at both three and 
ten days post transfer into HA28 mice (Figure 4-11 B, left panel).   
 
Taken together, these data demonstrate that CD4+CD25+ Treg cells can 
maintain high levels of CD25 expression when exposed to low, but not high, 
levels of their cognate antigen.  Moreover, maintenance of CD25 expression  
appears to be inversely related to the extent of proliferation by the CD4+CD25+ 
Treg cells. 
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Figure 4-11 CD4+CD25+ Treg cells can maintain high levels of CD25 expression
upon exposure to low, but not high, levels of cognate antigen (A) 1x106 CFSE-
labeled TS1xHA28 CD4+CD25+ cells were adoptively transferred into HACII (high 
HA levels) or HA28 (low HA levels) mice.  Proliferation of the donor cells (identified 
by CFSE and the mAb 6.5) was analyzed at days 3 (left panel) and 10 (right panel) 
post transfer.  Dot plots are gated on CD4+ cells. (B) Dot plots show Foxp3 and 
CD25 staining of donor TS1xHA28 CD4+CD25+ Treg cells in HACII and HA28 mice 
at days 3 (left panel) and 10 (right panel) post transfer.  Data is representative of 
three separate experiments.
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4.2.10 S1 peptide can activate the in vitro suppressor function of 
CD4+CD25+ cells expressing a TCR with low reactivity for S1 
 
 The finding that BALB/c CD4+CD25+ Treg cells (which have no exposure 
to S1 peptide or HA), but not TS1xHA28 CD4+CD25+ Treg cells (which are 
enriched for highly reactive S1-specific cells), can prevent arthritis development 
in TS1xHACII mice strongly suggests that enrichment for cells that recognize S1 
peptide is detrimental to CD4+CD25+ Treg cell suppression of arthritis.  Data 
presented in this chapter also demonstrate that interactions with high levels of 
cognate antigen can induce phenotypic changes (i.e. cytokine production, CD25 
downregulation) in CD4+CD25+ Treg cells that express the 6.5 TCR, which 
possesses high reactivity for S1 peptide.  However, TS1xHA28 CD4+CD25+ Treg 
cells were able to maintain high levels of CD25 expression when exposed to low 
levels of S1 peptide, suggesting that the strength of signal through the TCR can 
affect the phenotype of CD4+CD25+ Treg cells.  Thus, we examined whether a 
population of CD4+CD25+ Treg cells that was enriched for cells expressing a 
TCR with low reactivity for S1 peptide would be able to modulate arthritis in 
TS1xHACII mice by using TS1(SW)xPevSW mice which co-express CD4+ T cells 
that express the TS1(SW) TCR and the SW virus HA (driven by a β-globin locus 
control region) as a self-antigen. The TS1(SW) TCR (identified by antibodies to 
Vα8.3 and Vβ10) is specific for the S1(SW) peptide, which differs from the PR8 
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S1 peptide by two amino acid substitutions, and possesses much lower reactivity 
for the S1 peptide (Jordan et al. 2001).  TS1(SW)xPevSW mice generate a high 
frequency of CD4+CD25+Foxp3+ cells that are enriched for expression of the 
TS1(SW) TCR (Figure 4-12 A). 
 
To confirm that suppressor function in CD4+CD25+ cells from 
TS1(SW)xPevSW mice can be triggered in an antigen-specific manner, we 
conducted in vitro assays using S1(SW) peptide to stimulate the CD4+CD25+ 
cells.  CFSE-labeled responder CD4+ T cells were cultured alone or with 
TS1(SW)xPevSW CD4+CD25+ cells at a 1:2 Treg:responder cell ratio.  Three 
days later we examined proliferation and cytokine production by responder CD4+ 
T cells.  When cultured alone responder CD4+ T cells underwent extensive 
proliferation and approximately 75 percent of the cells produced IFN-γ (Figure 4-
12 B, left panel).  In contrast, when CD4+CD25+ cells from TS1(SW)xPevSW 
mice were present, responder CD4+ T cells proliferated less and only 10.4  
percent of the cells differentiated to produce IFN-γ (Figure 4-12 B, left panel).  
This inhibition was also reflected in the recoveries of total and IFN-γ+ responder 
CD4+ T cells, which were far lower in the presence of TS1(SW)xPev(SW) 
CD4+CD25+ cells than when responder CD4+ T cells were cultured alone (Figure 
4-12 B, right panel). 
 
Figure 4-12  The suppressor function of CD4+CD25+ cells expressing the TS1(SW) 
TCR can be activated by non-cognate interactions with S1 peptide (A) Vα8.3+Vβ10+ 
cells in CD4+CD25+Foxp3+ LN cells from TS1(SW)xPevSW mice.  Numbers indicate 
the percentage of cells in the respective gates.  (B) CFSE-labeled CD4+ T cells were 
cultured alone or with TS1(SW)xPevSW CD4+CD25+ cells at a 1:2 Treg:responder 
cell ratio.  CD4+CD25+ cells were stimulated with S1(SW) peptide.  Left panel, Dot 
plots show CFSE versus IFN-γ production after three days of culture.  Numbers 
indicate the percentage of IFN-γ+ cells among the responder CD4+ cells.  Right panel, 
Graphs show the numbers of total and IFN-γ+ responder cells in the respective culture 
conditions.  (C) CFSE-labeled CD4+ T cells were cultured alone or in the presence of 
CD4+CD25+ cells from TS1xHA28 or TS1(SW)xPevSW mice at 1:2 Treg:responder 
cell ratio.  HACII splenocytes (which present S1 peptide) were used to stimulate the 
cultures.  Left panel, Dot plots show CFSE versus IFN-γ production after three days 
of culture. Numbers indicate the percentage of IFN-γ+ cells among the responder CD4+ 
cells.  Right panel, Graphs show the numbers of total and IFN-γ+ responder cells in the
respective culture conditions.
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We next determined whether CD4+CD25+ cells from TS1(SW)xPevSW mice 
could exert in vitro regulatory function when activated by S1 peptide, which is 
less reactive with the TS1(SW) TCR. CFSE-labeled responder CD4+ T cells were 
co-cultured with CD4+CD25+ cells from TS1(SW)xPevSW mice, or as a control 
for 6.5+CD4+CD25+ Treg cells, TS1xHA28 mice.  HACII splenocytes, which 
present S1 peptide, were used to stimulate the cultured cells. After three days of 
culture, we examined proliferation and cytokine production by responder CD4+ T 
cells.  When cultured alone, responder CD4+ T cells underwent robust 
proliferation, and approximately 45 percent of the cells produced IFN-γ (Figure 4-
12 C, left panel).  The addition of TS1xHA28 CD4+CD25+ cells reduced 
responder CD4+ T cell proliferation and cytokine production, as only 1.5 percent 
of the cells produced IFN-γ (Figure 4-12 C, left panel).  When co-cultured with 
CD4+CD25+ cells from TS1(SW)xPevSW mice, responder CD4+ T cells also 
proliferated less and only 9.1 percent of the cells produced IFN-γ (Figure 4-12 C, 
left panel).   
 
CD4+CD25+ Treg cell suppression of responder CD4+ T cells was also 
evident in the numbers of total responder CD4+ T cells in the cultures, which 
were much lower in the presence of either set of CD4+CD25+ cells than when the 
responder CD4+ T cells were cultured alone (Figure 4-12 C, lower panel).  
Moreover, the numbers of total responder CD4+ T cells were comparable in 
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cultures with either TS1xHA28 or TS1(SW)xPevSW CD4+CD25+ cells.  In 
comparison to when responder CD4+ T cells were cultured alone, co-culture of 
CD4+CD25+ cells also dramatically reduced the numbers of IFN-γ+ responder 
CD4+ T cells.  However, reflecting the difference in percentages of IFN-γ+ cells in 
cultures with TS1xHA28 or TS1(SW)xPevSW CD4+CD25+ cells (Figure 4-12 C, 
upper panel), more IFN-γ producing responder CD4+ T cells were recovered from 
cultures with TS1(SW)xPevSW CD4+CD25+ cells than TS1xHA28 CD4+CD25+ 
cells (Figure 4-12 C, lower panel).  
 
Thus, the in vitro suppressor function of CD4+CD25+ Treg cells enriched 
for expression of the TS1(SW) TCR can be activated by both cognate (S1(SW) 
peptide) and non-cognate interactions (S1 peptide).  Moreover, although the 
TS1(SW) TCR has much lower reactivity for the S1 peptide than the 6.5 TCR, 
stimulation with S1 peptide induced comparable suppression of responder CD4+ 
T cells by both TS1(SW)xPevSW and TS1xHA28 CD4+CD25+ cells. 
 
4.2.11 CD4+CD25+ Treg cells expressing a TCR with low reactivity for S1 
peptide can modulate arthritis development in TS1xHACII mice 
 
We have established that CD4+CD25+ Treg cells expressing the TS1(SW) 
TCR can be activated S1 peptide, and to examine the ability of  
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TS1(SW)xPevSW CD4+CD25+ cells to modulate arthritis development in 
TS1xHACII mice we purified and transferred 1x106 CD4+CD25+ cells from 
TS1(SW)xPevSW mice into pre-arthritic TS1xHACII mice and tracked the 
recipients for disease development.  At each time point during the nine week 
period of analysis, TS1xHACII mice that received TS1(SW)xPevSW CD4+CD25+ 
cells averaged fewer arthritic limbs per mouse than unmanipulated TS1xHACII 
mice (Figure 4-13 A).  To determine whether this was a reflection of reduced 
disease incidence or lower numbers of affected limbs per arthritic mouse, we 
examined the kinetics of arthritis incidence in both cohorts of TS1xHACII mice. 
TS1xHACII mice that received TS1(SW)xPevSW CD4+CD25+ cells exhibited a 
slightly delayed kinetics in disease development, but by 15 weeks of age 75 
percent of both TS1(SW)xPevSW CD4+CD25+ cell recipient and unmanipulated 
TS1xHACII mice had developed arthritis (Figure 4-13 B). 
 
We also examined 12 and 15 week old TS1xHACII mice to determine 
whether the administration of TS1(SW)xPevSW CD4+CD25+ cells reduced the 
number of affected limbs in arthritic TS1xHACII mice.  Among 12 week old 
arthritic mice, the majority (6 of 9, 66.7 percent) of unmanipulated TS1xHACII 
mice had three or four affected limbs, where as the majority (4 of 6, 66.7 percent) 
of TS1xHACII mice that received TS1(SW)xPevSW CD4+CD25+ cells had two or 
one affected limbs (Figure 4-13 C, upper left panel).  Thus, in 12 week old mice,  
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the reduction in arthritis incidence in TS1xHACII mice that received 
TS1(SW)xPevSW CD4+CD25+ cells was accompanied by a decrease in the 
number of affected limbs per arthritic TS1xHACII mouse.  By 15 weeks of age 
despite having the same incidence of arthritis development, 77.8 percent (7 of 9) 
of arthritic unmanipulated TS1xHACII mice possessed three or four affected 
limbs, in comparison to 44.4 percent (4 of 9) of TS1xHACII mice that received 
TS1(SW)xPevSW CD4+CD25+ cells (Figure 4-13 C, right graph).  Moreover, 44.4 
percent (4 of 9) of arthritic TS1xHACII mice that received TS1(SW)xPevSW 
CD4+CD25+ cells had only one affected limb, whereas only 11.1 percent (1 of 9) 
of arthritic unmanipulated TS1xHACII mice had one affected limb.   
 
In contrast, the transfer of TS1xHA28 CD4+CD25+ cells into TS1xHACII 
mice (Figure 4-2) did not result in a reduction in the number of affected limbs in 
arthritic mice.  Among 12 week old arthritic mice, 50 percent of unmanipulated 
TS1xHACII mice and 57.1 percent of TS1xHACII mice that received TS1xHA28 
CD4+CD25+ cells had three or four affected limbs (Figure 4-13 C, lower left 
panel).  Moreover, by 15 weeks of age, the representation of arthritic mice with 
three or four affected limbs had increased to 87.5 percent in TS1xHACII mice 
that received TS1xHA28 CD4+CD25+ cells (Figure 4-13 C, lower right panel).  
These data suggest that CD4+CD25+ Treg cells possessing low reactivity for S1 
peptide can ameliorate arthritis severity in TS1xHACII mice. 
 
 151 
 
 Collectively, these data show that CD4+CD25+ Treg cells enriched for 
expression of the TS1(SW) TCR, which possesses low reactivity for the disease 
target antigen S1 peptide, can modulate arthritis development in TS1xHACII 
mice by delaying the kinetics of disease incidence and reducing arthritis severity.   
 
4.2.12 CD4+CD25+ Treg cells enriched for the TS1(SW) TCR proliferate less 
and can maintain CD25 expression upon exposure to high levels of the 
mis-matched S1 peptide 
 
We previously showed that CD4+CD25+ cells from TS1xHA28 mice 
downregulate CD25 in response to high levels of HA present in TS1xHACII or 
HACII mice (Figure 4-10).  Given the low reactivity of the TS1(SW) TCR for S1 
peptide, we hypothesized that CD4+CD25+ Treg cells from TS1(SW)xPevSW 
mice might be less susceptible to CD25 downregulation upon exposure to the 
high levels of HA present in TS1xHACII mice.  Since TS1xHACII mice do not 
contain endogenous CD4+ cells that express the TS1(SW) TCR, we could 
identify the donor CD4+CD25+ cells from TS1(SW)xPevSW mice by staining for 
co-expression of Vα8.3 and Vβ10, and examine the Foxp3 and CD25 profiles of 
the donor Vα8.3+Vβ10+CD4+ cells.  LN and spleen cells from unmanipulated 
TS1xHACII mice and mice that received TS1(SW)xPevSW CD4+CD25+ cells 
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were stained for Vα8.3, Vβ10, CD4, Foxp3, and CD25.  Nine weeks after 
transfer, donor Vα8.3+Vβ10+CD4+ cells could be detected in the LNs and spleens 
of TS1xHACII mice that received TS1(SW)xPevSW CD4+CD25+ cells (Figure 4-
14 A, upper panel).  Among Vα8.3+Vβ10+CD4+ cells recovered from the LNs of 
TS1xHACII mice, approximately 50 percent of the cells were Foxp3+CD25+, and 
36.9 percent expressed neither Foxp3 nor CD25 (Figure 4-14 A, lower left panel).  
In Vα8.3+Vβ10+CD4+ cells recovered from the spleens of TS1xHACII mice, up to 
72.6 percent of cells retained Foxp3 and CD25 expression, 13.9 percent of cells 
were Foxp3+CD25-, and 5.8 percent of the cells expressed neither Foxp3 nor 
CD25 (Figure 4-14 A, lower right panel). 
 
The maintenance of Foxp3 and CD25 expression in Vα8.3+Vβ10+CD4+ 
cells recovered from TS1xHACII mice was striking when compared to TS1xHA28 
CD4+CD25+ cells, which had dramatically downregulated CD25 expression after 
just three days in TS1xHACII or HACII mice (Figure 4-10).  Indeed, after ten days 
in HACII mice, the majority of TS1xHA28 CD4+CD25+ cells were either 
Foxp3+CD25- or Foxp3-CD25- (Figure 4-11).  To examine whether CD4+CD25+ 
cells from TS1(SW)xPevSW mice could better maintain CD25 expression in 
response to high levels of HA we purified and adoptively transferred CFSE-
labeled CD4+CD25+ cells from TS1(SW)xPevSW mice into PevSW (which 
contain low levels of the cognate S1(SW) peptide) or HACII (which contain high  
Figure 4-14 Foxp3 and CD25 profile of TS1(SW)xPevSW CD4+CD25+ cells exposed
to high levels of the mis-matched S1 peptide (A) LN cells from TS1xHACII mice that 
received 1x106 TS1(SW)xPevSW CD4+CD25+ cells were stained for CD4, CD25, 
Foxp3, Vα8.3, and Vβ10 expression ten weeks post transfer.  Upper panel, Dot plots 
show Vα8.3+Vβ10+ cells in the LNs and spleen of TS1xHACII mice.  Right plot shows
representative staining from a control TS1xHACII mouse that did not receive cells. 
Lower panel, Foxp3 and CD25 profile of recovered Vα8.3+Vβ10+CD4+ cells. (B) 1x106 
CFSE-labeled TS1(SW)xPevSW CD4+CD25+ cells were adoptively transferred into 
PevSW or HACII mice.  Three days later donor cells were analyzed for their CFSE 
and Foxp3 and CD25 expression profiles.  Upper panel, histograms show CFSE 
profiles of donor cells in PevSW and HACII mice. Lower panel, Foxp3 and CD25 
profiles of CFSE+ cells from PevSW and HACII mice.  Numbers indicate the 
percentage of cells in the respective quadrants.
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levels of the mis-matched S1 peptide) mice.  Three days post transfer we 
examined the CFSE and Foxp3 and CD25 expression profiles of the donor cells. 
 
At three days post transfer, a subset of TS1(SW)xPevSW CD4+CD25+ 
cells had proliferated in PevSW mice, with some cells undergoing up to five 
divisions (Figure 4-14 B, upper panel).  The dividing cells are most likely the 
Vα8.3+Vβ10+ population responding to the presence of their cognate antigen 
S1(SW) peptide in PevSW mice.  In contrast, TS1(SW)xPevSW CD4+CD25+ 
cells proliferated less in HACII mice, and the cells that did expand underwent 
fewer cell divisions than proliferating cells in PevSW mice (Figure 4-14 B, upper 
panel).  Additionally, the majority of TS1(SW)xPevSW CD4+CD25+ cells 
recovered from PevSW mice maintained high levels of CD25 expression (Figure 
4-14 B, lower panel), similar to what was observed with TS1xHA28 CD4+CD25+ 
cells in HA28 mice (Figure 4-11).  Interestingly, the majority of TS1(SW)xPevSW 
CD4+CD25+ cells recovered from HACII mice also maintained high levels of 
CD25 expression (Figure 4-14, lower panel), which is in marked contrast to the 
phenotype of TS1xHA28 CD4+CD25+ cells after transfer into HACII mice.  
 
Collectively these data demonstrate that CD4+CD25+ cells from 
TS1(SW)xPevSW mice proliferate more extensively in response to lower levels 
of the cognate antigen S1(SW) peptide in PevSW mice than to high levels of the 
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mis-matched S1 peptide (which can activate their suppressor function) present in 
HACII mice.  Moreover, although a subset of TS1(SW)xPevSW CD4+CD25+ cells 
lost CD25 expression upon transfer into TS1xHACII mice, our data suggest that 
the phenotypic changes may occur more slowly than in 6.5+CD4+CD25+ Treg 
cells, since TS1(SW)xPevSW CD4+CD25+ cells but not TS1xHA28 CD4+CD25+ 
cells could maintain high levels of CD25 expression after three days in HACII 
mice.  These data suggest that the low reactivity of the TS1(SW) TCR for S1 
peptide counters the high levels of HA present in TS1xHACII or HACII mice.  
Therefore, although the mis-matched S1 peptide can activate comparable in vitro 
suppressor function in TS1xHA28 and TS1(SW)xPevSW CD4+CD25+ Treg cells, 
it has disparate effects on the in vivo proliferation and CD25 maintenance of 
CD4+CD25+ Treg cells enriched for expression of the 6.5 TCR (cognate 
interaction) versus the TS1(SW) TCR (non-cognate interaction).  
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4.3 Summary of Results and Discussion 
 
4.3.1 CD4+CD25+ Treg cells that are enriched in specificity for a disease 
target antigen fail to suppress arthritis development in TS1xHACII mice  
 
 The recognition of S1 peptide by 6.5+CD4+ T cells is required for arthritis 
development in TS1xHACII mice.  Strikingly, we found that CD4+CD25+ Treg 
cells enriched in specificity for S1 peptide were unable to modulate arthritis 
development in TS1xHACII mice, as the administration of CD4+CD25+ cells from 
TS1xHA28 mice, which generate a high frequency of 6.5+Foxp3+ cells (Jordan et 
al. 2001), did not reduce arthritis incidence or disease severity (as defined by the 
number of affected limbs per arthritic mouse) in TS1xHACII mice.  
GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice, a more stringently 
isolated CD4+CD25+ Treg cell population (since GFP was used as a surrogate for 
Foxp3 expression), also failed to suppress arthritis development in TS1xHACII 
mice.  Collectively, these data demonstrate that CD4+CD25+ Treg cells with high 
reactivity for a critical disease target antigen fail to prevent arthritis in TS1xHACII 
mice.  Moreover, the failure of TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells to 
suppress arthritis development in TS1xHACII mice indicates that the inability of 
TS1xHA28 CD4+CD25+ cells (in which GFP expression was not used as a 
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parameter for CD4+CD25+ Treg cell purification) to prevent disease in TS1xHACII 
mice is not solely due to the presence of 6.5+CD4+CD25+Foxp3- cells in the initial 
transfer population. 
 
 Donor TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells could be detected in 
lymphoid organs throughout TS1xHACII mice (including the popliteal LNs) for up 
to ten weeks post transfer, indicating that the failure of CD4+CD25+ Treg cells 
that are enriched for 6.5 TCR expression to prevent arthritis in TS1xHACII mice 
could not be attributed to deletion of the donor CD4+CD25+ Treg cells or an 
inability to traffic to the joint-draining LNs, which are a primary site of 
autoimmune pathology.  However despite accessing the joint draining LNs, 
CD4+CD25+ Treg cells from TS1xHA28 and TS1xHA28.Foxp3EGFP mice could not 
suppress the accumulation of immune cells or the Th-17 response that develops 
in the popliteal LNs of TS1xHACII mice, whereas both responses were 
significantly diminished in TS1xHACII mice that received protective HACII 
CD4+CD25+ cells.  Furthermore, TS1xHA28 CD4+CD25+ cells were also unable 
to suppress IL-17 production by systemic LN cells in TS1xHACII mice.  Strikingly, 
beyond an inability to suppress the systemic Th-17 response in TS1xHACII mice, 
CD4+CD25+ cells from TS1xHA28 mice appeared to enhance production of other 
cytokines that could contribute to Th-17 differentiation, as unfractionated LN 
cultures from TS1xHACII mice that received TS1xHA28 CD4+CD25+ cells 
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contained significantly higher levels of IL-1β, and also slightly higher levels of IL-
1α and IL-6 in comparison to unmanipulated TS1xHACII mice (Figure 4-7 B and 
C).  Thus, CD4+CD25+ Treg cells that are enriched in specificity for a disease 
target antigen not only fail to suppress a cytokine that is critical for arthritis 
development in TS1xHACII mice, but also appear to enhance the production of 
other cytokines that not only contribute to Th-17 differentiation, but also have 
roles in arthritis pathogenesis. 
 
4.3.2 Interactions with high levels of cognate antigen can induce 
phenotypic changes in CD4+CD25+ Treg cells  
 
Recent work has shown that activated human CD4+CD25+Foxp3+ Treg 
cells can produce IL-17 (Ayyoub et al. 2009; Beriou et al. 2009; Voo et al. 2009), 
and interestingly, there is some indication that strong TCR signals are more 
effective at inducing IL-17 production by CD4+CD25+Foxp3+ Treg cells (Voo et al. 
2009).   We found that 6.5+GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP 
mice could differentiate to produce both IL-17 and IFN-γ in HACII.Tcrα-/- but not 
Tcrα-/- mice (Figure 4-8), indicating that high levels of cognate antigen coupled 
with lymphopenia but not lymphopenia alone could induce CD4+CD25+Foxp3+ 
Treg cells to produce cytokines.  Moreover, we also observed that 
6.5+CD4+CD25+Foxp3+ Treg cells in HACII.Tcrα-/- mice preferentially produced 
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IL-17 over IFN-γ, whereas conventional CD4+ T cells that were enriched for 6.5 
expression produced more IFN-γ than IL-17 upon transfer into HACII.Tcrα-/- mice, 
suggesting that CD4+CD25+ Treg cells may be predisposed towards IL-17 
production.  Studies in human CD4+CD25+ Treg cells have shown that memory 
CD4+CD25+ Treg cells produce more IL-17 than IFN-γ (Ayyoub et al. 2009), and 
attempts to induce in vitro cytokine production by murine CD4+CD25+Foxp3+ 
Treg cells suggest that CD4+CD25+ Treg cells may favor IL-17 production (Xu et 
al. 2007; Osorio et al. 2008). 
 
However, despite our observation that 6.5+CD4+CD25+Foxp3+ Treg cells 
could acquire the ability to produce cytokines in response to strong TCR signals, 
TS1xHA28.Foxp3EGFP 6.5+GFP+CD4+CD25+ cells did not produce IL-17 or IFN-γ 
upon transfer into TS1xHACII mice regardless of the duration of exposure (up to 
ten weeks post transfer) or localization (popliteal versus non-draining LNs) in 
TS1xHACII mice.  These data indicate that the inability of CD4+CD25+ Treg cells 
enriched for S1-specificity to prevent arthritis in TS1xHACII mice is not due to IL-
17 production by the donor CD4+CD25+Foxp3+ Treg cells.  It is interesting that 
6.5+CD4+CD25+Foxp3+ Treg cells differentiate to produce IL-17 and IFN-γ in 
HACII.Tcrα-/-, but not TS1xHACII mice, which not only contain high levels of their 
cognate antigen, but also an inflammatory environment that supports the 
differentiation of endogenous pathogenic IL-17 producing cells.  Indeed, work in 
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both humans and mice have demonstrated the important role that cytokines (e.g. 
IL-6, IL-1β, IL-23) play in inducing IL-17 production by CD4+CD25+Foxp3+ Treg 
cells (Koenen et al. 2008; Beriou et al. 2009; Voo et al. 2009).  One possibility is 
that competition for cytokines between donor 6.5+CD4+CD25+ Treg cells and 
endogenous CD4+ T cells in TS1xHACII mice prevents the donor CD4+CD25+ 
Treg cells from differentiating to produce IL-17.  However, it is also possible that 
CD4+CD25+ Treg cells must be exposed to high levels of cognate antigen 
coupled with extreme lymphopenia for in vivo differentiation to produce cytokines 
and although young TS1xHACII mice are lymphopenic, they do not recapitulate 
the condition in HACII.Tcrα-/- mice, which completely lack αβ TCR T cells.   
 
 In addition to the observation that Foxp3+ Treg cells are capable of 
producing Th-1 or Th-17 cytokines, recent work has further highlighted the 
plasticity of the CD4+CD25+ Treg cell population, as multiple groups have shown 
that CD4+CD25+ Treg cells can lose Foxp3 expression and undergo 
differentiation to acquire effector T cell properties (Komatsu et al. 2009; Murai et 
al. 2009; Zhou et al. 2009).  Thus, although GFP+CD4+CD25+Foxp3+ cells from 
TS1xHA28.Foxp3EGFP mice did not differentiate to produce IL-17 in TS1xHACII 
mice, we could not eliminate the possibility that a subset of 6.5+CD4+CD25+ Treg 
cells had lost Foxp3 expression and acquired effector functions that could 
contribute to arthritis pathogenesis in TS1xHACII mice.  Indeed work in the NOD 
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diabetes model has shown that CD4+CD25+ Treg cells that have lost Foxp3 
expression can become pathogenic and promote diabetes development (Zhou et 
al. 2009).  In the absence of a congenic mismatch between TS1xHA28 
CD4+CD25+ Treg cells and TS1xHACII cells, we could not distinguish between 
the donor and endogenous 6.5+CD4+ cells to analyze whether a subset of 
6.5+CD4+CD25+ Treg cells lost Foxp3 expression after long term exposure to the 
environment in TS1xHACII mice.  However, to begin to address the potential 
instability of 6.5+CD4+CD25+ Treg cells we conducted short term experiments 
with CFSE-labeled TS1xHA28 CD4+CD25+ cells in TS1xHACII mice, and 
extended analyses in single HA-transgenic mice that did contain any 
endogenous 6.5+CD4+ cells to examine whether TS1xHA28 CD4+CD25+ cell 
might undergo phenotypic changes that could lead to loss of Foxp3 expression. 
 
Interestingly, we observed that CD4+CD25+ cells from TS1xHA28 mice 
downregulated CD25 expression upon transfer into arthritic TS1xHACII or 
healthy HACII mice, but not in BALB/c mice.  This demonstrated that strong TCR 
signals (via high levels of HA) alone could induce the loss of CD25 expression, 
and that the inflammatory environment present in TS1xHACII mice was not 
required for this change. CD25 has been shown to be critical for CD4+CD25+ 
Treg cell survival and also for maintenance of Foxp3 expression (D’Cruz et al. 
2005; Fontenot et al. 2005; Setoguchi et al. 2005; Zorn et al. 2006), as signaling 
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through the IL2Rα chain has been shown to potentiate both CD25 and Foxp3 
expression (Fontenot et al. 2005).  Since TS1xHA28 CD4+CD25+ cells 
downregulate CD25 upon exposure to high levels of HA in TS1xHACII mice, it is 
possible that with time some of the Foxp3+CD25- cells will also lose Foxp3 
expression.  This would generate a population of 6.5+CD4+CD25-Foxp3- cells that 
possess high reactivity for S1 peptide in TS1xHACII mice, and the potential to 
differentiate and develop effector functions that could contribute to arthritis 
development.  
 
Interestingly, whereas TS1xHA28 CD4+CD25+ cells downregulated CD25 
after transfer into HACII mice, the cells were able to maintain high levels of CD25 
expression in HA28 mice, which express low levels of HA, suggesting that the 
amount of cognate antigen correlates with the degree of CD25 downregulation.  
However, it is also possible that the differences in maintenance of CD25 
expression by TS1xHA28 CD4+CD25+ cells in HACII and HA28 mice are due to 
the more extensive proliferation of TS1xHA28 CD4+CD25+ cells in HACII mice.  
Indeed, TS1xHA28 CD4+CD25+ cells at day ten post transfer in HA28 mice had 
undergone fewer rounds of division than TS1xHA28 CD4+CD25+ cells in HACII 
mice at day three post transfer.  Accordingly, it is possible that TS1xHA28 
CD4+CD25+ cells would also begin to downregulate CD25 expression in HA28 
mice after undergoing additional rounds of proliferation.  Therefore, while 
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exposure to high levels of cognate antigen can induce rapid downregulation of 
CD25 by CD4+CD25+ Treg cells, low levels of the same antigen either do not 
induce or significantly delay CD25 downregulation. 
 
4.3.3 CD4+CD25+ Treg cells enriched for cells with low reactivity for S1 
peptide can modify arthritis in TS1xHACII mice 
 
We have shown that interactions with high levels of cognate interaction 
can induce phenotypic changes in TS1xHA28 CD4+CD25+ Treg cells that could 
contribute to their failure in preventing arthritis development in TS1xHACII mice.  
Furthermore, the ability of CD4+CD25+ Treg cells from HACII or BALB/c mice, 
neither of which contain 6.5+ cells, to suppress arthritis development in 
TS1xHACII mice demonstrates that CD4+CD25+ Treg cells that are not enriched 
for cells with high reactivity for S1 peptide can prevent disease.  Taken together, 
these data suggest that interactions with high levels of cognate antigen are 
detrimental to the ability of 6.5+CD4+CD25+ Treg cells to suppress arthritis in 
TS1xHACII mice.  Indeed, interactions with high levels of cognate antigen can 
promote cytokine production and CD25 downregulation by CD4+CD25+ Treg cells 
(Figures 4-8 and 4-11).  However, CD4+CD25+ Treg cells were able to maintain 
high levels of CD25 expression when exposed to lower levels of their cognate 
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antigen, indicating that adjusting the strength of TCR signaling could alter the 
CD4+CD25+ Treg cell response to the same S1 peptide. 
 
Thus, we examined whether reducing the reactivity of the CD4+CD25+ 
Treg cell TCR for S1 peptide would allow CD4+CD25+ Treg cells that were 
enriched for S1 peptide reactive cells to modulate arthritis development in 
TS1xHACII mice.  We found that CD4+CD25+ Treg cells from TS1(SW)xPevSW 
mice, which are enriched for cells expressing the TS1(SW) TCR  (identified by 
Vα8.3+Vβ10+ staining) that possesses low reactivity for S1 peptide, could delay 
the kinetics of arthritis development in TS1xHACII mice and also appeared to 
ameliorate disease severity among arthritic TS1xHACII mice.  We found that 
TS1(SW)xPevSW CD4+CD25+ cells proliferated better in response to low levels 
of their cognate S1(SW) peptide than to high levels of the mis-matched S1 
peptide in HACII mice, indicating that increased amounts of antigen cannot 
overcome the low reactivity of the TS1(SW) TCR to induce robust proliferation of 
the CD4+CD25+ cells.  However, the poor proliferation of TS1(SW)xPevSW 
CD4+CD25+ cells in HACII mice may explain the interesting result that 
TS1(SW)xPevSW CD4+CD25+ cells were able to maintain high levels of CD25 
expression in the presence of both low levels of their cognate antigen S1(SW) 
peptide (in PevSW mice) and high levels of the mis-matched S1 peptide (in 
HACII mice).  These data suggest that the lower reactivity of the TS1(SW) TCR 
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for S1 peptide counteracts the effects of high HA levels in HACII mice, similar to 
the effect of reducing HA levels on CD25 maintenance by TS1xHA28 
CD4+CD25+ cells.  However, it is clear that TS1(SW)xPevSW CD4+CD25+ cells 
can lose CD25 expression and potentially Foxp3 expression in TS1xHACII mice 
(Figure 4-14), and it is therefore possible that the lower reactivity TCR simply 
delays this process. 
 
Although CD4+CD25+ cells from TS1(SW)xPevSW mice were more 
effective than CD4+CD25+ cells from TS1xHA28 mice at modulating arthritis in 
TS1xHACII mice, they were not as successful as HACII or BALB/c CD4+CD25+ 
cells, suggesting that the presence of CD4+CD25+ Treg cells that recognize the 
S1 peptide is detrimental to CD4+CD25+ Treg cell suppression of arthritis in 
TS1xHACII mice, regardless of whether the CD4+CD25+ Treg cells express 
TCRs possessing high or low reactivity for the S1 peptide.  Indeed the different 
abilities of TS1(SW)xPevSW CD4+CD25+ cells and TS1xHA28 CD4+CD25+ cells 
to modulate arthritis in TS1xHACII mice could be due to differences in the 
representation of cells that can recognize the S1 peptide rather than differences 
in the respective TCR reactivities for S1 peptide.  Whereas approximately 30 
percent of TS1(SW)xPevSW CD4+CD25+ cells express the TS1(SW) TCR, 
upwards of 60 percent of CD4+CD25+ cells from TS1xHA28 mice express the 6.5 
TCR.  Thus, if CD4+CD25+ Treg cells that are enriched for cells that recognize S1 
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peptide are unable to prevent arthritis development in TS1xHACII mice because 
of the de-differentiation of CD4+CD25+Foxp3+ Treg cells to Foxp3- cells, it is likely 
that the transfer of TS1xHA28 CD4+CD25+ cells into TS1xHACII mice would 
result in a larger population of effector cells originating from former CD4+CD25+ 
Treg cells, due to both the increased size of the starting 6.5+ population and also 
enhanced proliferation of 6.5+CD4+CD25+ cells in response to S1 peptide.  The 
most accurate way to assess how reactivity alone affects the ability of 
CD4+CD25+ Treg cells to suppress arthritis in TS1xHACII mice would be to use 
clonotype in addition to CD4 and CD25 to sort 6.5+CD4+CD25+ cells from 
TS1xHA28 mice and Vα8.3+Vβ10+CD4+CD25+ cells from TS1(SW)xPevSW 
mice.  
 
4.3.4 CD4+CD25+ Treg cells enriched in specificity for S1 peptide may be 
unable to suppress arthritis development in TS1xHACII mice 
 
 While we have considered whether TCR specificity for S1 peptide could 
lead to dysfunctional CD4+CD25+ Treg cell activity that renders CD4+CD25+ Treg 
cells unable to suppress arthritis in TS1xHACII mice, another possibility is that 
CD4+CD25+ Treg cells that are enriched for S1-specificity function normally in 
TS1xHACII mice, but do not prevent disease development.  Activated TS1xHA28 
CD4+CD25+ Treg cells could promote the differentiation of pathogenic IL-17-
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producing CD4+ cells by producing high levels of the regulatory cytokines TGF-β, 
which in the context of cytokines such as IL-6 and IL-1 (which are present in 
TS1xHACII mice) can induce Th-17 differentiation.  Indeed, early studies 
examining Th-17 differentiation identified TGF-β as a key factor in IL-17 
production because of the presence of CD4+CD25+ Treg cells in the in vitro 
cultures (Veldhoen et al. 2006).  Thus, it is possible that upon transfer into 
TS1xHACII mice, TS1xHA28 CD4+CD25+ Treg cells become activated, undergo 
extensive proliferation, produce TGF-β, and thus foster an environment that is 
even more supportive of the development of pathogenic IL-17 producing cells. 
 
 Another possibility is that CD4+CD25+ Treg cells from TS1xHA28 or 
TS1(SW)xPevSW mice, while enriched for cells that recognize S1 peptide, do not 
contain the appropriate specificities to suppress cells that are mediating the 
effector stage of arthritis in TS1xHACII mice.  Although recognition of S1 peptide 
by 6.5+CD4+ T cells is important for arthritis development in TS1xHACII mice, as 
disease progresses other autoreactive CD4+ T cells may be recruited to 
participate in subsequent stages of arthritis pathogenesis in TS1xHACII mice.  
Indeed, epitope spreading has been reported in a variety of murine autoimmune 
diseases (Vanderlugt and Miller 2002).  An intriguing aspect of this possibility is it 
that it implies that in vivo CD4+CD25+ Treg cell suppression of target cells is 
antigen specific, as opposed to in vitro studies demonstrating that while 
 
 168 
CD4+CD25+ Treg cells require antigen-specific TCR engagement for activation, 
they are capable of suppressing responder CD4+ T cells regardless of their 
specificity.  Therefore, if CD4+CD25+ Treg cells from TS1xHA28 or 
TS1(SW)xPevSW mice can suppress 6.5+CD4+ T cells that initiate arthritis 
development in TS1xHACII mice, it would be interesting to examine whether 
adoptive transfers of TS1xHA28 or TS1(SW)xPevSW CD4+CD25+ into 
TS1xHACII mice that are younger than 5 to 6 weeks of age could prevent arthritis 
development. 
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Chapter 5: Discussion and Speculation 
5.1 Introduction 
 
It is well established that CD4+CD25+ Treg cells play a critical role in the 
prevention of autoimmunity (Bennett et al. 2001; Gambineri et al. 2003; Fontenot 
and Rudensky 2005; Kim et al. 2007), but how CD4+CD25+ Treg cells mediate 
suppression remains unknown.  In particular, the role that TCR specificities play 
in guiding the in vivo regulatory function of CD4+CD25+ Treg cells is unclear.  
While studies in several different models of murine autoimmune disease (e.g. 
AOD, diabetes, EAE) indicate that CD4+CD25+ Treg cells that are specific for 
disease-associated antigens are more effective at suppressing organ-specific 
autoimmune diseases than polyclonal CD4+CD25+ Treg cells (Hori et al. 2002; 
Tarbell et al. 2004; Samy et al. 2005; Samy et al 2008; Wheeler et al. 2009), how 
the antigen-specificity of CD4+CD25+ Treg cells affects their ability to modulate 
autoimmune arthritis is unknown.  We have shown that CD4+CD25+ Treg cells 
that are enriched in specificity for a critical disease target antigen fail to prevent 
arthritis development in TS1xHACII mice, whereas CD4+CD25+ Treg cells that 
have not been educated by the disease target antigen can suppress disease.  
This chapter discusses these results in the context of antigen-specificity and 
CD4+CD25+ Treg cell mediated suppression of other autoimmune disease 
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models, and also examines how expression of a TCR with high reactivity for a 
target antigen may contribute to the failure of antigen-specific Treg cells to 
prevent arthritis in TS1xHACII mice. 
 
5.2 The role of CD4+CD25+ Treg cells in arthritis development 
 
Studies in human arthritis patients and in mouse models of inflammatory 
arthritis have reached the seemingly paradoxical conclusion that arthritis 
develops despite the presence of CD4+CD25+Foxp3+ Treg cells.  The presence 
of a normal and in some instances increased representation of 
CD4+CD25+Foxp3+ cells in arthritis patients and arthritic mice raises questions 
about whether CD4+CD25+ Treg cells are capable of modifying the disease.  
However, several studies have provided some evidence for CD4+CD25+ Treg cell 
activity during arthritis as CD4+CD25+ cells isolated from human arthritis patients 
(Ehrenstein et al. 2004; Valencia et al. 2006; Nadkarni et al. 2007) and arthritic 
mice (Kang et al. 2008; Monte et al. 2008) have been shown to possess in vitro 
suppressor function.  More importantly, there are indications that CD4+CD25+ 
Treg cells are exerting regulatory effects in vivo.  Among individuals with JIA, an 
enrichment of CD4+CD25+ T cells correlates with persistent oligoarticular JIA, a 
milder form of the disease (de Kleer et al. 2004), suggesting that CD4+CD25+ 
Treg cells may modulate disease severity in human arthritis patients.  In mice, 
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depletion of CD4+CD25+ Treg cells by anti-CD25 treatment results in more 
severe CIA (Morgan et al. 2003; Kelchtermans et al. 2005), and in lymphocytic 
infiltration into otherwise unaffected organs in K/BxN mice (Kang et al. 2008).  
Moreover, K/BxN.Foxp3-sf mice, which lack CD4+CD25+Foxp3+ cells, develop an 
accelerated and more severe disease (Nguyen et al. 2007).  Collectively, these 
data indicate that CD4+CD25+ Treg cells are active in arthritic patients and in 
arthritic mice, and while they are unable to fully prevent arthritis, they can 
ameliorate disease severity and/or modify other aspects of the autoimmune 
response.   
 
TS1xHACII mice contain CD4+CD25+Foxp3+ cells, including a population 
of 6.5+CD4+CD25+Foxp3+ cells that recognize S1 peptide (Figure 3-3 A and B), 
and similar to observations in the CIA and K/BxN arthritis models, 
CD4+CD25+Foxp3+ cells are present in the joint-draining LNs of TS1xHACII mice 
(Figure 3-5).  Additionally CD4+CD25+ cells isolated from arthritic TS1xHACII 
mice possess in vitro suppressor function (Figure 3-4).  Thus, TS1xHACII mice 
develop arthritis despite the presence of endogenous CD4+CD25+Foxp3+ cells, 
including a population of cells that are specific for the disease target antigen S1 
peptide.  However, the arthritis that develops in TS1xHACII mice is susceptible to 
CD4+CD25+ Treg cell activity, as the administration of exogenous polyclonal 
CD4+CD25+ Treg cells can prevent arthritis development in TS1xHACII mice 
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(Figures 3-6 and 3-13).  Given the ability of exogenous CD4+CD25+ Treg cells to 
suppress arthritis in TS1xHACII mice, why do the endogenous 
CD4+CD25+Foxp3+ cells fail to prevent disease?  Studies in human arthritis 
patients have indicated that effector CD4+ T cells isolated from individuals with 
RA are resistant to CD4+CD25+ Treg cell mediated suppression (de Kleer et al. 
2004; van Amelsfort et al. 2007).  Additionally, work in the EAE system has also 
demonstrated that effector CD4+ T cells can become refractory to CD4+CD25+ 
Treg cell activity, as wildtype CD4+CD25+ Treg cells could not suppress CD4+ T 
cells isolated from the CNS (which is the primary disease site) of mice with acute 
EAE (Korn et al. 2007).  However, it is clear that in TS1xHACII mice effector 
CD4+ T cells (or other immune system cells) that contribute to arthritis 
development are not refractory to CD4+CD25+ Treg cell activity, since the 
administration of exogenous CD4+CD25+ Treg cells can modulate disease.   
 
Another possibility is that CD4+CD25+ Treg cells are functional in 
TS1xHACII mice, and are able to suppress autoimmune responses in other 
organs, but not in the joints, as the joints or draining LNs may be enriched for 
cytokines such as IL-6 or TNF-α that have been shown to interfere with 
CD4+CD25+ Treg cell function (Pasare and Medzhitov 2003; Ehrenstein et al. 
2004; Valencia et al. 2006; Nadkarni et al. 2007).  Indeed, although HA 
expression is systemic in TS1xHACII mice, the primary manifestation of 
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autoimmunity is the development of inflammatory arthritis, with some mice also 
exhibiting a pulmonary lymphocyte infiltration and/or valvulitis.  We do not 
observe lymphocyte infiltration in most organs (e.g. kidney, liver, salivary glands) 
(Rankin et al. 2008), and it is possible that the regulatory activity of endogenous 
CD4+CD25+Foxp3+ cells prevents the development of more systemic 
autoimmunity in TS1xHACII mice.  Interestingly, recent work demonstrates that 
CD4+CD25+ Treg cell mediated suppression of spontaneous lympophenia 
induced proliferation, which is thought to favor the expansion of more highly self-
reactive T cells (Min et al. 2004; Min et al. 2005), helps to generate a more 
diverse repertoire of T cells (Winstead et al. 2010).  Accordingly, the CD4+CD25+ 
Treg cells present in TS1xHACII mice may limit the expansion of other (non S1-
specific) CD4+ T cells with high reactivity for different self-antigens in young, 
lymphopenic TS1xHACII mice and thus prevent a more systemic manifestation of 
autoimmunity.  Moreover, the ability of TS1xHACII CD4+CD25+ cells that have 
been depleted of 6.5+CD4+CD25+ cells (which comprise Foxp3+ and Foxp3- cells) 
to modulate arthritis development in TS1xHACII mice (Figure 3-11), clearly 
demonstrates that CD4+CD25+ Treg cells from arthritic TS1xHACII mice are 
functional in vivo.  In contrast to CD4+CD25+ cells used in the CIA model, which 
were obtained from healthy mice, this is a unique demonstration that CD4+CD25+ 
cells isolated from arthritic mice are capable of ameliorating disease.   
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Although TS1xHACII 6.5-CD4+CD25+ cells can modulate arthritis in 
TS1xHACII mice, they are less effective than CD4+CD25+ cells obtained from 
HACII or BALB/c mice.  Studies in human arthritis patients have demonstrated 
that CD4+CD25+ cells isolated from RA patients are less effective in vitro 
suppressors than CD4+CD25+ cells isolated from healthy individuals (Ehrenstein 
et al. 2004; Valencia et al. 2006).  However, the suppressor function of 
CD4+CD25+ cells from RA patients was improved upon anti-TNF-α treatment 
(Ehrenstein et al. 2004; Valencia et al. 2006; Nadkarni et al. 2007), suggesting 
that the inflammatory disease environment negatively impacts CD4+CD25+ Treg 
cells.  In the CIA model, CD4+CD25+ T cells from IFN-γ receptor knockout mice, 
which develop accelerated and more severe arthritis (Manoury-Schwartz et al. 
1997; Vermeire et al. 1997), exhibit less potent suppressor activity in vitro, and 
express lower levels of Foxp3 mRNA, akin to the effects of TNF-α on 
CD4+CD25+ Treg cells in RA patients (Manoury-Schwartz et al. 1997).  Thus, it is 
possible that CD4+CD25+ Treg cells in TS1xHACII mice are less functional due to 
development in or prolonged exposure to the inflammatory environment 
associated with autoimmune arthritis.  Moreover, the diminished function of 
CD4+CD25+ Treg cells could be a contributing factor to arthritis development in 
TS1xHACII mice, as the progressive loss of CD4+CD25+ Treg cell function could 
ultimately tip the balance between tolerance and autoimmunity in favor of the 
pathogenic immune response and arthritis development in TS1xHACII mice.  In 
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NOD mice, a reduction in CD4+CD25+ Treg cell function and numbers prior to 
disease onset has been linked to diabetes development (Tang et al. 2008; Tritt et 
al. 2008). 
  
 Thus, the administration of exogenous CD4+CD25+ cells to TS1xHACII 
mice may mediate arthritis prevention by increasing the representation of 
CD4+CD25+ Treg cells relative to pathogenic effector CD4+ T cells.  In NOD 
mice, the diminished function of CD4+CD25+ Treg cells mice (Tritt et al. 2008) 
essentially results in a decrease in the representation of effective CD4+CD25+ 
Treg cells in relation to the diabetogenic CD4+ T cells.  The striking observation 
that endogenous TS1xHACII CD4+CD25+ cells can ameliorate arthritis in 
TS1xHACII mice upon depletion of 6.5+CD4+CD25+ cells, which recognize the 
disease target S1 peptide, also supports the concept that altering the balance 
between Treg cells and pathogenic effector T cell influences the development of 
autoimmunity.  As described previously, 6.5+CD4+CD25+ cells in TS1xHACII 
mice include both Foxp3+ and Foxp3- cells (Figure 3-3 B), and thus it is possible 
that elimination of 6.5+CD4+CD25+Foxp3- cells allows the endogenous 6.5-
CD4+CD25+ cells to be more effective suppressors by reducing the 
representation of pathogenic cells that drive arthritis development in TS1xHACII 
mice.  Furthermore, the concomitant transfer of a population of CD4+ cells 
enriched for 6.5+Foxp3- cells rendered HACII CD4+CD25+ cells less protective in 
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TS1xHACII mice (Figure 3-12), indicating that even a subtle increase in the 
representation of 6.5+CD4+ T cells could alter CD4+CD25+ Treg cell function. 
 
Collectively, these observations suggest that a contributing factor to the 
development of arthritis (and autoimmunity in general) may be an imbalance of 
CD4+CD25+ Treg cells relative to pathogenic effector cells during the time period 
that precedes disease development.  Moreover, observations in TS1xHACII mice 
suggest that the presence of certain TCR specificities may play a more critical 
role in altering the equilibrium between successful CD4+CD25+ Treg cell activity 
and the development of a pathogenic autoimmune response.  For the adoptive 
transfer experiments, endogenous CD4+CD25+ cells were purified from arthritic 
TS1xHACII mice, and it is therefore likely that other CD4+ cells (which do not 
express the 6.5 TCR) within the population have acquired pathogenic properties, 
such as the ability to produce IL-17.  However, the elimination of a very small 
population of 6.5+CD4+CD25+ cells rendered the remaining 6.5-CD4+CD25+ cells 
better able to modulate arthritis in TS1xHACII mice, demonstrating the particular 
importance of the representation of 6.5+CD4+ T cells that recognize S1 peptide 
for arthritis development in TS1xHACII mice.  These data also argue against the 
idea that the CD4+CD25+ Treg cell repertoire itself is somehow compromised in 
TS1xHACII mice because of the severe thymocyte deletion that occurs in young 
TS1xHACII mice. 
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What conditions might contribute to creating an imbalance between 
CD4+CD25+ Treg cells and pathogenic autoreactive CD4+ T cells?  One 
possibility is that lymphopenia, which has been associated with the development 
of autoimmunity (King et al. 2004; Khoruts and Fraser 2005; Marleau and 
Sarvetnick 2005), has differing effects on distinct T cell populations.  Both 
conventional CD4+ T cells and CD4+CD25+ Treg cells undergo proliferation in 
lymphopenic settings (Min et al. 2004; Min et al. 2005; Zhang et al. 2005), but 
how differences in their responses may contribute to the maintenance of 
tolerance as opposed to the development of autoimmunity remain unclear.  
Studies in human patients who have undergone allogeneic hematopoetic stem 
cell (HSC) transplantation have documented that while both conventional and 
CD4+CD25+ Treg cells undergo extensive proliferation in the lymphopenic 
environment induced by the treatment, CD4+CD25+ Treg cells appear to be more 
susceptible to apoptosis than conventional CD4+ T cells (Matsuoka et al. 2010).  
Moreover, humans that had more severe and prolonged lymphopenia had 
greater defects in the CD4+CD25+ Treg cell pool after reconstitution of the 
immune system, and a greater incidence of graft-versus-host disease (GVHD) 
(Matsuoka et al. 2010).  These findings suggest that the differential responses of 
conventional CD4+ T cells and CD4+CD25+ Treg cells in response to 
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lymphopenia can result in a decreased representation of CD4+CD25+ Treg cells 
that may contribute to the development of systemic autoimmunity.   
 
Work in the NOD diabetes model has shown that conventional CD4+ T 
cells undergo more extensive proliferation than CD4+CD25+ Treg cells in 
lymphopenic environments (Le Campion et al. 2009).  Moreover, in NOD.scid 
mice, diabetes development (which is induced by the adoptive transfer of CD4+ 
cells) was reduced when higher numbers of CD4+ cells were transferred, 
effectively reducing the degree of lymphopenia in the recipient mice, and 
protection correlated with a higher percentage of Foxp3+ cells among the 
transferred CD4+ cells (Le Campion et al. 2009).  Interestingly, it appears that 
lymphopenia induced proliferation of CD4+CD25+ Treg cells is dependent on 
interactions with self-peptides (Cozzo et al. 2003; Hsieh et al. 2004), whereas 
conventional CD4+ T cells can undergo lymphopenia induced proliferation in the 
absence of their cognate antigen (Cozzo et al. 2003).  Moreover, conventional 
CD4+ T cells expressing the 6.5 TCR underwent more extensive proliferation in 
response to low levels of S1 peptide in an irradiation induced lymphopenic 
environment than CD4+CD25+ Treg cells expressing the same 6.5 TCR (Cozzo 
et al. 2003), indicating that even in the presence of their cognate antigen, 
CD4+CD25+ Treg cells proliferate less than conventional CD4+ T cells in a 
lymphopenic setting.  These observations suggest that TCR specificity for self-
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peptides exerts ongoing effects on conventional CD4+ T cells and CD4+CD25+ 
Treg cells, and can play an important role in shaping the balance of these 
respective cell populations in response to lymphopenia and potentially influence 
the development of autoimmunity.  
 
Accordingly, it is possible that the lymphopenia in young, pre-arthritic 
TS1xHACII mice promotes the expansion of not only S1-specific 6.5+CD4+ T 
cells, which are exposed to high levels of their cognate antigen, but also 6.5-
CD4+ T cells that can differentiate to acquire pathogenic properties.  Moreover it 
seems likely that 6.5+CD4+ T cells (and also other CD4+ T cells with high 
reactivity for other self-peptides) would undergo more extensive proliferation than 
CD4+CD25+Foxp3+ cells, including the population of 6.5+CD4+CD25+Foxp3+ 
cells.  Thus, differences in lymphopenia induced proliferation between 
conventional CD4+ T cells and CD4+CD25+ Treg cells may lead to the 
preferential expansion of 6.5+ and other highly self reactive CD4+ T cells in 
TS1xHACII mice.  Therefore, while functional CD4+CD25+ Treg cells are present 
in pre-arthritic TS1xHACII mice, it is possible that they are not present in 
sufficient numbers to inhibit the response of 6.5+CD4+ T cells (and other 
pathogenic cells) in young TS1xHACII mice.   
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 Both the studies presented here and work in the CIA system have shown 
that increasing the representation of CD4+CD25+ Treg cells by administering 
exogenous Treg cells to pre-arthritic mice can ameliorate or prevent arthritis.  
However, many questions remain regarding where and how CD4+CD25+ Treg 
cells are acting to modulate the immune response in arthritis.  In the CIA model, 
protective exogenous CD4+CD25+ T cells that have been injected systemically 
can be found in the draining lymph node, synovial fluid, and synovial tissue as 
early as one day post transfer, indicating that the cells are trafficking to the 
disease site (Morgan et al. 2005).  Interestingly, it has also been reported that 
CD4+CD25+ T cell transfers were more effective at modifying disease severity 
when the cells were injected systemically rather than directly into the joints, 
raising questions about where the CD4+CD25+ Treg cells are acting to modulate 
disease (Ohata et al. 2007).  Moreover, although CD4+ T cells have been found 
in the joints of arthritic mice (Hirota et al. 2007; Jacobs et al. 2009), recent work 
suggests that CD4+ T cells may play a more important role in the joint-draining 
LNs, as CD4+ T cells that were blocked from exiting the LNs were still able to 
contribute to arthritis pathogenesis (Angyal et al. 2010).  
  
 We found that protective HACII CD4+CD25+ Treg cells could inhibit the 
accumulation of cells in the joint draining popliteal LNs that normally occurs in 
TS1xHACII mice (Figures 3-2 E and 3-8 A).  Work in the NOD diabetes model 
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has illustrated the importance of the regional LN immune response in the 
development of autoimmunity (Hoglund et al. 1999; Gagnerault et al. 2002).  
Excision of the pancreatic LNs in young NOD mice prevented diabetes onset, 
demonstrating that the local immune response is required for disease 
pathogenesis (Gagnerault et al. 2002).  However, while removal of the pancreatic 
LN could prevent diabetes development in young mice, it was no longer 
protective in 10 week old mice (Gagnerault et al. 2002), suggesting that once a 
certain threshold is achieved it becomes more difficult to alter the course of 
disease.  Therefore, it is possible that protective CD4+CD25+ Treg cells suppress 
arthritis in TS1xHACII mice by preventing the development of an enhanced 
immune response in the popliteal LN, which may be a critical step for arthritis 
pathogenesis. 
 
Studies in other murine arthritis models suggest that another potential 
mechanism by which CD4+CD25+ Treg cells may affect arthritis development is 
by altering the inflammatory environment.  In the CIA model, mice that received 
Treg cells had reduced serum levels of TNF-α and IL-6 (Morgan et al. 2005; 
Kelchtermans et al. 2009).  Additionally, treatment with IL-35, which has been 
identified as a CD4+CD25+ Treg cell effector cytokine (Collison et al. 2007), can 
reduce disease severity in CIA, which is associated with a decrease in IL-17 
levels (Niedbala et al. 2007), suggesting that CD4+CD25+ Treg cell production of 
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IL-35 could inhibit IL-17 production in arthritic mice.  We found that protective 
HACII CD4+CD25+ Treg cells inhibit the pathogenic Th-17 response in 
TS1xHACII mice (Figures 3-8, 3-9, and 3-10).  While the mechanism by which 
the exogenous CD4+CD25+ Treg cells inhibit IL-17 production in TS1xHACII mice 
remains unknown, TS1xHACII mice that received protective HACII CD4+CD25+ 
Treg cells also produced decreased amounts of IL-1 and IL-6 (Figure 3-10), two 
cytokines that can contribute to Th-17 cell differentiation (Acosta-Rodriguez et al. 
2007).  Innate immune cells, which are potential sources of cytokines such as IL-
1 and IL-6, may play an important role in the in vivo development of IL-17 
producing CD4+ T cells (Korn et al. 2009), and recent work has shown that 
monocytes from arthritic patients can induce Th-17 cell differentiation (Evans et 
al. 2009).  Thus, protective CD4+CD25+ Treg cells may decrease IL-17 
production in TS1xHACII mice by acting upon an innate immune system cell(s) 
that is instrumental in inducing the differentiation of Th-17 cells. 
 
We have shown that the arthritis that develops in TS1xHACII mice is 
susceptible to CD4+CD25+ Treg cell activity, as the administration of exogenous 
CD4+CD25+ cells to 5 to 6 week old TS1xHACII mice can ameliorate or 
completely prevent arthritis.  The majority of unmanipulated TS1xHACII mice do 
not develop arthritis until 10 to 12 weeks of age, and this lag period most likely 
reflects the time required to establish the pathogenic immune response (e.g. 
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development of IL-17 producing cells, immune response in the popliteal LNs) that 
can overcome regulatory mechanisms in TS1xHACII mice.  Thus, increasing the 
representation of CD4+CD25+ Treg cells during this incipient stage of the 
autoimmune response in TS1xHACII mice may be critical for effective 
suppression of disease.  Indeed, in the CIA model, there appeared to be a limited 
time frame in which transferred Treg cells could modulate disease severity.  
CD4+Foxp3+ T cells could best ameliorate CIA when they were transferred prior 
to the primary immunization with collagen.  At later time points, such as after a 
secondary immunization, a greater number of transferred Treg cells was required 
to achieve a comparable reduction in disease severity, and if transferred after the 
booster immunization, the Treg cells had no effect on arthritis development 
(Ohata et al. 2007).  It remains to be determined whether the administration of 
protective CD4+CD25+ Treg cells would be as effective at later time points in 
TS1xHACII mice.  
 
5.3 The effect of CD4+CD25+ Treg cell antigen-specificity in preventing 
autoimmunity 
 
 While studies from our lab and others have shown that interactions with 
cognate antigens can direct the thymic selection of CD4+CD25+ Treg cells 
(Jordan et al. 2001; Apostolou et al. 2002; Hori et al. 2002; Kawahata et al. 2002; 
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Walker et al. 2003), the importance of these interactions in guiding the in vivo 
suppressor activity of CD4+CD25+ Treg cells is less clear.  Work in multiple 
murine autoimmune diseases (e.g. AOD, CIA, colitis, diabetes, gastritis) has 
shown that that the adoptive transfer of polyclonal CD4+CD25+ Treg cells can 
prevent or ameliorate disease (Olivares-Villagomez et al. 1998; Van de Keere 
and Tonegawa 1998; Singh et al. 2001; Sarween et al. 2004; Morgan et al. 2005; 
Zwar et al. 2006; Kelchtermans et al. 2009), indicating that CD4+CD25+ Treg 
cells that are not necessarily enriched for disease-associated antigen specific 
cells can mediate suppression of an organ specific disease.  However, there is 
also a significant body of work demonstrating that antigen- or disease-specific 
CD4+CD25+ Treg cells are more effective than polyclonal CD4+CD25+ Treg cells 
at suppressing organ-specific autoimmune diseases (e.g. AOD, diabetes, EAE) 
(Hori et al. 2002; Reddy et al. 2004; Tarbell et al. 2004; Samy et al. 2005; Samy 
et al. 2008). 
  
Whereas the role of CD4+CD25+ Treg cell specificity in disease 
suppression has been better established in other models of murine 
autoimmunity, how CD4+CD25+ Treg cell specificity may affect the suppression 
of arthritis is unknown.  The primary approach to examining the role of antigen-
specificity in CD4+CD25+ Treg cell modulation of arthritis development has been 
to examine whether modifications to the CD4+CD25+ Treg cell population (i.e. 
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depletion or administration of exogenous Treg cells) result in antigen-specific 
changes in the autoimmune response.  K/BxN mice, which develop arthritis due 
to CD4+ T cell recognition of a GPI peptide and the subsequent activation of GPI-
specific B cells, exhibit an accelerated accumulation of anti-GPI antibodies when 
crossed to Foxp3-sf mice (Nguyen et al. 2007), suggesting that endogenous 
CD4+CD25+ Treg cells are tempering the GPI-specific immune response.  There 
is additional evidence for antigen-specific CD4+CD25+ Treg cell activity in the CIA 
model, with observations of increased collagen-specific T and B cell responses 
after CD4+CD25+ Treg cell depletion, as well as a reduction in collagen-specific 
antibodies after the transfer of exogenous CD4+CD25+ Treg cells (Morgan et al. 
2003; Ohata et al. 2007).  However, there are also data showing no alterations in 
the collagen-specific immune response upon manipulation of CD4+CD25+ Treg 
cells in CIA (Morgan et al. 2005; Kelchtermans et al. 2009).  In contrast, beyond 
the observation that K/BxN mice contain CD4+CD25+Foxp3+ cells that express 
Vβ6 (Vβ chain of the KRN Tg TCR) and can mediate in vitro suppression in 
response to the GPI peptide (Kang et al. 2008), there is little information 
regarding how CD4+CD25+ Treg cell specificity for a target antigen can affect 
affect arthritis suppression.  
 
TS1xHACII mice are a useful system to examine how the TCR specificity 
of CD4+CD25+ Treg cells can affect their ability to modulate arthritis development 
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since we have established the identity of a critical disease target antigen (S1 
peptide).  Similar to the observations in K/BxN mice, the finding that TS1xHACII 
mice contain 6.5+CD4+CD25+Foxp3+ cells (Figure 3-3 B) shows that arthritis can 
develop despite the presence of CD4+CD25+Foxp3+ cells that are specific for a 
disease target antigen.  Moreover, the results from the adoptive transfers of 
TS1xHA28 CD4+CD25+ Treg cells into pre-arthritic TS1xHACII mice demonstrate 
that CD4+CD25+ Treg cells that are enriched in specificity for S1 peptide fail to 
suppress disease (Figures 4-2 and 4-3), whereas polyclonal CD4+CD25+ Treg 
cells from HACII or BALB/c mice can prevent arthritis in TS1xHACII mice 
(Figures 3-6 and 3-13).  Indeed no enrichment in specificity for the S1 peptide 
appears to be necessary for Treg cell mediated suppression of arthritis, as 
BALB/c CD4+CD25+ Treg cells have not developed in the presence of S1 peptide 
or any other HA-derived peptides. 
 
In contrast, studies from the Tung laboratory suggest that CD4+CD25+ 
Treg cells with specificity for disease-associated antigens possess superior 
ability to prevent organ-specific autoimmune diseases than polyclonal 
CD4+CD25+ Treg cells.  Work in thymectomized mice that develop autoimmune 
ovarian disease (AOD) has shown that the transfer of CD4+CD25+ Treg cells 
isolated from the draining LNs are more effective suppressors of AOD than 
CD4+CD25+ Treg cells from non-draining LNs (Samy et al. 2005; Samy et al. 
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2008; Wheeler et al. 2009).  Draining LNs have been shown to uniquely present 
organ-specific peptides (Hoglund et al. 1999; Gagnerault et al. 2002; 
Scheinecker et al. 2002), and CD4+CD25+ Treg cells isolated from the ovary-
draining LNs may be more effective at suppressing AOD because they are 
enriched for ovarian antigen-specific CD4+CD25+ Treg cells (Samy et al. 2005; 
Samy et al. 2008).  Moreover, studies in male mice that develop experimental 
autoimmune prostatis (EAP) have demonstrated that CD4+CD25+ Treg cells can 
acquire the ability to suppress organ-specific autoimmune diseases after 
exposure to organ-derived antigens (Setiady et al. 2006).  Male mice subjected 
to a neonatal orchiectomy do not exhibit normal prostate development due to the 
absence of testicular androgen, but re-introduction of the hormone into neonatal 
orchiectomized mice can induce normal prostate development and expression of 
prostate antigens.  Interestingly, CD4+CD25+ Treg cells isolated from male mice 
undergoing androgen treatment (and thus experiencing prostate-derived 
antigens) can better suppress EAP than CD4+CD25+ Treg cells purified from 
male mice subjected to only the neonatal orchiectomy, suggesting that exposure 
to the normal prostate antigens confers the ability to suppress prostate-specific 
autoimmune disease (Setiady et al. 2006).  Thus, it possible that upon transfer 
into TS1xHACII mice, BALB/c CD4+CD25+ Treg cells are educated by exposure 
to the HA protein and gain specificity to HA derived peptides. 
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Given the ability of polyclonal CD4+CD25+ Treg cells to suppress arthritis, 
it was surprising that CD4+CD25+ Treg cells from TS1xHA28 and 
TS1xHA28.Foxp3EGFP mice, which are enriched for 6.5+Foxp3+ cells, failed to 
prevent arthritis in TS1xHACII mice despite expanding, becoming activated, and 
trafficking to the joint draining popliteal LNs (Figures 4-4 and 4-10).  This finding 
is at odds with observations in other murine models of autoimmune disease (e.g. 
diabetes, EAE, pneumonitis) where antigen-specific CD4+CD25+ Treg cells are 
able to inhibit disease that is initiated by CD4+ T cells of the same specificity 
(Hori et al. 2002; Tarbell et al. 2004; Huang et al. 2005).  What might explain the 
discrepancy in our observations of antigen-specificity requirements for 
CD4+CD25+ Treg cell suppression of autoimmunity?  Although recognition of S1 
peptide by 6.5+CD4+ T cells is a critical step in arthritis development in 
TS1xHACII mice, it is possible that other non S1-specific CD4+ T cells are 
recruited later in the response and become more important during the effector 
stage of arthritis in TS1xHACII mice.  Indeed, epitope spreading can play a role 
in the pathogenesis of a variety of autoimmune diseases, including arthritis, and 
is also a mechanism by which viral infections can trigger the development of 
autoimmunity (Vanderlugt and Miller 2002).   
 
Thus it is possible that the cells that must be suppressed in TS1xHACII 
mice are not the 6.5+CD4+ T cells, and that CD4+CD25+ cells from HACII or 
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BALB/c mice, but not TS1xHA28 or TS1xHA28.Foxp3EGFP mice, contain the 
appropriate specificities to mediate suppression, suggesting that in vivo 
suppression of CD4+ T cells by CD4+CD25+ Treg cells is antigen-specific.  This is 
consistent with the finding of antigen-specific CD4+CD25+ Treg cell suppression 
of effector CD4+ T cells in a model of fatal autoimmune pneumonitis (Huang et al. 
2005).  While the adoptive transfer of 6.5+CD4+ T cells into transgenic mice 
expressing HA protein in the lungs induces pneumonitis, disease does not 
develop if the cells are transferred into mice that express HA in the lungs but also 
contain 6.5+CD4+CD25+ Treg cells.  Moreover, transfer of 6.5+CD4+CD25+ Treg 
cells but not polyclonal CD4+CD25+ Treg cells could prevent pneumonitis in 
single transgenic HA mice.  Protection, which is mediated by IL-10 and TGF-β, 
results in the inhibition of proliferation and cytokine production (IFN-γ) by 
pathogenic 6.5+CD4+ T cells (Huang et al. 2005).  Interestingly, 6.5+CD4+CD25+ 
Treg cells could suppress proliferation by 6.5+CD4+ T cells but not CD4+ T cells 
of a different specificity (Tanchot et al. 2004; Huang et al. 2005), indicating that 
CD4+CD25+ Treg cell suppression of in vivo proliferation by responder CD4+ T 
cells is antigen-specific. 
 
However, the ability of TS1xHACII CD4+CD25+ cells to ameliorate arthritis 
in TS1xHACII mice when depleted of 6.5+ cells argues that 6.5+CD4+ T cells 
continue to play an important role in arthritis development in TS1xHACII mice at 
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the time of the exogenous CD4+CD25+ Treg cell transfers (Figure 3-11).  In 
addition, the co-transfer of a population of conventional 6.5+CD4+CD25- cells 
rendered HACII CD4+CD25+ Treg cells less protective in TS1xHACII mice 
(Figure 3-12).  Furthermore, the development of arthritis in TS1xHACII.RAG-/- 
mice demonstrates that CD4+ T cells of other TCR specificities are not required 
for arthritis pathogenesis, and that 6.5+CD4+ T cells alone can mediate arthritis 
(Rankin et al. 2008).  Collectively, these observations suggest that S1-specific 
6.5+CD4+ T cells are a critical pathogenic population not only during disease 
initiation, but also in other stages of arthritis in TS1xHACII mice, and it remains 
surprising that the administration of CD4+CD25+ Treg cells enriched for 6.5+ cells 
are unable to suppress or even ameliorate arthritis in TS1×HACII mice.   
 
Moreover, studies in the NOD diabetes and EAE models provide evidence 
that CD4+CD25+ Treg cells can suppress CD4+ T cells that possess specificity for 
different antigens.  The majority of CD4+CD25+ cells from BDC2.5 mice that were 
expanded in vitro with BDC peptide pulsed APCs express the BDC2.5 TCR.  
However, the adoptive transfer of these BDC peptide expanded CD4+CD25+ cells 
could suppress diabetes development in NOD.scid mice, which is induced by the 
adoptive transfer of splenocytes from diabetic NOD mice (Tarbell et al. 2004).  
Thus, in this case CD4+CD25+ Treg cells that are enriched for expression of the 
BDC2.5 TCR were able to suppress diabetes that is driven by CD4+ T cells with a 
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diverse array of pathogenic TCRs, although the CD4+CD25+ Treg cells and 
diabetogenic CD4+ T cells may recognize the same target antigen(s).  Work in 
the EAE model has shown that pre-activated Ig-proteolipid protein 1 (PLP1) 
specific CD4+CD25+ Treg cells could suppress EAE driven by responses to 
myelin oligodendrocyte glycoprotein (MOG) or myelin basic protein (MBP) 
peptides (Yu et al. 2005), again demonstrating that CD4+CD25+ Treg cells could 
mediate suppression regardless of the specificity of effector CD4+ T cells. 
 
The question of antigen-specificity and CD4+CD25+ Treg cell function has 
primarily been considered in relation to suppression of effector CD4+ T cells.  
However, CD4+CD25+ Treg cells can also inhibit innate immune cells (Maloy et 
al. 2003), and how the antigen-specificity of CD4+CD25+ Treg cells might 
influence this suppression is less clear.  While protective HACII CD4+CD25+ cells 
suppressed IL-17 production by CD4+ T cells in the popliteal LNs of TS1xHACII 
mice (Figure 3-8 B and C), whether the reduction in IL-17, IL-1, and IL-6 
production by systemic LN cells (Figure 3-9) is attributed to CD4+CD25+ Treg 
cells acting upon CD4+ T cells or other immune cells is unknown.  Moreover, in 
addition to producing cytokines such as IL-1 or IL-6, innate immune cells can 
also produce IL-17 (Buonocore et al. 2010).  Indeed, 6.5+CD4+ T cells may 
promote arthritis development in TS1xHACII.RAG-/- by inducing inflammation that 
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recruits innate immune cells (e.g. neutrophils, macrophages) that can mediate 
joint damage (Niki et al. 2001).   
 
Interestingly, S1-specific CD4+CD25+ cells not only failed to suppress IL-
17 production in TS1xHACII mice, but also appeared to increase production of 
IL-1 and IL-6 (Figure 4-7).  It has been shown that T cell mediated inhibition of 
innate immune cells is MHC dependent (Kim et al. 2007), and more recent work 
demonstrates that upon interactions with cognate antigen, memory CD4+ T cells 
can induce the production of inflammatory cytokines and chemokines by innate 
immune cells, (Strutt et al. 2010).  Thus, one can speculate as to whether 
interactions between CD4+CD25+ Treg cells and innate immune cells presenting 
their cognate antigen could induce a similar induction of inflammatory proteins.  
Given that HA expression is driven by a MHC Class II promoter in TS1xHACII 
mice, it is likely that innate immune cells expressing MHC Class II can also 
present HA-derived peptides (such as S1 peptide) and activate TS1xHA28 
CD4+CD25+ cells, which are enriched for expression of the 6.5 TCR.  Moreover, 
activated TS1xHA28 CD4+CD25+ Treg cells could also promote the 
differentiation of pathogenic IL-17-producing CD4+ cells by producing high levels 
of the regulatory cytokines TGF-β, which in the context of cytokines such as IL-6 
and IL-1, can induce Th-17 differentiation.  
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5.4 Plasticity of CD4+CD25+ Treg cells: implications for suppression of 
autoimmunity 
 
Recent studies have demonstrated the plasticity of the CD4+CD25+ Treg 
cell population, as a subset of CD4+CD25+ Treg cells can lose Foxp3 when 
exposed to conditions of lymphopenia or inflammation in an autoimmune setting 
(Komatsu et al. 2009; Murai et al. 2009; Zhou et al. 2009).  Foxp3 expression is 
critical for the maintenance of the CD4+CD25+ Treg cell phenotype (Wann and 
Flavell 2007; Williams and Rudensky 2007), and CD4+CD25+ Treg cells that lose 
Foxp3 expression can acquire the ability to produce cytokines such as IFN-γ and 
IL-17 (Xu et al. 2007; Komatsu et al. 2009; Murai et al. 2009; Zhou et al. 2009).  
Work from the Bluestone laboratory has shown that ex-CD4+CD25+ Treg cells 
can differentiate into pathogenic CD4+ T cells and mediate diabetes development 
in NOD mice (Zhou et al. 2009).  Interestingly, upon transfer into NOD mice, a 
greater percentage of BDC2.5 TCR expressing CD4+CD25+ Treg cells lost Foxp3 
expression than did CD4+CD25+ cells that did not express the Tg TCR, 
suggesting that interactions between the TCR and its cognate antigen could 
further promote the loss of Foxp3 and the development of effector functions by 
CD4+CD25+ Treg cells.  Moreover, repetitive in vitro stimulation of human 
CD4+CD25+ Treg cells can induce loss of Foxp3 (Hoffman et al. 2009), providing 
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additional evidence that TCR engagement can contribute to phenotypic changes 
in CD4+CD25+ Treg cells. 
 
TS1xHA28 CD4+CD25+ cells, which are enriched for expression of the 6.5 
TCR, rapidly downregulated CD25 upon transfer into TS1xHACII or HACII mice, 
which contain high levels of their cognate antigen (Figure 4-10).  In contrast, 
TS1xHA28 CD4+CD25+ cells were able to maintain high levels of CD25 
expression in HA28 mice, which contain low levels of S1 peptide (Figure 4-11).  
Interestingly the downregulation of CD25 in response to high levels of S1 peptide 
appeared to be delayed if CD4+CD25+ Treg cells expressed a TCR with low 
reactivity for S1 peptide (Figure 4-14), suggesting that the lower reactivity of the 
TS1(SW) TCR for S1 peptide counteracts the effects of high levels of S1 peptide 
in HACII mice, similar to the effect of reducing S1 peptide levels on CD25 
maintenance by TS1xHA28 CD4+CD25+ cells.  Taken together these data 
support a role for strong TCR signals in inducing CD25 downregulation by 
CD4+CD25+ Treg cells.  Signaling through the IL-2Rα chain has been shown to 
potentiate both CD25 and Foxp3 expression (Fontenot et al. 2005; Zorn et al. 
2006), and recent work has shown that CD4+CD25-Foxp3+ cells are more prone 
to lose Foxp3 expression than CD4+CD25+Foxp3+ cells (Komatsu et al. 2009).   
Thus, it is possible that upon exposure to highly stimulatory levels of S1 peptide, 
a subset of TS1xHA28 CD4+CD25+ cells loses CD25 and Foxp3 expression, and 
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in the context of the inflammatory disease setting, differentiates into pathogenic 
effector CD4+ T cells in TS1xHACII mice.  Certain inflammatory cytokines, such 
as IL-1β (which was elevated in TS1xHACII mice that received TS1xHA28 
CD4+CD25+ cells), have been shown to contribute to CD4+CD25+ Treg cell 
conversion to Th-17 cells (Deknuydt et al. 2009).   
 
Although the findings presented here suggest that TCR signals can induce 
phenotypic changes in CD4+CD25+ Treg cells that could lead to loss of Foxp3 
and regulatory function, whether a subset of TS1xHA28 CD4+CD25+ cells loses 
Foxp3 expression and acquires cytokine production in TS1xHACII mice remains 
to be determined.  The adoptive transfer of CD4+CD25+ Treg cells purified from 
TS1xHA28.Foxp3EGFP mice into congenically mismatched TS1xHACII mice would 
allow us to better address whether 6.5+CD4+CD25+ Treg cells become 
pathogenic upon exposure to the high levels of S1 peptide and inflammation 
present in TS1xHACII mice, since the congenic marker could be used to detect 
all donor CD4+CD25+ Treg cells rather than the use of GFP which only identifies 
the cells that have maintained Foxp3 expression.  Additionally, recent studies 
have shown that the methylation status of the Foxp3 promoter plays an important 
role in Foxp3 stability in CD4+CD25+ Treg cells (Kim and Leonard 2007; Janson 
et al 2008).  However, the signals and mechanisms involved in establishing and 
maintaining the demethylation of the Foxp3 promoter remain unknown.  It would 
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be of interest to determine whether the strength of signal through the TCR could 
affect the methylation status of the Foxp3 promoter and therefore the stability of 
Foxp3 protein expression in CD4+CD25+ Treg cells.  Recent work has linked the 
loss of Foxp3 expression in human CD4+CD25+ Treg cells that have been 
subjected to repetitive in vitro stimulation to changes in the methylation status of 
the Foxp3 promoter (Hoffman et al. 2009). 
 
5.5 Summary and working model 
 
 The studies presented in this dissertation demonstrate that the TCR 
specificity(s) of CD4+CD25+ Treg cells can be a significant determinant of their 
ability to suppress autoimmune disease.  Polyclonal CD4+CD25+ Treg cells, but 
not CD4+CD25+ Treg cells that are enriched in specificity for a critical disease 
target antigen (S1 peptide), are able to prevent arthritis development in 
TS1xHACII mice, which is driven by recognition of the S1 peptide by 6.5+CD4+ T 
cells (Rankin et al. 2008).  Moreover, CD4+CD25+ Treg cells that have not 
developed in the presence of S1 peptide or any other HA-derived peptides can 
prevent arthritis in TS1xHACII mice, demonstrating that specificity for this 
disease target antigen is not required for CD4+CD25+ Treg cell mediated 
suppression of arthritis.  What might explain the ability of polyclonal CD4+CD25+ 
Treg cells to prevent disease development in TS1xHACII mice?  The 
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administration of exogenous CD4+CD25+ cells to pre-arthritic TS1xHACII mice 
increases the representation of CD4+CD25+ Treg cells relative to pathogenic 
CD4+ T cells in recipient mice, and it is possible that this increase is enough to 
shift the balance in favor of regulation and away from autoimmunity. 
 
 Yet, if simply altering the balance of CD4+CD25+ Treg cells and effector 
cells in favor of the regulatory population is sufficient to prevent arthritis 
development, CD4+CD25+ Treg cells that are enriched for 6.5+ cells should also 
be able to suppress arthritis in TS1xHACII mice.  One possible explanation for 
the failure of CD4+CD25+ Treg cells enriched for S1-specificity to prevent arthritis 
development in TS1xHACII mice is that the CD4+ T cells mediating the effector 
stage of arthritis are not the 6.5+CD4+ T cells, and that CD4+CD25+ Treg cells 
that are enriched for S1-specific cells do not possess the appropriate TCR 
specificities to suppress the effector CD4+ T cells.  This would suggest that 
CD4+CD25+ Treg cell suppression of CD4+ T cells is antigen-specific, and thus a 
highly diverse population of polyclonal CD4+CD25+ Treg cells may contain the 
necessary TCR specificities to suppress the relevant effector CD4+ T cells in 
TS1xHACII mice.  Indeed, the transfer of exogenous CD4+CD25+ Treg cells into 
TS1xHACII mice could serve to increase the diversity of the TCR repertoire of 
CD4+CD25+ Treg cells present in TS1xHACII mice, and thereby increase the 
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probability of recognizing a critical target peptide to mediate suppression of 
arthritis. 
  
 However, the ability of CD4+CD25+ cells from TS1xHACII mice to 
modulate arthritis when depleted of a small population of 6.5+ cells indicates that 
6.5+CD4+ T cells are still active participants in promoting arthritis development at 
the time of the exogenous CD4+CD25+ Treg cell transfers into TS1xHACII mice. 
Accordingly, if 6.5+CD4+ T cells continue to play an important role in arthritis 
pathogenesis in TS1xHACII mice, increasing the representation of CD4+CD25+ 
Treg cells enriched in expression for the 6.5 TCR should be able to modulate 
arthritis development by suppressing the endogenous 6.5+CD4+ T cells.  
Furthermore, CD4+ T cells of other TCR specificities are not required for arthritis 
development as TS1xHACII.RAG-/- mice also develop disease (Rankin et al. 
2008).  Thus, the question of why CD4+CD25+ Treg cells enriched for S1-specific 
cells are unable to prevent arthritis in TS1xHACII mice remains.  Additional data 
presented in this dissertation suggest that strong stimulation with cognate 
antigen can induce effector functions and/or phenotypic changes in CD4+CD25+ 
Treg cells that may be detrimental in the context of certain autoimmune diseases.   
 
CD4+CD25+ Treg cells expressing the 6.5 TCR are strongly reactive to the 
S1 peptide, and we have shown that the CD4+CD25+ cells enriched for 6.5+ cells 
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undergo extensive proliferation and become activated in response to the high 
levels of HA present in TS1xHACII mice.  CD4+CD25+ Treg cells undergoing 
strong stimulation may produce high levels of regulatory cytokines such as TGF-
β, which in the context of other inflammatory cytokines (e.g. IL-1, IL-6, IL-23), can 
promote Th-17 differentiation.  Therefore, activated 6.5+CD4+CD25+ Treg cells 
may contribute to the development of pathogenic Th-17 cells in TS1xHACII mice.  
Another possibility is that a subset of 6.5+CD4+CD25+ Treg cells loses Foxp3 
expression upon exposure to high levels of their cognate antigen, and 
differentiates into pathogenic effector CD4+ T cells in TS1xHACII mice.  Indeed, 
in light of our data suggesting that the ability of CD4+CD25+ Treg cells to 
suppress arthritis development in TS1xHACII mice is incredibly sensitive to the 
presence of effector 6.5+CD4+ T cells, a population of de-differentiated 
6.5+CD4+CD25+ Treg cells may alter the balance of Treg cells and effector cells 
in favor of the pathogenic CD4+ T cells and arthritis development in TS1xHACII 
mice.  A working model of how exogenous CD4+CD25+ Treg cells can affect 
arthritis development in TS1xHACII mice is presented in Figure 5-1. 
 
Collectively, these data indicate that CD4+CD25+ Treg cells have the 
ability to modulate arthritis, but that the antigen-specificity of the CD4+CD25+ 
Treg cells is critical for successful suppression of disease. Therefore, while there 
is potential for the use of CD4+CD25+ Treg cells in therapeutic settings to treat 
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autoimmunity, careful consideration should be given to nature of the autoimmune 
disease, both from the perspective of predominant disease-associated antigens 
and the inflammatory environment associated with the disease. 
Figure 5-1 Working model: The balance of CD4+CD25+ Treg cells to pathogenic 
6.5+CD4+ T cells is a critical parameter for arthritis prevention in TS1xHACII mice 
(A) In unmanipulated TS1xHACII mice the balance between CD4+CD25+ Treg cells 
and effector CD4+ T cells favors pathogenic 6.5+CD4+ T cells and arthritis development.
(B) The administration of exogenous polyclonal CD4+CD25+ Treg cells increases the
representation of Treg cells relative to the representation of pathogenic 6.5+CD4+ T 
cells in TS1xHACII mice, favoring Treg cell activity and suppression of arthritis.
(C) The administration of exogenous CD4+CD25+ Treg cells enriched for 6.5+Foxp3+ 
cells are unable to prevent arthritis development in TS1xHACII mice. Potential 
mechanisms of failure:  (1) A subset of 6.5+CD4+CD25+ Treg cells de-differentiates to 
lose Foxp3 expression and acquire pathogenic effector function. (2) Strongly activated 
6.5+CD4+CD25+ Treg cells produce high levels of TGF-β and promote the differentiation 
of pathogenic Th-17 cells. 
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